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Abstract 
 
Influenza A virus infection and innate immunity in a novel murine 
alveolar-like macrophage model 
Connor Wood 
Influenza is both a seasonal and occasional pandemic respiratory infection in humans, 
with the most vulnerable of society at the highest risk. With vaccine efficiency 
dropping and resistance against treatments, better understanding of the host-viral 
interactions is required to find novel therapy targets. Much of the current 
understanding for the host-viral interactions comes from epithelial cells or imperfect 
macrophage models. Alveolar macrophages (AMs) are crucial in the first stages of 
infection, but due to limited availability, true functional experiments have been 
impossible.  
By using the novel AM-like macrophage, Max Plank Institute (MPI) cells, which are 
available in practically unlimited numbers,  this research hopes to expand the current 
understanding with in-depth functional assays on IAV-macrophage entry mechanisms, 
immune sensing and signalling, and the resulting effector molecules such as cytokines, 
chemokines and type I IFNs. 
MPI macrophages are susceptible to IAV infection but this results abortive replication, 
following established understandings. However, MPI macrophages are much more 
sensitive to influenza infection than non-AM models, resulting in a greater pro-
inflammatory cytokine, chemokine, and type I IFN responses. This sensitivity 
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highlighted the differences between both strains and individual isolates, with specific 
binding, infectivity and resulting immune responses all highly variable in different cell 
types. The effective cleavage of the viral hemagglutinin was key to successful infection, 
with TPCK-treated trypsin in cell culture much less efficient than the egg counterpart. 
Influenza propagation techniques that result in this less efficient cleavage limit the 
impact of downstream functional immune assays. In MPI macrophages reduced pro-
inflammatory cytokines and type-I IFN production was observed as a result of this 
difference in cleavage, however chemokine remained primarily unaffected. 
The entry mechanisms of IAV in macrophages are much more complex than their 
epithelial counterparts. While in both cell types sialic acid is the primary attachment 
receptor for the viruses, in macrophages co-receptor binding by a variety of receptors 
is utilised to internalise influenza efficiently. Receptors such as the C-type lectins MMR 
and MGL are utilised to different extents in different macrophage models. However, in 
MPI macrophages the scavenger receptor MARCO seems to be the main co-receptor, 
involved in viral uptake but not in direct viral binding to the cell surface. 
Viral uptake in MPI cells showed that both macropinocytosis and clathrin mediated 
endocytosis are required for optimal infection, unlike epithelial counterparts where 
the two mechanisms work in a redundancy partnership. Following from this the 
current model of IAV endosome escape is the same in MPI macrophages as epithelial 
cells. With endosomal acidification facilitating HA fusion to the endosome to allow viral 
RNP escape. 
Upon detection of IAV by the macrophage three distinct immune response phases 
occur, two ‘early’ before RNA replication and one ‘late’ after replication. These phases 
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line up with the binding, endosomal, and RNA replication phases of the viral infection 
cycle, resulting in the production of key effector molecules at each point. These two 
‘early’ responses occur independently of viral RNA replication resulting in MAPK and 
NF-κB activation. The resulting pro inflammatory cytokines produced from these early 
responses aid the early influx of innate and adaptive immune cells to the infection site. 
On the other hand, the ‘late’ response is dependent on viral RNA replication, utilising 
TBK-1 and IRF-3 signalling to induce an antiviral state and viral killing. This late 
response also seems to play a role in resolving the ‘early’ responses to prevent the 
cytokine storm associated with severe uncontrolled response. 
The complexity and varied response to influenza in MPI macrophages, show the 
benefits of using relevant cell models, which are available in sufficient numbers for 
functional immune studies. Understanding influenza and AM interactions is paramount 
for future therapies against a disease with rising health burdens.  
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MDA5 Melanoma Differentiation-Associated Gene 5 
MDM monocyte derived macrophage 
MEK/ERK Mitogen-activated protein kinase kinase/extracellular signal-
regulated kinase 
MEM Minimum Essential Medium 
mg milli grams 
MGL macrophage galactose-type lectin 
MHC II Major Histocompatibility Complex Class II 
mins minutes 
MIP-1α/CCL3 macrophage inflammatory protein 1-alpha/chemokine (C-C motif) 
ligand 3 
MIP-2/CXCL2 macrophage inflammatory protein 2/chemokine (C-X-C motif) 
ligand 3  
ml milli litres 
mM milli molar 
mm milli meters 
MMR macrophage mannose receptor 
MOI multiplicity of infection 
MPI Max Planck Institute 
mRNA messenger Ribonucleic acid 
MSK1/2 Mitogen- and stress-activated protein kinase 1 and 2 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
myd88 Myeloid differentiation primary response 88 
NA Neuraminidase 
NaCl sodium chloride 
NEP nuclear export protein 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NK natural killer cell 
NLRC2/NOD2 NLR family CARD-containing protein 2/nucleotide-binding 
oligomerization domain-containing protein 2 
NLRP3 NLR family PYD-containing protein 3/Cryopyrin 
NLRs NOD-like receptors 
NLRX1 NLR family member X1 
NLSs nuclear localisation signals 
nm Nano meters 
NP Nuclear protein 
NS1 Non-structural protein 1 
NS2 Non-structural protein 2 
NTC sodium chloride, Tris, calcium chloride buffer 
ntc non-template control 
oC degrees centigrade 
OD optical density 
P phosphorylated 
P2X7 P2X purinoceptor 7 
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p38 protein 38 
p58IPK PKR regulatory factor 
PAMPs pathogen associated molecular patterns 
PB2 Polymerase basic protein 2 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PFU plaque forming units 
pg Pico gram 
PKR induced RNA-dependent protein kinase 
Pro-IL-18 interleukin-18 precursor 
Pro-IL-1β interleukin-1 beta precursor 
PRRs Pattern Recognition Receptors 
q-PCR quantitative polymerase chain reaction 
RANTES/CCL5 Regulated on activation, normal T cell expressed and 
secreted/chemokine (C-C motif) ligand 5 
RIG-I retinoic acid-inducible gene I 
RIP Receptor Interacting Protein 
RIPA Radio immunoprecipitation assay 
RLRs RIG-I like receptors 
RNA Ribonucleic acid 
RNP ribonucleoprotein particles 
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute, 
RT-PCR Reverse Transcriptase polymerase chain reaction 
s seconds 
S.E.M standard error of the mean 
SA sialic acid 
SDS sodium dodecyl sulphate 
SPF specific pathogen free 
ssRNA single stranded Ribonucleic acid 
STAT signal transducer and activator of transcription 
tbk1 TANK-binding kinase 1 
TBS Tris Buffered Saline 
TEMED Tetramethyl ethylenediamine 
TLRs Toll-like receptors 
TNFR1 Tumour necrosis factor receptor 1 
TNFR2 Tumour necrosis factor receptor 2 
TNF-α Tumour necrosis factor alpha 
TPCK L-1-Tosylamide-2-phenylethyl chloromethyl ketone 
TRIF TIR-domain-containing adapter-inducing interferon-β 
TTBS tween Tris Buffered Saline 
U Units 
UV ultraviolet 
v volts 
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vol volume 
vRNA viral Ribonucleic acid 
WT wild type 
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1.1 Influenza and ‘the flu’ 
Influenza is a respiratory disease in humans, mainly caused by influenza A (IAV) and 
influenza B (IBV) viruses. In Layman’s terms, ‘the flu’ presents as either a mild 
respiratory disease confined to the upper respiratory tract, with fever, cough, 
headache, muscle pain, runny nose, sore throat, and fatigue, or as severe/fatal 
pneumonia caused by the viral infection and secondary bacterial infection (Krammer et 
al., 2018). Influenza is mainly perceived as seasonal epidemics, yet sporadic global 
pandemics also occur unpredictably, from IAV strains from zoonotic origin. These 
pandemics are the result of an antigenically new IAV strain introduced into an 
immunologically naïve population, resulting in increased infection severity and 
mortality. For IAV there are 144 possible different subtypes of IAV (Tong et al., 2013), 
made from 18 HA and 11 NA, however currently only two circulate seasonally in 
humans; H1N1 and H3N2 (Beare and Webster, 1991). 
1.1.1 IAV Structure 
1.1.1.1 Genome  
Influenza viruses are negative-sense, single-stranded RNA (ssRNA) viruses, with an 
eight-segment genome. Segments 1, 3, 4, 5, and 6 all encode for a single separate 
protein; PB2, PA, HA, NP and NA proteins respectively. Segments 2, 7, and 8 each 
encode two proteins. PB1 is encoded by segment 2, and via a +1 alternate reading 
frame, also encodes PB1-F2 (Chen et al., 2001). Segment 7 encodes for the M1 matrix 
protein and the M2 ion channel by RNA splicing (Hatta and Kawaoka, 2003). NS1 and 
NEP/NS2 are also encoded on a single segment via RNA splicing, segment 8 (Lamb et 
al., 1981). The ends of these segments form a helical hairpin, to which the RNA 
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polymerase complex, consisting of two polymerase basic and one polymerase acidic 
subunits (PB1, PB2, and PA) binds. The rest of the segment is covered in NP, which 
with a net positive charge, binds to the negatively charged phosphate backbone of the 
vRNA (Lo et al., 2018). This segmentation of the genome is the key cause of antigenic 
shift, by where segments, specifically HA and NA, ‘swap’ between strains. This 
reassortment is key in the emergence of influenza pandemics and will be examined in 
greater detail further in this thesis. 
1.1.1.2 Virion Structure 
The IAV virion tends to appear as either 100nm spherical (Figure 1.1) or 300nm 
filamentous forms with glycoprotein ‘spikes’ protruding from host-derived lipid 
membrane (envelope), (Lamb, 1996) these ‘spikes’ are a mixture of HA and NA at a 
ratio of 4:1. Across the lipid membrane, although at much lower concentration than 
either HA or NA, are matrix ion channels (M2), with a M2 to HA ration of between 1:10 
and 1:100 (Zebedee and Lamb, 1988). Under this spiked envelope lies a matrix of M1 
protein, all of which encompass the core of the virion, containing segmented genome. 
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Figure 1.1 Visual representation of the Influenza structure (Based on work of Krammer et al. (2018)) A. 
represents spherical morphology. B. represents filamentous morphology. Images not to scale. 
 
A B 
 
32 
 
Table 1.1 Influenza A proteins and functions.* indicates segments encoding multiple proteins. 
 
1.1.2 Disease 
1.1.2.1 Seasonal IAV 
Generally, IAV disease occurs in seasonal epidemics, with more infections occurring in 
either the young or the old. Currently both H3N2 and H1N1 circulate seasonally in 
humans, but this has not always been the case, with H2N2 circulating from 1957 to 
1968 (Krammer et al., 2018). The outbreaks of these seasonal IAV epidemics 
traditionally occur in the winter months, with the lower temperatures and humidity 
aiding transmission (Yu et al., 2013b). During this time the young appear to be the 
main human transmission reservoir, with child vaccination reducing the incidence of 
severe infections in older populations.(Cohen et al., 2011)  
Segment Protein Function 
1 PB2 Polymerase subunit: mRNA cap recognition 
2* PB1 Polymerase subunit: RNA elongation, endonuclease activity 
PB1-F2 Pro-apoptotic activity 
3 PA Polymerase subunit; protease activity 
4 HA Surface glycoprotein: Major antigen, receptor binding and 
fusion 
5 NP RNA binding protein: nuclear import regulation 
6 NA Surface glycoprotein: sialidase activity, virus release 
7* M1 Matrix Protein: vRNP interaction, RNA nuclear export 
regulation, viral budding 
M2 Ion channel: virus uncoating and assembly 
8* NS1 Interferon antagonist protein: Regulation of host gene 
expression 
NEP/NS2 Nuclear export of RNA 
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Recent estimates have put the attributed deaths to these seasonal epidemics at 
around 291,243 to 645,832 per year, (Iuliano et al., 2018) with age (young and old), 
pregnancy, and pre-existing medical conditions being key risk factors. In this way the 
infection often affects the most vulnerable populations, with compromised immune 
systems (Thompson et al., 2004). With each new season, minor changes to the 
antigenic characteristics of the surface glycoproteins, HA and NA, as a result of point 
mutations in the RNA segments encoding these proteins (Koel et al., 2013). These 
minor changes or ‘antigenic drifts’ are responsible for the evasion of the antibody-
mediated immunity generated by previous infections/vaccinations. This results in the 
cycle of seasonal infections and requires the annual update of vaccines to the 
emerging virus. 
1.1.2.2 Pandemic IAV 
The segmented nature of the IAV genome causes high rates of reassortment with HA 
and NA segments swapping between strains. Pandemic IAV strains emerge when this 
reassortment occurs between human and animal viruses (pigs, horses, and birds) 
resulting in completely novel antigenic IAV glycoproteins, to which a human population 
has no existing immunity. This has led to the emergence four pandemic IAV strains 
from avian and swine origin since the first characterisation of IAV in 1918 (Zimmer and 
Burke, 2009). These pandemics spread quickly through the naïve population from the 
origin point, with several waves of infection throughout the world. As immunity grows, 
they gradually fade into seasonally circulating strains, resulting in the loss of the 
previous seasonally circulating strain.  (Krammer et al., 2018; Moghadami, 2017) 
The limited number of pandemic outbreaks makes predicting the next very difficult. 
Human IAV infections with diverse avian and swine strains are detected, but the 
 
34 
 
Figure 1.2 Process of IAV antigenic shift and drift in yielding seasonal and pandemic human strains 
(Based on work of Krammer et al. (2018)) 1. Avian or swine IAV strain with black HA and red NA. 2. 
Seasonal human IAV strain with purple HA and red NA. 3. Drifted seasonal human IAV strain with slightly 
changed purple HA and red NA. 4. Pandemic human IAV strain with mixed black HA from avian or swine 
strain and blue NA from seasonal human strain. 5. Drifted seasonal human IAV strain with slightly 
changed black HA and blue NA. 
 
absence of human to human transmission shows further unknown adaptations are 
needed, making predictions almost impossible (Russell et al., 2012). The lethality of 
these pandemics can be disastrous in an immunologically naïve population. The 1918 
pandemic, which resulted from avian H1N1 is associated with well over 40 million 
deaths, making it the most lethal recorded.  (Palese et al., 2006) 
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1.1.3 Transmission 
For human to human transmission, viral shedding occurs 24-48hrs prior to 
presentation of symptoms and can last up to 10 days, with longer periods occurring in 
more susceptible populations (young, old, and immunocompromised) (Carrat et al., 
2008; Wong et al., 2010). Spreading is predominantly facilitated by droplets, with 
larger droplets (>5µm) containing significant viral loads, which are transmitted to 
others via coughing and sneezing (Bhat et al., 2005). Both small and large droplets 
facilitate the spread of the virus, with the smaller droplets (aerosols) able to remain 
suspended in the air, being the main route for airborne transmission. The larger 
droplets, which are unable to remain in the air facilitate transmission by surface 
contamination, and share transmission rate 50-50 with the smaller airborne droplets 
(Fiore et al., 2011).  
IAV is originally a wild bird disease, and thus this can be considered the main reservoir 
for emerging strains. Infection between these wild birds is direct contact with 
contaminated water, mostly leading to an asymptomatic intestinal infection (van Gils 
et al., 2007). Transmission of these viruses to domestic poultry or swine occurs via 
farming on these contaminated waters, or via species raised together without proper 
biosafety procedures (Perkins and Swayne, 2002). In swine, the disease presents as a 
respiratory disease similar in nature to IAV in humans, thus is able to be spread via the 
airborne route to humans (Vincent et al., 2014). Domestic poultry exhibit the similar 
intestinal infection as wild birds, in most cases, with transmission to humans mainly 
from direct or indirect contact.  These interspecies transmissions involve viral 
adaptations to the new host, which are usually multifactorial. Adaptations of the HA, 
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Figure 1.3 IAV transmission mechanisms from reservoir to human, and human to human (Based on work 
of Krammer et al. (2018)). Species origin of the four recorded pandemic IAV out breaks, H1N1 (1919), 
H2N2 (1957), H3N2 (1968), and H1N1 (2009).  
 
RNA polymerase, and M1 and M2 proteins either via point mutations or reassortment 
have all been suggested (Krammer et al., 2018).  
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1.1.4 Current Clinical Diagnosis, Treatment, and Vaccination 
1.1.4.1 Current Diagnosis  
For the majority of ‘flu’ cases in non-vulnerable people, the presentation of symptoms 
is enough to diagnose the infection. However, in certain situations, such as those in 
high risk individuals, or in the case of outbreaks, rapid and/or molecular test can be 
performed. These rapid tests identify the pathogen via viral antigens based on patients 
respiratory secretions, and can provide diagnosis quickly (Chu et al., 2012). These tests, 
while rapid cannot specify the strain, which is where molecular tests are utilised, with 
PCR screening able to identify both type and subtype based on multiple genetic targets 
(Kumar and Henrickson, 2012). When used in the relevant clinical circumstances, the 
information gained from PCR screening proves invaluable for disease management, 
irrespective of a greater cost and time. 
1.1.4.2 Current Treatment Approaches 
In the majority of cases, an infected immunocompetent person is able to overcome the 
infection and recover without the need for clinical interventions, with mainly just bed 
rest and fluid intake. However, in patients deemed ‘high risk’, clinical intervention 
within the first 24hrs of infection can have beneficial results.  (Harper et al., 2009) 
Currently there are four antivirals available for IAV intervention; amantadine, 
rimantadine (adamantanes), Oseltamivir, and zanamivir (NA inhibitors).  
Adamantanes target the M2 ion channel effectively limiting cellular infection, however 
due to recent rise in antiviral resistance these are no longer widely used. NA inhibitors 
target the enzyme activity of NA and were widely used during the last IAV pandemic in 
2009, (Muthuri et al., 2014) however their use for seasonal IAV, other than a symptom 
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reliever is less effective (Hsu et al., 2012b). Regardless of their limitations, these 
current treatment methodologies are still reported to improve the outcomes of 
infection. Treatment significantly reduces the risk of pneumonia, hospitalisation, and 
mortality associated with IAV disease  (Muthuri et al., 2014).  
1.1.4.3 Current Vaccination Programs  
Prevention of the disease by effective vaccination of the high-risk individuals is 
currently the most effective strategy for combating infection by seasonal IAV. 
Unfortunately the high rate of mutation in IAV leading to antigenic drift, means new 
vaccines are produced annually in an attempt to predict what strains will be in 
circulation for that season (Glezen, 2008). Live attenuated Vaccines (LAIV) is based on 
the strains B/Ann Arbor/1/1966 and A/Ann Arbor/6/1960 which are passaged at cold 
temperatures (25oC) to cold adapt them. These strains then provide the 6-segment 
backbone for the circulation HA and NA segments specified for that year. Inactivated 
vaccines, use a similar backbone for the circulating HA and NA segments, but use the 
A/Puerto Rico/8/34 strain, with inactivation by formalin after propagation (Plotkin, 
2012).  
Current vaccine programs use a combination of these vaccines based on the 
determination of circulating strains by multiple laboratories to different levels of 
success. LAIV are more effective in inducing broad immunity in the young, yet are less 
effective vaccinations for the H1N1 component (Caspard et al., 2017; Plotkin, 2012). 
Overall the success of a seasonal vaccine comes down to accurate prediction of the 
strains that will be circulating. This is evident from the vaccine success in UK, with a 
2016/2017 season vaccine effectiveness of 40%, (PHE, 2017) followed by a dramatic 
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decline in efficiency for the 2017/18 season, where the vaccine efficiency was 15% 
(PHE, 2018).  
1.1.5 Laboratory Isolation 
The isolation of IAV strains in a laboratory setting is crucial for propagation and in-
depth analysis, as well as the production of vaccines. Two techniques are mainly used, 
isolation in embryonated hen eggs or cell culture in MDCK cells. The use of these two 
methods usually comes down to a strain specific-nature, with some strains unable to 
be isolated in eggs and vice versa (Szretter et al., 2006). Embryonated hen eggs tend to 
be the preferred method, mainly due the production of higher viral titres in shorter 
times, with the absence of mammalian pathogens (Xue et al., 2016). Although there is 
still the question of how IAV strains adapted to either eggs or MDCK cells during 
isolation and propagation, change from the clinical isolates. 
1.2 IAV infection mechanisms  
IAV mainly infects and replicates in the epithelial cells of the respiratory tract, although 
infection of innate immune cells, specifically the lung resident alveolar macrophages 
(AMs) has also been observed. Infection of epithelial cells results productive virus 
infections, with the release of many infectious virions. However, macrophage infection 
tends to result in abortive replication for seasonal strains, with no virions produced. 
The exception here is the high pathogenic IAV strains where infection of macrophages 
does result in productive replication. Therefore macrophages do have all the 
machinery needed by the virus to successfully infect and replicate, however there 
appears to be blocks in place that the seasonal strains cannot overcome (Lai and 
Tamm, 2007; Londrigan et al., 2015; Marvin et al., 2017).  
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1.2.1 Attachment 
1.2.1.1 Virus receptors 
The viral HA protein is the key facilitator of viral binding to the cell surface and can be 
described as the ‘key’ IAV utilises to unlock target cells. HA is a trimer that protrudes 
from the viral envelope via a triple-stranded coiled-coil of alpha-helices stalk region, 
with a globular head of antiparallel beta-sheet (Wilson et al., 1981). This globular 
region is the receptor binding site for target cell sialic acid residues but must be 
cleaved by serine proteases into HA1 and HA2 in order to facilities infectivity. HA1 is 
where the binding and antigenic sites are located, for attachment to the host cell 
surface. HA2 mediates fusion between virus and cell membrane to facilitate vRNA 
escape from the endosome, once the virion has been internalised (Steinhauer, 1999).  
N-linked glycosylation is a post-translational modification to mammalian glycoproteins, 
where oligosaccharide side chains are attached (Larkin and Imperiali, 2011). HA has 
potential sites for these linkages both on the stalk and the globular head. Sites for the 
head vary by number and location depending on the HA type, and these attachments 
are commonly made of high mannose, complex, or hybrid type oligosaccharides 
(Reading et al., 2007). These attached glycan’s on the head of HA act as a shield against 
antibodies, or may in fact modify antigenic sites (Skehel and Wiley, 2000). Attachment 
sites on the stalk region of HA, are well conserved between IAV strains and these have 
been implicated in maintaining the stability and conformation of HA (Daniels et al., 
2003).  
 This variation in glycosylation on the head of HA between IAV strains could prove key 
in evaluating why certain strains infect immune cells and others do not (Tate et al., 
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2010), they may also play a role in the virulence of the strain. However it appears to be 
a balance between viral efficiency and HA glycosylation, as while these glycan’s are 
proposed to shield HA antigenic sites, they can interfere with HA binding of sialic acid 
(SA), and even provide recognition sites for the cells of the innate immune system 
(Londrigan et al., 2011).  
1.2.1.2  Host Receptors 
1.2.1.2.1 Receptors Found on Both Epithelial Cells and Macrophages 
Sialic Acid 
N-acetylneuraminic (Sialic) acids (SA) are nine-carbon acidic monosaccharides 
commonly found at the termini of many glycol-conjugates and are expressed in 
abundance on mammalian cells. SA is attached to underlying galactose residues via 
α(2,3)-Gal or α(2,6)-Gal linkages (Skehel and Wiley, 2000). These linkages play a crucial 
role in IAV strain dependent attachment, due to preferential specificity of HA to either 
of these linkages. Human IAV strains preferentially bind to α(2,6)-Gal linkages, due to a 
greater abundance of these linkages in human tracheal epithelium (Thompson et al., 
2006). Whereas avian strains have a preference to α(2,3)-Gal due to their abundance 
in the avian gastro-intestinal tract (Suzuki et al., 2000).  
SA has been proved to play an important role in promoting IAV infection in both 
epithelial cells and immune cells (Reading et al., 2000) in a variety of species including 
human and murine (Londrigan et al., 2011). However it appears IAV infection can occur 
independently of SA, with desialylated cells still susceptible to IAV entry (Stray et al., 
2000; Thompson et al., 2006). In immune cells, SA expression alone may not be 
sufficient to mediate IAV entry, but also require N-linked glycoproteins (Chu and 
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Whittaker, 2004). Therefore, in immune cells SA may act to enhance and concentrate 
IAV to the cell surface, allowing increased interactions with secondary or co-receptors 
that are required for IAV entry. This interaction with secondary or co-receptors may 
play a greater role in IAV infection in immune cells, specifically macrophages over 
epithelial cells due to the increased expression of phagocytosis receptors that may act 
as these secondary of co-receptors.  
 Major histocompatibility complex (MHC) class II 
The MHC class II receptors are involved in antigen presentation to T-cells, with their 
expression limited to macrophages, DCs, and B cells (possibly endothelial cells). MHC 
class II binds to peptides derived from phagocytosed antigens that are processed by 
lysosome-like antigen-processing compartments (Berger and Roche, 2009). Currently 
MHC class II has not been reported to be actively involved with human IAV binding, 
however has recently been shown to bind bat IAV (Karakus et al., 2019). Here the MHC 
class II human leukocyte antigens (HLA) DR, DQ, and DP provide susceptibility of 
various epithelial cell lines, including human lung epithelia to Bat IAV. Moreover, MHC 
class II HLA DR from multiple species, including humans can bind bat IAV, and facilitate 
uptake independently of sialic acid, with bat IAV HA unable to bind to sialic acid. This 
hijacking of the MHC class II molecule of various species, may add another zoonotic 
route for cross-species transmission of IAV into humans. However the distribution and 
transmission of bat IAV are not fully understood, but from this new finding, the lack of 
bat IAV infecting humans so far might be due solely to lack of opportunity (Barclay, 
2019). Moreover, while MHC class II has not been seen to be utilised by human IAV for 
binding and entry, it is entirely feasible that it may play a similar role to DC-SIGN in 
‘passing’ virions to neighbouring cells, as discussed further on.  
 
43 
 
Platelet-derived growth factor receptor β (PDGFRβ) 
The PDGFRβ (CD140b) is a transmembrane receptor tyrosine kinase, which recognises 
platelet-derived growth factor, which is a mitogen and chemoattractant of vascular 
smooth muscle cells (He et al., 2015). This receptor, expressed on a variety of immune 
and non-immune cells, has recently been shown to be involved in IAV internalisation in 
human airway epithelial cells. Cell surface glycan sialic acid bound anchors IAV, which 
is then drawn towards GM3 ganglioside-positive lipid rafts, activating PDGFRβ, 
facilitating uptake (Vrijens et al., 2019).  
1.2.1.2.2 Macrophage specific receptors 
Macrophage Mannose Receptor (MMR) 
MMR (CD206) is a mannose specific C-type lectin receptor (CLR) with specificity for D-
mannose, N-acetyl-D-glucosamine and L-fucose (Pontow et al., 1992). MMR has been 
detected on human AMs (Stephenson and Shepherd, 1987) and is implicated in 
bacterial and viral recognition, however with viral interactions, it is not clear if MMR is 
directly involved in endocytosis or by promoting binding to a second receptor. The 
receptor alone does not appear to give SA-independent uptake of IAV, in fact SA-HA 
interaction is a pre-requisite for the interaction of host MMR and viral N-linked 
glycan’s in murine macrophages. (Reading et al., 2000; Upham et al., 2010).  
Macrophage Galactose-type Lectin (MGL) 
MGL is another CLR transmembrane protein implicated in IAV uptake, however there 
are two isoforms in mice, which are structurally similar, but have different specificity 
(Tsuiji et al., 2002). MGL-1 has specific interactions with terminal galactose, Lewis-X 
structures, and terminal GalNAc residues; MGL-2 on the other hand only binds to 
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GalNAc residues (Singh et al., 2009). MGL has been found on a variety of macrophage 
types, however it has not been found in tissue-specific macrophages, like AMs. 
However inhibiting this receptor in murine macrophages that do express this receptor 
shows a reduction in IAV infected in those cells (Sato et al., 2005; Upham et al., 2010). 
Whether these results can be replicated in more relevant models that may not express 
this receptor will determine if MGL is a significant co-receptor in IAV entry in 
macrophages. 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-
SIGN) 
DC-SIGN (CD209) is a CLR with specific activity towards high mannose and fuctosylated 
oligosaccharides (Guo et al., 2004; Mitchell et al., 2001). DC-SIGN has been shown to 
be highly expressed on macrophages, including AMs, (Soilleux et al., 2002) and has 
already been determined as having a role in cell adhesion, pattern recognition, and 
uptake of various bacteria (Khoo et al., 2008). The role of DC-SIGN in IAV infection has 
been studied little, which little knowledge on its use in AMs. In Humans high 
pathogenic IAV strains like H5N1 are able to bind to DC-SIGN and cells expressing this 
receptor ‘pass’ virus particles to other cells (Wang et al., 2008). This suggests that high 
pathogenic IAV strains may use DC-SIGN to infect neighbouring cells, whether this is 
also something applicable to seasonal IAV strains is yet to be determined. DC-SIGN 
enables IAV strains that have defective HA binding to replicate effectively, without the 
need for HA-SA binding (Hillaire et al., 2013). DC-SIGN could prove not only to act as a 
co-receptor with SA for facilitation of IAV infection but may act independently of SA. 
Macrophage Receptor with Collagenous Structure (MARCO) 
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MARCO (SR-A6) is expressed constitutively only on only some subsets of macrophages 
but not all (Bowdish and Gordon, 2009), this includes AM’s (Arredouani et al., 2004). 
MARCO has been implicated in bacterial pathogen uptake and clearance (Arredouani 
et al., 2004) as well as in adenovirus entry and pathogenesis in AMs, (Maler et al., 
2017; Stichling et al., 2018) and may also play a role in IAV entry. There has been little 
work looking at the role of this receptor in IAV pathogenesis and entry, however what 
has been done shows the presence of MARCO increases mortality rate and IAV 
replication but reduces the induction of pro-inflammatory cytokines in mice (Ghosh et 
al., 2011). This may be that that MARCO is a key regulator in IAV infection and acts to 
reduce an early inflammatory response, which aids viral clearance and recovery from 
infection. The role of MARCO in IAV entry cannot be fully determined and may have a 
hidden role which is not yet understood. 
1.2.2 Endosomal Uptake and Release 
1.2.2.1 Endosomal Uptake 
Immediately following attachment of the virus to the cell surface, entry into the 
cellular endosomal compartments begins. This uptake occurs via two separate 
mechanisms; (Figure 1.4) clathrin-dependent endocytosis and micropinocytosis (de 
Vries et al., 2011). Clathrin-dependent endocytosis occurs at specialised sites, where 
the ‘coated pit’ containing clathrin, adaptor protein-2 is assembled. The interactions of 
these proteins at the site, causes clathrin to form flat hexagonal lattices and closed 
polyhedrons that surround the vesicle in a basket like structure. These coated pits then 
invaginate, and pinch off from the cell membrane in a dynamin-dependent 
mechanism, resulting in a clathrin coated vesicle (Mousavi et al., 2004). The uncoating 
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of this vesicle by cofactors like auxilin facilitate the shedding of this clathrin coat and 
transmission to the early endosome (Lemmon, 2001).  
Macropinocytosis occurs via external stimulation, triggering receptor tyrosine kinase 
activation (Mercer and Helenius, 2009). This results in activation of actin and 
microfilaments in contact with the plasma membrane, via GTPases and kinases, 
leading to membrane ruffling. These ruffles form planar folds (lamellipodia), circular 
cup-shaped extensions (circular ruffles), and large extrusions (blebs), these protrusions 
then close via a single fission event forming the macropinosome. The dynamic nature 
of these membrane extensions provides both the energy and membrane for endocytic 
vacuoles. After the uptake of the virus, the membrane protrusions and ruffles then 
disappear back into the plasma membrane.(Mercer and Helenius, 2009) 
For IAV uptake in epithelial cells these two mechanisms act together to facilitate 
infection, with a loss of one unable to remove infection (de Vries et al., 2011; Sun et 
al., 2013). However, if this is the same or if these are even the main mechanisms in 
macrophages is not fully known. 
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Figure 1.4 Summary of the currently accepted mechanisms for IAV endosomal uptake (Based on work of 
Mayor et al. (2014)). Macropinocytosis (visualised as planar fold mechanism for simplicity) and 
dynamin-dependent endocytosis both allow for uptake of IAV to the early endosome. 
k 
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1.2.2.2 Endosomal Release 
Viral escape from the endosome is crucial to avoid destruction in the late endosome, 
and the acidity of the compartment triggers this. Initially the lowering of endosomal 
pH causes a conformational change in the viral HA, allowing it to fuse to the endosome 
membrane. This creates a pore from the inner viral core, through endosome 
membrane, to the cell cytoplasm, by which the viral RNP can escape (Sieczkarski and 
Whittaker, 2005). Moreover, the viral M2 ion channel moves hydrogen ions from the 
endosomal compartment, into the virion. This acidification of the virion affects internal 
protein-protein interactions, which allows the release of the viral RNPs from the viral 
core, out into the cellular cytoplasm (Martin and Helenius, 1991). It is this aspect of the 
viral cycle that the amantadine antivirals target, in order to prevent infection. The pH 
of the endosome that facilitates the HA changes, is not universal across IAV strains, 
some strains requiring more acidic environments than others. If these levels are not 
reached, viral RNPs and not released and there is a poor level of infectivity (Marvin et 
al., 2017).  
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Figure 1.5 Visualisation of IAV endosomal escape mechanisms 1. Endosomal and virion acidification. 2. 
Fusion and vRNP escape. (Based on the work of Skehel and Wiley (2000)) 
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1.2.3 RNA and Protein Synthesis 
1.2.3.1 RNA synthesis 
Following release from the endosome, the viral RNPs move to the host cell nucleus 
following nuclear localisation signals (NLSs) from viral proteins. These signals cause 
host cell proteins to import the viral RNPs and proteins into the nucleus (Cros and 
Palese, 2003). Within the nucleus is where all viral RNA synthesis occurs, both mRNA 
acting as the template for protein translation, and cRNA which acts as the template for 
more copies of genomic vRNA (Bouvier and Palese, 2008). The viral mRNA is 
polyadenylated via the viral polymerase transcribing its poly(A) tail from uracil residues 
to adenosines (Luo et al., 1991). Capping also occurs to the viral mRNA here, with the 
viral PB1 and PB2 proteins ‘stealing’ 5’ capping primers from host pre-mRNA to initiate 
viral mRNA synthesis, in a process dubbed ‘cap snatching’ (Krug, 1981). Finally, viral 
mRNA is exported and translated just like host mRNA, however the viral protein M1 
interferes to bring genomic vRNA and NP together to from the RNP complex. This 
complex is exported via the nucleoporins into the cytoplasm via the viral NEP-NS2 
protein (Cros and Palese, 2003).  
1.2.3.1.1 Protein synthesis 
With both the RNP complex and mRNA now in the host cell cytoplasm, the translation 
of viral proteins can commence via endoplasmic reticulum bound ribosomes reading 
the mRNA. HA, NA, and M2 proteins for the viral envelope are all synthesised and 
transported to the Golgi for post-translational modification. These proteins have apical 
sorting signals, which they then follow to the cell membrane, for virion assembly 
(Bouvier and Palese, 2008). Non-envelope protein translation and trafficking is less 
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well understood, but the M1 protein interacts with the RNP-NEP complex, bringing it 
into contact with the other viral proteins at the host cell membrane (Lamb, 1996).  
1.2.4 Viral packaging and Release 
All eight segments of the IAV genome must be present in the virion to yield a fully 
infectious virus. To ensure the greatest efficiency in infectious virion production, there 
are ‘packaging signals’ on all genome segments to confirm the full genome is 
incorporated into as many virions as possible.(Fujii et al., 2003) The budding of the 
new virion occurs at the cell membrane with viral envelope proteins protruding, and a 
build-up of the M1 matrix under the bi-lipid layer. Even after this budding is complete, 
the new virions remain attached to the host cell surface via HA-SA interaction. The 
sialidase activity of the viral NA protein is required to cleave the terminal SA residues 
from the cell surface receptors (Bouvier and Palese, 2008). This allows the daughter 
virions to escape the infected cell to go on to infect neighbouring cells, thus enhancing 
the replication of the virus and the progression of the disease. The NA protein also acts 
to remove SA residues from the viral envelope itself following the budding process. 
This is key in preventing the clumping of multiple virions, thus enhancing infectivity 
(Palese and Compans, 1976). It is possible that NA enhances viral infectivity via 
additional mechanisms, as it is thought to break down muscins in respiratory tract 
secretions, causing better penetration of the virus into the respiratory epithelium 
(Matrosovich et al., 2004).  
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Figure 1.6 IAV infection cycle of productive replication. 1. Binding. 2. Entry. 3. Endosome formation. 4. 
Endosome escape. 5. RNA synthesis. 6. Proteins synthesis. 7. Virion assembly. 8. Budding and release. 
(Based on work of Krammer et al. (2018)) 
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1.3 Innate immune responses to IAV 
1.3.1 Cells of the innate immune system involved  
1.3.1.1 Respiratory epithelial cells 
The epithelial cells lining the respiratory tract are the prime target of IAV infection, 
resulting in the release of great numbers of infectious virions. The epithelial cells in the 
lung are of two types, firstly the Type I epithelial cells that are thin and low in number 
involved in gas exchange (Wang et al., 2018b). Secondly the Type II epithelial cells, 
which are cuboidal in shape, make up 60% of all lung epithelial cells, and contain the 
secretory organelles that secrete pulmonary surfactant to lubricate the airways 
(Castranova et al., 1988). These Type II epithelial cells produce antiviral type I IFNs in 
response to this infection, in an attempt to limit the initial infection (Gerlach et al., 
2013; Hsu et al., 2012a; Pulendran and Maddur, 2015). Moreover the production of a 
variety of pro-inflammatory cytokines and innate immune cell recruiting chemokines , 
such as IL-6, TNF-α, IL-8, IP-10, and RANTES also occurs in the epithelial cells of the 
respiratory lining (Pulendran and Maddur, 2015).  
1.3.1.2 Neutrophils  
Neutrophils are one of the first cells to arrive at the infection site, apart from the tissue 
resident macrophages, and therefore are in the first line of cellular defence against 
respiratory pathogens such as IAV. Neutrophils themselves are not infected by IAV, but 
they do phagocytose the virus, effectively controlling both the replication and spread 
(Brandes et al., 2013; Fujisawa, 2001; Tate et al., 2011b). This effect is enhanced by the 
identification, uptake, and destruction of other IAV infected cells by the recruited 
neutrophils (Hashimoto et al., 2007). While these cells have been seen to accumulate 
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in great numbers and have significant impact on the course of the infection, the exact 
mechanisms of anti-viral immunity still need further study. 
1.3.1.3 Monocytes 
Monocyte subsets reside in the blood, made up of three identified groups; Classical 
(CD14++CD16-), intermediate (CD14++CD16+), and patrolling (CD14lowCD16++) (Ziegler-
Heitbrock et al., 2010).  Numbers of monocytes increase with IAV infection, both at the 
site of infection and in the peripheral blood, mediated by type I IFN and chemokine 
production (Oshansky et al., 2014). Monocytes themselves are infected by IAV, but 
results in an inhibited response to monocyte attracting chemokines (MCP-2 and MCP) 
via receptor downregulation (Brandes et al., 2013). Whether this is a result of viral 
modification of the immune response to prevent influx, or the way the cells persist at 
the site of infection is debatable.  
Upon influx to the infected tissues, monocytes themselves differentiate into monocyte 
derived macrophages or dendritic cells, depending on the factors encountered. TNF-α 
and GM-CSF cause the rapid transformation of dendritic cells, while M-CSF and GM-
CSF result in macrophages (Cao et al., 2012; Sander et al., 2017). The regulation of 
these monocytes is crucial in not only resolving the infection, but absolving the 
inflammatory response once it is cleared, leading to tissue repair. 
1.3.1.4 Dendritic cells 
Dendritic cells (DCs) are widely distributed throughout the body, but in relatively low 
numbers, split into conventional or myeloid DCs (CD11chi) (cDC)and plasmacytoid DCs 
(CD11clo) (pDC) (Guilliams et al., 2013b; Yu et al., 2013a). In the non-infectious 
environment, conventional DCs line the epithelial layer, with long dendrites extended 
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into the airway, with additional conventional and plasmacytoid DCs under the 
epithelial layer in the lamina propria. With IAV infection, additional DCs, inflammatory 
DCs (Inf-DC) differentiated from monocytes are recruited to the inflammation site to 
aid in antigen presentation (Guilliams et al., 2013b). The phenotypes of each of these 
subsets are characterised differently in mice and humans, based on key surface 
receptors (Table 1.2) (Wylie et al., 2019) DCs are susceptible to IAV infection, that yield 
productive replication, but to differing levels within each subtype. DCs are important in 
the production of pro-inflammatory cytokines IL-6, TNF-α, and MCP-2 and type I IFNs 
(pDCs), as wells key inducers of adaptive immune responses, via antigen presentation 
leading to viral clearance (cDCs and Inf-DCs) (Pulendran and Maddur, 2015).  
Table 1.2 Phenotype markers of DC subsets in humans and mice. 
 Mouse Human 
pDC CD45R, CD45RA, CD3117 CD123, CD303, CD304, CD45RA 
cDC1 CD8α or CD103, DEC205, 
Clec9A, XCR1 
CD141, DEC205, Clec9A, XCR1 
cDC2 CD11b, Sirpα CD1c, CD1a (skin), CD103 (mucosa) 
Inf-DC F4/80, Ly6C, CS64, FcεR1 CD1c, CD1a, FcεR1, CD14, CD206 
 
1.3.1.5 Natural Killer cells 
Natural killer cells possess unique natural cytotoxicity receptor, (NKp46 and NKp30 in 
humans, and NCR1 in mice), involved in viral recognition, which activate the cell (Jost 
and Altfeld, 2013).  Specifically, with IAV the NCR1 in mice and NKp46/NKp44 in 
humans recognise HA. While IAV productively infects these cells, their main function in 
the innate immune response is detecting and lysing IAV infected cells, via granzyme B 
and perforin, thereby controlling the infection (Hwang et al., 2012). Natural killer cells 
are able to recognise the viral HA protein, protruding from the infected cell 
membrane, during virion assembly (Draghi et al., 2007). IFN-α,  MIP-1a, MIP-1b and 
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RANTES are produced as a result of IAV detecting by natural killer cells, however both 
this and the killing ability are diminished upon infection of the natural killer cells 
themselves (Guo et al., 2009; Mao et al., 2010). These two aspects of NK response are 
related to two separate subsets of NK cells, with CD56dim subsets being the more 
cytotoxic and the CD56bright producing greater amounts of cytokines (Cooper et al., 
2001). 
1.3.1.6 Macrophages 
Both tissue resident alveolar macrophages (AMs) and the recruited monocyte derived 
macrophages are involved in the IAV induced innate immune response. AMs are the 
initial responders to IAV but are soon outnumbered by the migrating monocytes which 
differentiate into macrophages (Herold et al., 2008). Macrophages, due to their 
phagocytosis ability, are key in the clearance of IAV infected cells, as well as ‘mopping’ 
up virions, due to their resistance to productive infection with seasonal strains 
(Londrigan et al., 2015; Watanabe et al., 2005). Macrophages are also key regulators 
for both the innate and adaptive immune responses, with significant levels of IP-10, 
TNF-α, IL-1β, IL-6, RANTES, MIP-1α, and type I IFNs produced (Cheung et al., 2002; 
Zhou et al., 2006). Further details of macrophages are discussed in 1.4 
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Figure 1.7 Summary of the interactions between cells of the innate immune system during IAV infection 
(Based on work of Cole and Ho (2017)) 1. Shows the early phase of the innate immune response by the 
lung surveillance cells. 2. Shows the late phase of the innate immune response with the infiltrating 
innate immune cells from blood vessels. Dashed arrows show the actions of effector molecules, solid 
arrows show the production of effector molecules. 
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1.3.2 Viral immune recognition 
IAV is sensed by a variety of pattern-recognition receptors (PRRs) that detect specific 
pathogen associated molecular patterns (PAMPs) present in the virus, or damage 
associated molecular patterns (DAMPs) generated by the infection. There are a variety 
of PRRs on the cells of the innate immune system, which tailor the innate immune 
response to the type of pathogen encountered. The specific PRRs associated with IAV, 
and how they activate the innate immune response are discussed below.  
1.3.2.1 C-type lectins 
C-type lectin receptors (CLRs) are transmembrane proteins which contain at least one 
carbohydrate recognition domain, expressed mainly on monocytes, macrophages, and 
dendritic cells. As mentioned in 1.2.1.2 CLR’s that recognise mannose and galactose on 
the viral HA stalk region have been observed to play a role in IAV entry in macrophages 
(Khoo et al., 2008; Reading et al., 2000; Reading et al., 2007; Tate et al., 2014; Upham 
et al., 2010). However these receptors (MGL, MMR, and DC-SIGN) are also believed to 
be involved in antigen processing and presentation to other PRRs and the adaptive 
immune system (Geijtenbeek and Gringhuis, 2009; Sancho and Reis e Sousa, 2012). 
Direct activation of the immune response by these three CLRs in response to IAV has 
currently not been identified, however the signalling pathways other CLRs sensing a 
range of bacteria, fungi, and viruses, have been described (Hoving et al., 2014). Other 
CLRs, such as Dectin-1 and Mincle have been shown to signal via immunoreceptor 
tyrosine-based activating motifs (ITAMs) leading to MAPK and NF-κB activation (Del 
Fresno et al., 2018). Therefore, it is feasible the specific CLRs involved with IAV 
recognition may directly activate immune signalling via similar mechanisms. 
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1.3.2.2 Platelet-derived growth factor receptor β (PDGFRβ) 
PDGFRβ has been recently identified as an IAV entry receptor, but moreover viral 
uptake using the mechanism, results in raf/MEK/ERK signalling.  This suggests that 
while IAV utilises this receptor for more efficient cellular entry, it also activates an 
immune response in the host cell, giving an opportunity for an antiviral response 
(Vrijens et al., 2019). However, this novel sensing mechanism has only been shown in 
epithelial cells, not innate immune cells.  
1.3.2.3 Toll-like Receptors 
Of the 13 identified toll-like receptors (TLRs), only 10 are found functionally in humans, 
and 9 in mice (Kawai and Akira, 2010). Of these, only four have been implicated in IAV 
sensing, TLR-3, TLR-7/8, and TLR-4. 
1.3.2.3.1 TLR-3 
TLR-3 is an endosomal membrane bound receptor that is expressed in macrophages, 
and some subsets of DCs (Kadowaki et al., 2001). TLR-3 senses dsRNA in the 
endosome, signalling via the adaptor molecule TRIF to activate NF-kB and IRF3 
transcription factors to upregulate genes for pro-inflammatory cytokines and type-I 
IFN respectively (Pulendran and Maddur, 2015). However it is important to note that 
due to the cellular RNA helicase UAP56, which allows for viral mRNA nuclear export 
dsRNA is not produced in detectable quantities with IAV infection (Wisskirchen et al., 
2011). Whether there is a separate PAMP stimulating TLR-3, or in fact dsRNA is 
produced, with studies unable to detect it is currently unknown. What is clear is that 
TLR-3 is important for resolving the infection, playing a role in viral clearance and 
inhibiting viral spread, thus improving the disease outcome (Le Goffic et al., 2006).  
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1.3.2.3.2 TLR-7/8 
TLR-7 and 8 are both endosomal-membrane bound receptors, expressed in 
macrophages, and certain DC subsets. Both of these receptors sense ssRNA, and signal 
via myd88, hence why they are often grouped together in analyses. Activation of this 
signal pathway leads to the secretion of pro-inflammatory cytokines and type I IFNs via 
NF-kB and IRF7 respectively. However IFN-α secretion, at least in dendritic cells, has 
been shown to be independent of TLR-7/myd88 signalling (Koyama et al., 2007). 
Mature IL-1β secretion however was seen to require TRL-7 signalling (Ichinohe et al., 
2010). The exact role of TLR-7 in IAV infection is still debated, with some studies 
showing a role for controlling viral load and mortality (Seo et al., 2010), whereas other 
studies have shown TLR-7 is dispensable in controlling the viral load and disease 
pathology (Jeisy-Scott et al., 2012; Pang et al., 2013). All of this suggests a cell-specific 
role for TLR-7, as there are limited studies in macrophages; the exact role needs to be 
clarified. 
1.3.2.3.3 TLR-4 
TLR-4 is a membrane bound TLR expressed on neutrophils, monocytes, DCs, and 
macrophages that mainly sense LPS. TLR-4 utilises both mydd88 and TRIF adaptor 
molecules to activate NF-kB and IRF3 respectively to secrete IL-6, TNF-α, pro-IL-1β, IL-
18 and type I IFNs (Pulendran and Maddur, 2015). As IAV does not possess LPS as a 
PAMP, TLR-4 is instead activated by the DAMP; S100A9 that is released upon IAV 
infection (Tsai et al., 2014). S100A9 is a calcium binding protein which is released by 
neutrophils, monocytes, and macrophages during inflammation (Wang et al., 2018a). 
In IAV infection S100A9 release by infected  macrophages binds TLR-4, which activates 
the myd88 dependent pathway to exaggerate the innate immune response, cell death, 
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and viral pathogenesis (Tsai et al., 2014). This suggests that TLR-4 activation may be 
important in the creation of the ‘cytokine storm’ and increased cellular damage to the 
mucosal membranes of the lung airways by extended inflammation. Therefore, the 
TLR-4 receptor or SA100A9 may both be good targets for controlling the disease state 
(Shirey et al., 2013).  
1.3.2.4 RIG-I like receptors 
RIG-I like receptors (RLRs) are cytosolic receptors that sense RNA that are found in 
most mammalian cells. RLRs represent a set of RNA helicases, RIG-I, Melanoma 
Differentiation-Associated Gene 5 (MDA5) and Laboratory of Genetics and Physiology-
2 (LGP-2). All of these receptors have the RNA helicase domain, with RIG-1 and MDA5 
also having two N-terminal caspase activation and recruitment domains (CARDs). LGP-
2 lacks a CARD domain, and instead functions as a negative regulator of the other two 
(Loo and Gale, 2011). RIG-I recognises ssRNA with 5’- triphosphate with secondary 
panhandle-like structures, whereas MDA5 senses longer dsRNA (Takeuchi and Akira, 
2009). Both RLRs signal the adaptor protein, IFN-β promoter stiumlaror-1 (IPS-1), 
which is more commonly referred to as mitochondrial antiviral signalling (MAVS). 
Activation of this pathway, ultimately leads to the activation of NF-kB and IRF3/7 
transcription factors, which induce mature forms ofIL-1β and IL-18 (NF-κB) and type I 
IFNs (IRF3/7) respectively (Loo and Gale, 2011).  
RIG-I is the predominant IAV PRR in the infected cell cytosol, and although it is 
expressed in low levels, pre-infection, is greatly upregulated during infection as a result 
of type I IFN (Loo and Gale, 2011). Activation of RIG-I by IAV occurs after viral 
replication within the cells, during the transport from the host nucleus to the budding 
site (Rehwinkel et al., 2010). RIG-1 activation restricts and controls virus replication in 
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lethal doses, acting as important control mechanism for the infection, however at sub-
lethal IAV doses RIG-I signalling is less crucial for control (Koyama et al., 2007). 
Regardless, RIG-I is a key receptor in the induction of the innate immune response to 
IAV, leading to the production of type I IFNs, IL-6, TNF-α, IL-1β, and IL-18 (Guo and 
Thomas, 2017). 
MDA5 due to the sensing of dsRNA, which is not produced in IAV infected cells at 
detectable quantities, has a limited role during IAV infection. However MDA5 is 
believed to play some type of role in the production of IFN-β, but to a much lower 
extent than RIG-I. MDA5 is theorised to act as a redundancy mechanism for RIG-I, or 
may have an undefined PAMP in the sensing process (Kato et al., 2006).  
1.3.2.5 NOD-like receptors 
NOD-like receptors (NLRs) are a group of over 20 receptors, which are expressed in the 
cytosol of cells. NLRP3 (NLR family PYD-containing protein 3/Cryopyrin), NLRC2/NOD2 
(NLR family CARD-containing protein 2), and NLRX1 have all been shown to respond to 
IAV PAMPS (Kanneganti, 2010).  
NLRP3; in epithelial cells, macrophages, monocytes, some DC subsets and possibly 
neutrophils, requires a two-step activation to result in IL-18 and IL-1β production 
(Pulendran and Maddur, 2015). The first signal is provided by ssRNA sensing of TLR-7 
activation NF-kB which upregulates genes for NLRP3, pro-IL-18, and pro-IL-1β (Allen et 
al., 2009). The second signal requires the activation of NLRP3, but how this is achieved 
in IAV infections is not fully understood. Initially NLRP3 was believed to sense viral 
RNA, (Allen et al., 2009) however it is now more accepted that activation is a result of 
newly synthesised viral proteins.  
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Viral M2 synthesis results in multiple changes within the host cell, such as; ionic 
imbalance of the trans-Golgi pH, potassium efflux through the P2X7 receptor, 
maturation/release of cathepsin B, and cellular reactive oxygen species (Ichinohe et 
al., 2010; Lietzen et al., 2011). These signals act alone or in combination to activate 
NLRP3.  Moreover, the viral protein PB1-F2 is also able to activate NLRP3 alone 
(Ichinohe et al., 2010). While the exact mechanism of the secondary signal is complex, 
and the NLRP3 IAV PAMP is not specifically identified, both signals are crucial to 
cellular production of mature IL-18 and IL-1β. Therefore NLRP3 activation is required 
for; late IAV infection control, mediating other innate immune responses, and possibly 
mediating protective immunity via the adaptive response (Allen et al., 2009; Ichinohe 
et al., 2010).  
NLRC2/NOD2 and NLRX1, expressed intracellularly in macrophages and DCs are 
believed to act as negative regulators of NLRP3 and RIG-1 induced immunity (Allen et 
al., 2011; Lupfer et al., 2014). NOD2 recognises viral genomic ssRNA and recruits MAVS 
to activate IRF3-mediated type I IFN production (Pulendran and Maddur, 2015). NLRX1 
is located in the mitochondria and is activated by the viral protein PB-F2. This 
activation prevents IAV induced apoptosis and promotes survival in macrophages 
(Jaworska et al., 2014). This differential role of these NLRs allows for a finely balanced 
response to IAV infection, a balance that if pushed too far in either direction, can have 
disastrous consequences for the host. 
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Figure 1.8 Summary of implicated IAV PRRs, their PAMPs and resulting signalling pathways  (Based on 
work of Pulendran and Maddur (2015))  
Black rectangles with indents represent PRRs (TLR-7, TLR-8, TLR-3, TLR-4, NOD2, NLRP3, RIG-I).  
Coloured rectangles adjacent to PRRs represent adaptor proteins (Myd88 - Myeloid differentiation 
primary response 88, TRIF - TIR-domain-containing adapter-inducing interferon-β, CARD9 - TIR-domain-
containing adapter-inducing interferon-β, CASPASE-1 - cysteine-aspartic protease, DHX29 - DExH-box 
helicase).  
Coloured ovals represent secondary adaptor proteins (TRAF6 - Tumour necrosis factor receptor-
associated factor 6, TRAF3 - Tumour necrosis factor receptor-associated factor 3, MAVS - Mitochondrial 
antiviral-signalling protein) 
Coloured squares represent kinases (Ikkα - Inhibitor of nuclear factor kappa-B kinase subunit alpha, 
IKKβ - Inhibitor of nuclear factor kappa-B kinase subunit beta, IKKε - Inhibitor of nuclear factor kappa-B 
kinase subunit epsilon, p38 – Protein 38, ERK - extracellular signal regulated kinase, JNK - Jun-N-terminal 
kinase, RIP2 - Raf1-activated mitogen-activated protein kinase kinase, TBK1 - TANK Binding Kinase 1). 
Coloured circles represent transcription factors (IRF7 - interferon regulatory factor 7, IRF3 - interferon 
regulatory factor 3, NF-κB - Nuclear Factor kappa-light-chain-enhancer, AP-1 - Activator protein 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
1.3.2.6 Mitogen-Activated Protein Kinases (MAPKs) 
MAPKs are considered some of the more crucial signal transducers involved in 
converting PRR sensing into cellular activation and various immune responses (Dong et 
al., 2002). Activation of these kinases occurs via dual phosphorylation on threonine 
and tyrosine mediated by MAP kinase kinases (MEKs) (Garrington and Johnson, 1999). 
Activation of the extracellular signal regulated kinase (ERK), Jun-N-terminal kinase 
(JNK) and p38 have all be observed with RNA virus infections, specifically IAV (Kujime 
et al., 2000; Ludwig et al., 2001; Pleschka et al., 2001) allowing different tailoring of the 
host cell immune response to the infection.  
The JNK pathway of activation by IAV is believed to be a key mediator in IFN induction, 
due to the resulting early activation of AP-1 transcription factor (Karin et al., 1997). In 
IAV infection, JNK activation requires the productive replication of IAV leading the 
build-up of vRNA (Maniatis et al., 1998) Activation of ERK via IAV infection also 
requires productive viral replication and accumulation of vRNA, however is beneficial 
to the infecting virus (Pleschka et al., 2001). ERK activation appears to actively 
promote viral growth, by controlling the nuclear export of vRNPs from the nucleus 
(Pleschka et al., 2001). Lastly p38 activation in IAV infection appears to have the role of 
promoting RANTES and TNF-α, both playing key roles in immune cell chemoattraction 
as detailed below (Kujime et al., 2000; Lee et al., 2005b). 
The exact role of MAPKs in IAV infection is not fully understood, with little know about 
the early effects in the infection. This makes them key factors to study in furthering the 
understanding of the host-viral interactions, leading to viral sensing and either viral 
killing or survival.  
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1.3.3 Effector molecules 
1.3.3.1 Cytokines  
Cytokines are key modulators of inflammation, with multiple types secreted by 
different immune cells. Individual cytokines have different effects based on the nature 
of the immune response, and even have different roles based on location and cell type. 
Moreover, individual cytokines can have pleiotropic effects, with both IL-6 and IL-18 
being shown to play roles in both inflammation progression and resolution/tissue 
repair (McInnes et al., 2000; Van Snick, 1990). The combination or lack of certain 
cytokines can also tailor the innate immune response, with different factors required 
to both recruit and activate immune cells, as wells as provide regulation (Hartmann et 
al., 2014; Tisoncik et al., 2012). The major pro-inflammatory cytokines are IL-6, TNF-α, 
and IL-1, all of which signal via structurally divergent type one cytokine receptors. 
1.3.3.1.1 IL-6 
IL-6 (interleukin-6) is produced by a wide range of immune cells, with macrophages 
being one of the most important sources (Akira et al., 1993). IL-6 has a role in 
activation of the adaptive immune system via; B-cell maturation and T-cell 
activation/differentiation. But possibly the most important role is the induction of 
acute phase proteins by hepatocytes. Other than these pro-inflammatory effects, IL-6 
also mediates anti-inflammatory effects, by terminating the up-regulatory cascade by 
which IL-1 and TNFα induce each other (Borish and Steinke, 2003).  
IL-6 exerts its effects via the membrane bound IL-6 receptor (IL-6R), which is expressed 
on lymphocytes and hepatocytes, or soluble IL-6R found in serum, both which signal 
via the membrane glycoprotein gp130 (Scheller et al., 2011). Signalling via the 
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membrane bound receptor is termed ‘classical signalling’ while signalling via the 
soluble receptor is termed ‘trans signalling’ (Tanaka et al., 2014). These different 
signalling mechanisms are believed to explain the pleiotropy of IL-6; whereby classical 
signalling results in anti-inflammatory effects and trans-signalling results in pro-
inflammatory ones (Su et al., 2017). IL-6 signalling utilises the JAK-STAT pathway 
leading to STAT3 phosphorylation, which upregulates specific IL-6 inducible genes. 
(Turner et al., 2014)  
In the specific context of IAV lung infection IL-6 appears to exert this pleotropic effect, 
with both pro- and anti-inflammatory effects.  Pro-inflammatory effects of IL-6 
enhance macrophage recruitment and phagocytic activities, both shown to be reduced 
in IL-6 deficient mice (Yang et al., 2017). Yet IL-6 also exhibits anti-inflammatory effects 
by regulating T-cell responses, resolving inflammation, tissue repair, and preventing 
viral induced apoptosis (Lauder et al., 2013). These multiple effects of IL-6 on various 
cell types implicate it as a key cytokine in generating the ‘cytokine storm’ associated 
with severe disease, with over expression having multiple negative consequences 
ranging from the survival of infected cells to the over-recruitment of macrophages 
(Velazquez-Salinas et al., 2019).  
1.3.3.1.2 TNF-α 
TNF-α (tumour necrosis factor-α) is produced from mononuclear phagocytes as from a 
wide range of stimuli, with the most potent being LPS (Beutler and Cerami, 1989). 
Initially TNF-α is produced bound to the cell membrane as a precursor form. Soluble 
TNF-α is then released via the cleavage of this precursor by the TNF-α converting 
enzyme (TACE or ADAM17), which belongs to the adamalysin family of metzincin 
metalloproteinases ((Black et al., 1997)). TNF-α has direct cytotoxic effects on tumour 
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cells as well as interacting with the endothelium to cause adhesion molecule 
production. Intracellular adhesion molecule (ICAM)–1, vascular cell adhesion molecule 
(VCAM)–1, and E-selectin all allow the influx of granulocytes to the inflammatory site. 
Furthermore, TNF-α also activates neutrophils, and induces vascular leakage further 
facilitating the migration and thus enhancing inflammation (Borish and Steinke, 2003).  
TNF-α signalling occurs via two receptors; TNFR1 and TNFR2 with TNFR1 expressed on 
a wide array of cells, and TNFR2 expression is more restricted, to myeloid cells, 
regulatory T-cells, glial cells, endothelial cell, epithelial cells, fibroblasts and certain T- 
and B-cell subsets (Medler and Wajant, 2019). Signalling of both receptors utilised the 
adaptor molecules TRAF2 and RIP to trigger signalling cascades that result in NF-kB, 
and AP-1 transcription factors leading to the expression TNF-α inducible genes. In a 
regulatory process, receptor binding with TNF-α, causes the cleavage of both TNFR1 
and TNFR2 to soluble forms. These soluble TNF-α receptors are able to bind free TNF-α 
preventing it from binding to membrane bound forms of TNFR1 and TNFR2, and 
regulating further TNF-α signalling (Turner et al., 2014).  
1.3.3.1.3 IL-1α/IL-1β 
IL-1α (interleukin-1α) and IL-1β (interleukin-1β) are both part of the IL-1 family of 
cytokines with are produced mainly from mononuclear phagocytes, among other cells 
(Dinarello and Wolff, 1993). Production of these cytokines requires their cleavage by 
caspase 1 from the pro-from (53kDa) to the active mature form (17kDa) that can be 
secreted, however IL-1α is believed to be active in both forms (Kaplanski et al., 1994). 
IL-1 indirectly activates T-cells and increases B-cell proliferation and is believed to be 
the cause of symptomatic ‘illness’ felt producing fever and lethargy. IL-1 cytokines also 
mimic the activities of TNF-α, by also upregulating endothelial adhesion molecules to 
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aid in leukocyte migration, acting as a redundant mechanism (Borish and Steinke, 
2003).  
IL-1α is slightly unique as it is expressed in the absence of infection on the cell surfaces 
of epithelial cells and is released upon stimulation acting as an alarmin. Moreover IL-1α 
acts as a dual function cytokine, by also binding to DNA acting as a transcription factor 
directly, as well as its receptor mediated function (Dinarello, 2018). IL-1β is produced 
by more limited cell types (monocytes, macrophages, and dendritic cells), and is only 
active in its processed from (Fields et al., 2019). IL-1β has a greater influence on fever 
and is able to regulate the production of active IL-1α (Dinarello, 2018). The structure of 
both active IL-1α and IL-1β are very similar, yet they have distinct individual effects, 
along with the more general effects of the IL-1 family. 
IL-1 signalling is facilitated by two receptors; IL-1R1 and IL-1R2, with IL-1α and IL-1β 
having similar affinities for each. IL-1R1 is predominantly expressed on T cells, 
fibroblasts, B cells, macrophages, and neutrophils while IL-1R2 is mainly expressed on 
B cells, macrophages, and neutrophils (Ito et al., 1999). Upon binding to IL-1R1, the 
accessory protein IL-1RAcP is recruited, leading to Myd88 mediated signalling, and 
activating both MAPKs (p38and JNK) and NF-kB, resulting in IL-1 induced gene 
expression. The IL-1R2 is inactive, and does not signal upon IL-1 binding, which is 
believed to be a mechanism to sequester IL-1 in an anti-inflammatory response. 
Moreover IL-1R antagonists exist mainly in the cytosol, acting as a block for further IL-1 
production, suggesting that IL-1 is able to self supress the inflammation (Turner et al., 
2014).  
 
70 
 
1.3.3.2 Chemokines 
Chemokines are relatively small secreted molecules that play a greater role in the 
chemotaxis of infiltration immune cells than their cytokine counterparts. Chemokines 
are divided into four families based upon the positioning of their N-terminal cysteine 
residues. CXC, CC, C, and CX3C, are the four characterised groups, with CC and CXC 
being the most numerous (Turner et al., 2014; Vilgelm and Richmond, 2019; Zlotnik 
and Yoshie, 2000). Chemokines interact with the 7-transmembrane, G-protein–
coupled receptor superfamily, causing GTP to associate with the Gα subunit. This 
results in disassociation from the G-protein complex, forming both Gα and Gβγ units. 
Both Sub units activate ERK and protein kinase B inducing multiple cellular processes, 
with Gα able to signal directly, while Gβγ signals via the phosphoinositide 3-kinase 
(PI3K) (Borish and Steinke, 2003; Legler and Thelen, 2018). One of these processes is 
the activation of integrins on leukocytes, which bind the leukocyte to the vessel wall. 
Via the process of ‘rolling adhesion’ the leukocyte will migrate following the 
concentration gradient of the chemokine (Mitchison and Cramer, 1996). The 
differential expression of chemokines, along with their receptors, allows the migration 
of specific lymphocytes, with the distribution of adhesion molecules contributing to 
this process (Akira et al., 1993).  
One of the major chemokines is IL-8, produced from both epithelial and mononuclear 
phagocytes. While it appears relatively late in the response, it is extremely potent for 
neutrophils. However, in mice both the genes encoding IL-8 and its receptor are 
deleted, with MIP-2 (CXCL2) acting as a functional homologue (Singer and Sansonetti, 
2004). MIP-2 is a highly important chemoattractant for neutrophil recruitment and is 
in fact around 10-fold more potent than IL-8. However, unlike IL-8 it has a minimal 
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effect on the production of oxidants and lysosomal enzymes by neutrophils (Sager et 
al., 1992; Wolpe et al., 1989). Therefore, it is suggested that MIP-2 provides a 
mechanism of leukocyte recruitment without the release of damaging mediators, until 
the cells reach the cite of infection (Driscoll, 1994). Other chemokines such as; 
RANTES, (CCL5) IP-10 (CXCL10), MIP-1α (CCL3), along with MIP-2 have been shown in 
multiple studies to be involved with lung inflammations (Borish and Steinke, 2003; 
Turner et al., 2014). RANTES mainly recruits monocytes, T-cells, and eosinophils, and is 
upregulated relatively early in viral infections (Culley et al., 2006). IP-10 is also 
increased during viral infections, resulting in an influx of Th1 cells, NK cells, and 
eosinophils (Hayney et al., 2017). Finally MIP-1α, which is important in monocyte, NK 
cell, and neutrophil recruitment, is also increased in viral infections, and appears 
important in protecting against subsequent protection (Jones et al., 2003). 
1.3.3.3 Type-I Interferons 
Interferons (IFNs) are a family of cytokines, separated from other cytokines by their 
ability to ‘interfere’ with viral growth. IFNs are split into two distinct types, viral type-I 
IFN (IFN-α,β, and ω) and immune type-II IFN (IFN-γ) (Samuel, 2001). Type I IFNs are 
produced from most cell types by a variety of receptor stimulations, however the 
recognition of viral nucleic acid is the most predominant way, via RLRs (Kawai and 
Akira, 2010). These receptors, signalling via TBK1, activate IRF3 which facilitates IFN 
gene transcription. The only non-TBK1 induction of type I IFN is from TLR-7 response to 
endosomal ssRNA, which instead signals via IRAK-4 to activate IRF7 that facilitates IFN 
gene transcription (Colonna et al., 2004). This IRF7 signalling along with IRF8 is also 
activated by type-I IFNs themselves, acting as a positive feedback loop to enhance 
production (Tailor et al., 2007). 
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Type I IFNs induce an antiviral state in cells before they come into contact with the 
virus to prevent infection. The type I IFN receptor signals via JAK1 and STAT1 upon 
binding to either IFN-α or IFN-β resulting in the activation of transcription factors 
STAT1 and STAT2 (Ivashkiv and Donlin, 2014). These two factors bind with IRF9 in the 
nucleus in a complex called IFN-stimulated gene factor 3 (ISGF3) which binds IFN-
stimulated response elements (ISREs) on DNA sequences transcribing IFN stimulated 
genes (ISGs) (Ivashkiv and Donlin, 2014). The exact nature of these genes differs 
between cell types, but generally induces an antiviral state by inhibition of viral 
transcription, translation, and replication, the degradation of viral nucleic acids, and 
the alteration of cellular lipid metabolism (MacMicking, 2012; Saka and Valdivia, 2012). 
 
 
 
 
 
 
 
 
 
 
 
73 
 
Table 1.3 Summary of ISGs associated with antiviral effects. 
Family ISGs Effect Observed in 
IAV infection 
IFITM  IFITM1 
IFITM2 
IFITM3 
Restrict viral entry and endosomal fusion Yes 
TRIM TRIM C I 
TRIM C II 
TRIM C III 
TRIM C IV 
TRIM C V 
TRIM C VI 
TRIM C VII 
TRIM C VIII 
TRIM C IX 
TRIM C X 
TRIM C XI 
Restrict viral uncoating No 
MX MX1 
MX2 
Block nucleocapsid transport Yes 
OAS OAS1 
OAS2 
OAS3 
OASL 
Inhibit RNA stability Yes 
PKR EIF2AK Inhibit viral protein translation Yes 
RNAase L RNAase L Inhibit RNA stability Yes 
APOBEC3 APOBEC3 Inhibit RNA reverse transcription No 
SAMHD1 SAMHD1 Inhibit RNA reverse transcription No 
ISG15 ISG15 Inhibit viral protein modification and 
formation 
Yes 
Tetherin Tetherin viral release No 
Viperin Viperin viral assembly Yes 
IFITM - interferon-inducible transmembrane protein, TRIM - tripartite motif 
protein, MX -  myxoma resistance protein, OAS - 2′-5′ oligoadenylate synthase, PKR 
-   Protein kinase RNA-activated,  RNase L (ISG20) -  IFN-stimulated gene 20 kDa 
protein,  APOBEC3 -  apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 
3,  SAMHD1 -  SAM-domain- and HD-domain-containing protein 1, ISG15 – IFN-
stimulated gene 15 kDa protein, Tetherin -  CD317, Viperin -  virus inhibitory 
protein endoplasmic reticulum-associated interferon-inducible. 
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1.3.3.4 The ‘cytokine storm’ 
In cases of severe influenza infection, the hosts resistance to the virus can become 
hyperactive, leading to an excessive inflammatory reaction termed the ‘cytokine 
storm’. This often leads to direct tissue injury and a worsening in the disease 
progression and prognosis of the influenza infection (Tisoncik et al., 2012). The primary 
mediators are of this amplified cytokine/chemokine and type I IFN response are 
believed to be the lung epithelial cells, as the primary targets for IAV infection and 
replication. However, it is the addition of innate immune cells such as macrophages 
and neutrophils that progress the hyperactivation (La Gruta et al., 2007). In worst case 
scenarios the over expression of these inflammatory mediators can progress beyond 
the acute inflammation of the lung into the circulatory system. This results in a 
systemic ‘cytokine storm’ which can lead to multi-organ dysfunction and failure 
(Tisoncik et al., 2012).  
Our understanding to how this hyperactivation of the immune system is initiated is 
limited. But quiet clearly it is more associated more with high pathogenic strains of IAV 
than seasonal strains (Gu et al., 2019). The differences between seasonal and highly 
pathogenic strains, such as their abilities to activate and evade different PRR’s and 
replication within macrophages, may go some way to explaining how this ‘cytokine 
storm’ is initiated. Hopefully further studies can highlight key interactions and 
virulence factors to allow therapeutic therapies to better control this hyperactivation.  
1.3.4 Viral virulence 
Certain IAV strains can elicit severe pulmonary injury and inflammation upon infection, 
these strains are termed ‘high pathogenic’ strains. The H5N1 avian IAV strain has an 
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extremely high mortality rate, causing acute respiratory distress and multiple organ 
failures. It is believed that cytokine dysregulation is the factor that determines the 
extent of this disease.  
This is a similar case to the 1918 H1N1 strain, which is the worst in recorded history, 
killing over 40 million people (Tumpey et al., 2005). What is yet to be determined is 
whether this dysregulation and resulting cytokine storm is at the level of epithelial cells 
or at the residing leukocytes (macrophages, DC cells, and NK cells), or both. 
There is a positive correlation between viral pathogenicity and IL-6, TNF-α, IP-10, MCP-
1, and type I IFN (Huo et al., 2018; Sandbulte et al., 2008; Vogel et al., 2014). H5N1 
strains, in comparison with seasonal H1N1 strains, induce enhanced immune 
responses as a result of infection in macrophages, however this increase in host 
response has no effect on the rate of viral replication (Lee et al., 2009). Moreover 
differences within isolates of H5N1, suggests that within IAV strains there may be both 
high and low cytokine inducing sets (Sakabe et al., 2011). H5N1 infections induce 
prolonged IFN-γ production, which enhances the ‘cytokine storm’ (Woo et al., 2010). 
IFN-γ upregulates IP-10 production in epithelial cells, resulting in excessive recruitment 
of effector (CD8+) T-cells (Oslund et al., 2014). 
The underlying mechanisms behind this enhanced host response are unclear, as it 
cannot be explained as a result of increased viral replication (Lee et al., 2009; Sakabe 
et al., 2011). Instead it is likely host responses are fundamentally different to these 
particular high pathogenic strains.  Differences in viral adhesion may affect both the 
distribution of the virus and alter the microenvironment within the lung. As already 
mentioned avian strains preferentially bind to α(2,3)-Gal linkages while human strains 
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preferentially bind to α(2,6)-Gal linkages (Suzuki et al., 2000; Thompson et al., 2006). 
Recombinant seasonal strains able to bind α(2,3)-Gal linkages produce higher levels of 
IFN-β, TNF-α, RANTES, IP-10, IL-6, MIP-1 than wild type strains binding α(2,6) (Ramos 
et al., 2011). This suggests the virulence may not entirely be down to the virus, but 
instead the subset of cells it is able to infect, with (2,3)-Gal linkages predominantly 
expressed lower down in the respiratory tract than (2,6)-Gal linkages (Kumlin et al., 
2008). 
Other pandemic IAV strains, such as the recent 2009 H1N1 also induce severe disease 
in a different manner to seasonal variants. In these strains, enhanced immune 
responses are not seen, in fact a reduction in the amount of pro-inflammatory 
cytokines and type I IFNs is seen compared to seasonal H1N1, and even reduced cell 
death (Zeng et al., 2011). It appears that this particular high pathogenic strain is able to 
evade detection by the immune system, possibly by inhibiting signalling pathways, or 
not being detected to start with. Under this situation viral replication is severely 
enhanced (Zeng et al., 2011). However, it is still not clear why some infected patients 
resulted in severe disease and some did not. 
Certain viral genes have been attributed to enhanced host immune responses such as 
H5N1 polymerases and NS gene, have been seen to enhance TNF-α secretion in 
macrophages (Mok et al., 2009). One key viral virulence protein is NS-1, which blocks 
type I IFN production via a variety of mechanisms (Haye et al., 2009). Inhibiting RIG-1 
directly (Guo et al., 2007), inhibition of STAT phosphorylation (NF-kB and IRF3 
activation), and binding to the cleavage and polyadenylation specificity factor (CPSF) to 
block cellular mRNA processing (Kochs et al., 2007). 
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Overall strains with high pathogenic NS-1 genes result in a delay in the viral clearance 
and enhanced pro-inflammatory cytokine secretion (Lipatov et al., 2005). While NS-1 is 
the most studied virulence protein, it is likely that differences in other viral proteins 
may enhance/modify the virulence in specific strains, and even isolates within strains. 
1.3.5 Viral innate immunity evasion mechanisms 
IAV has developed a variety of mechanisms to aid in its infection of host cells, while 
remaining undetected by the host innate immune response. A combination of immune 
derived selection pressures and the high rates of mutation associated with IAV (genetic 
shift/drift) are the driving factors for the mechanisms. Thus, it is a constant battle of 
adaptation between IAV infectivity and the host immune responses. 
The IAV NS1 protein is able to bind viral RNA directly using an RNA binding domain. 
This prevents recognition of the viral RNA by RIG-I, blocking the induction of the RIG-I 
mediated immune response (Guo et al., 2007). Furthermore if viral RNA is sensed, NS1 
is able to block RIG-I signalling via binding to signalling adaptor protein TRIM25 (Gack 
et al., 2009). If, however RIG-I signalling is successful and type I IFN genes are 
transcribed, IAV has a redundant mechanism. Both NS1 and M2 proteins are able to 
inhibit the IFN induced RNA-dependent protein kinase (PKR), which aids in inducing a 
cellular anti-viral state. This is achieved by association and activation of its regulatory 
factor (P58IPK), thus enabling viral replication within the cell (Sharma et al., 2011). 
Certain mutations in the IAV PB1-F2 protein allow for the binding and inactivating the 
RIG-I signalling adaptor MAVS, to further block RIG-I signalling from viral RNA 
recognition (Varga et al., 2012). This effect is exacerbated by vial PA and PB2 
polymerases also binding and inhibiting MAVS, due to a PB2 mutation (Graef et al., 
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Figure 1.9 Summary of IAV innate immune evasion mechanisms  (Based on work of Kreijtz et al. (2011)). 
Dashed arrows show host immune response, while squared lines show inhibition effects of viral 
proteins.  
NS1 – Bind viral RNA to prevent recognition. Block RIG-I signalling by binding TRIM25. Bind PKR to block 
anti-viral state. 
M2 – Bind the PKR inhibitor P58ipk to prevent PKR activation of the anti-viral state. 
NP – Cause disassociation of the regulatory factor hsp40 from P58ipk to prevent PKR activation of the 
anti-viral state. 
PB1-F2 – Binding the RIG-I adaptor protein MAVS to prevent RIG-I signalling. 
PB2 – Binding the RIG-I adaptor protein MAVS to prevent RIG-I signalling, binding to interferon 
promotor stimulator 1 (IPS-1) preventing IFN-β transcription. 
 
 
 
2010). Again there appears to be a redundant mechanism built-in, where if RIG-1 
signalling occurs then PB2 can also bind and inhibit interferon promotor stimulator 
(IPS-1), which is required for IFN-β gene transcription (Iwai et al., 2010). 
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1.4 Macrophages 
Macrophages are part of the mononuclear phagocyte family (along with monocytes 
and DCs) which can be argued to be the principle cells of the innate immune system. 
Macrophages are key phagocytic cells, engulfing invading pathogens and particles that 
place them as one of the first lines of defence against infection, as well as important 
‘housekeeping’ roles (Fejer et al., 2015; Gordon and Read, 2002; Okabe and 
Medzhitov, 2016). From this front line role, macrophages are the co-ordinators of host 
immune response using an abundance of PRR expression to recognise specific 
PAMPs/DAMPs to release key immune regulators like cytokines and chemokines 
(Gordon and Pluddemann, 2017).  As macrophages express the majority of currently 
identified PRRs, (Kumar et al., 2011) their role as both a phagocyte and immune co-
ordinator makes them indispensable.     
Macrophages exist in vivo as two separate lineages; the first being recruited 
macrophages. These macrophages initially are produced in the bone marrow from 
haematopoietic stem cells and circulate in the blood as monocytes. Upon infection, 
these monocytes are recruited into the infected tissue and differentiate to bone 
marrow derived macrophages (BMDMs). The environment and factors activating these 
monocyte derived macrophages results in distinct populations and phenotypes, as 
shown in Figure 1.10 (Fejer et al., 2015; Gordon and Pluddemann, 2017). The second 
lineage are the resident tissue macrophages, which are derived from precursors in 
specific tissues from the embryonic yolk sac and foetal liver. These resident 
macrophages persist in the tissue under homeostasis, being maintained and 
replenished via specific growth factors as shown in Figure 1.10 (Fejer et al., 2015; 
Gordon and Pluddemann, 2017).   
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Figure 1.10 Summary of macrophage development lineages  (Based on review by Fejer et al. (2015)) 
Tissue resident macrophages develop at embryonic stage of development, from the yolk sac or foetal 
liver and are able to self-renew under homeostasis. Includes; microglia (central nervous system), F4/80hi 
macrophage (peritoneal macrophages in various tissues), Langerhans cells (skin), alveolar macrophages 
(lung), IL-4 driven macrophage (various tissues), Kupffer cells (liver). Recruited macrophages develop 
after birth, from bone marrow derived monocytes, which differentiate at a site of infection based on 
signals and the environment. Includes; inflammatory macrophage (MCSF), atherosclerotic plaque 
macrophage (MCSF + blood vessels), anti-inflammatory macrophage (IL-4/13), intestinal macrophage 
(MCSF + intestine), microglia (MCSF + central nervous system), Langerhans cells (MCSF + skin). 
With infection of the lung environment, macrophages from both of these lineages are 
present (Gordon and Read, 2002). The specific resident macrophages in the lung are 
alveolar macrophages (AMs), which are present before the infection, with the 
infiltrating monocyte derived macrophages recruited upon infection, with numbers 
soon out numbering the resident AMs (Herold et al., 2008). 
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1.4.1 Alveolar macrophages 
Alveolar macrophages (AMs) are the resident lung macrophages, which are maintained 
under homeostasis independently from the bone marrow via GM-CSF (Guilliams et al., 
2013a). The GM-CSF secreted by the pulmonary epithelial cells cause AMs to self-
replicate, maintaining cell numbers even in the absence of infection (Hashimoto et al., 
2013). AMs fully colonise the alveolar air spaces by about 3 days after birth, with their 
generation occurring from foetal liver cells under the influence of GM-CSF, pushing 
them to the AM lineage (Guilliams et al., 2013a).  
These cells make up over 95% of the lung immune cell population during homeostasis 
and are therefore the first cells to come into contact with invading respiratory 
pathogens (Gordon and Read, 2002). Populating the alveoli, these macrophages reside 
in a constantly fluctuating environment, with both oxygen pressure environmental 
antigens constantly fluctuating (Hussell and Bell, 2014). Therefore, it is highly 
important that these cells are both highly regulated and controlled during ‘health’ yet 
provide a strong inflammatory response during infection.  
Ultimately AMs have contradicting functions, with their role of environmental control, 
regulation, and maintenance at odds with their role in pathogenic inflammatory 
response. How the macrophage is able to differentiate between these two roles is 
debatable, with several hypotheses suggested. The loss of regulatory ligands from 
airway epithelium due to damage is one mechanism believed to induce a pro-
inflammatory response in AMs (Hussell and Bell, 2014). Moreover, the clearance of 
either necrotic or apoptotic cells also tailors the response of AMs, with apoptotic cells 
for example resulting in an ‘anti-inflammatory’ state due to increased CD200 
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expression (Snelgrove et al., 2008).Because of their dual role and environment AMs 
are extremely specialised, expressing high levels of complement, mannose, 
immunoglobulin, scavenger receptors, and regulatory receptors (Figure 1.11 and Table 
1.4) (Hussell and Bell, 2014; Mosser, 1994). These features, along with phagocytosis 
and cytokine/chemokine production makes AMs crucial in both maintaining the lung 
environment and dealing with pathogens, dust, pollutants and foreign particles, all of 
which can be found in a single breath (Fejer et al., 2015; Gordon and Pluddemann, 
2017; Gordon and Read, 2002).  
AM’s are crucial in the initial response to IAV infection, and are required for successful 
immune response and efficient viral clearance (Hoeve et al., 2012; Kim et al., 2008). 
During this infection the AM population is depleted, however the remaining numbers 
of AMs can restore pre-infection numbers via self-proliferation. The maintenance of 
AM numbers is essential for both the clearance of IAV and the prevention secondary 
bacterial  infections (Califano et al., 2018; Tate et al., 2010). 
1.4.2 BMDMs 
Bone marrow derived macrophages (BMDMs) as already described are the tissue 
macrophages from recruited blood circulating monocytes, derived from 
haematopoietic stem cells in the bone marrow. These cells migrate to the lung, 
following RANTES, MIP-1α, and IL-8/MIP-2 chemokine signals, produced 
predominantly from AMs, upon lung infection. As stated, these cells soon outnumber 
the resident AMs, but are phenotypically different. BMDMs do not express the specific 
surface markers of AM’s and have much higher CD14 expression in comparison (Figure 
1.11 and Table 1.4)  
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(Fejer et al., 2015; Gordon and Pluddemann, 2017; Haugen et al., 1998). These cells 
can be generated ex vivo using M-CSF to generate macrophages from blood 
monocytes, and have been used to study the mononuclear phagocyte system 
extensively (Ezekowitz, 1985).  
1.4.3 MPI macrophages 
Max Planck Institute (MPI) are a described murine model of primary AMs, with the 
benefit of factor dependent, continuous replication. These macrophages are generated 
by culturing unseparated, embryonic-day 16–20, mouse foetal liver cells with GM-CSF, 
which are then maintained by normal cell culture in the presence of GM-CSF (Fejer et 
al., 2013). MPI macrophages have the characteristics of AM’s, with high levels of 
MARCO, Chitinase 3 like, sialoadhesin, and CD11 expression, but low levels of CD14 
expression (Table1.4) (Fejer et al., 2015). Unlike conventional ex vivo differentiated 
macrophages, MPI cells have maintained their ability to self-replicate. Moreover, 
because of their generation from the foetal liver they much closer mimic AMs.   
Functionally MPI macrophages have key similarities to AMs, LPS binding protein 
requirement for rough-LPS sensing, tuberculosis and adenovirus sensitivity, strong 
TNF-α / IL-1α induction, and a lack of IL-10 production (Fejer et al., 2015; Fejer et al., 
2013; Maler et al., 2017; Stichling et al., 2018; Woo et al., 2018). The availability of MPI 
macrophages (3 x 107 cells/T75 flask) compared to AMs (3 x 105 cells/mouse) (Fejer et 
al., 2015) shows the benefit of their use for functional studies, with high cell 
throughput, without the associated use of experimental animals.  
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Figure 1.11 Visual representation of morphology and surface receptor expression of AMs vs BMDMs vs 
MPIs  (Fejer et al., 2013; Hussell and Bell, 2014) MPI macrophages morphologically mimic AMs over 
BMDMS. Surface expression profile of MPIs mainly mimics AMs, with key surface markers SR-A6, CD11c, 
and Chitinase 3 like. However, MPIs also expresses receptors not found on AMs such as low levels of 
CD14 and CD11b. Unfortunately, data is not available for the expression of CD206, CD200R, and DEC205 
on MPI macrophages. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.4 Quantitative summary of surface marker expression of AMs vs BMDMs vs MPI (Fejer et al., 
2013; Hussell and Bell, 2014). While MPI macrophages follow the expression profile of AMs, with both 
cells expressing high levels of SR-A6 and Chitinase 3 like, there are a few exceptions, such as low levels 
of CD11c and no MHC class II. Overall MPIs have a more similar surface marker to AMs than BMDMs. 
 
Surface Marker Alveolar 
Macrophage 
BMDM MPI 
MHC class II +++ - - 
CD206 +++ + / 
CD11b - ++ + 
CD11c +++ - + 
CD14 - ++ + 
CD200R +++ + / 
SIGLEC-1 +++ - ++ 
F4/80 + ++ + 
DEC205 ++ - / 
SR-A6(MARCO) +++ - +++ 
Chitinase 3 like +++ - +++ 
+++ = High expression, ++ = intermediate expression, + = low expression, - = no expression, / = no data 
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Table 1.5 Comparison of functional characteristics of AMs vs BMDMs vs MPI (Fejer et al., 2013) MPIs and 
AM have similar functionalities, compared to BMDMs; no IL-10 production, LBP requirement for LPS 
sensing, and IL-1α production. 
 
 
 
 
 
 
 
 
 
 
 
 
Functionality Alveolar 
Macrophage 
BMDM MPI 
IL-10 production 
(LPS, Mtb, TDM, AD 
stimulation) 
No Yes No 
IL-1α production 
(LPS, Mtb, TDM, AD 
stimulation) 
Yes No Yes 
Strong IL-6 
production (Mtb, 
TDM, AD 
stimulation) 
Yes No Yes 
LBP required for 
LPS sensing 
Yes No Yes 
Mtb (murine Tuberculosis), TDM (cord factor), AD (Adenovirus), LBP (Lipopolysaccharide binding protein) 
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1.5 Rationale and Aims 
It is evident from the literature that there are gaps in the current research into IAV 
induced innate immune responses. Specifically, research into the early innate response 
and control generated by AMs is lacking full understanding due to the absence of 
models that can match up to AM specificity, while still providing large enough cell 
number for high throughput function experiments. MPI macrophages, with their 
abundant numbers, and AM-like phenotype could provide this needed model to push 
beyond the limitations of the current literature.  
The aims of this research are split into clearly defined objectives: 
I. Establish MPI macrophages as a superior model to study early IAV innate 
immunity, compared to BMDMs. 
II. Identify specific IAV strains, isolates, and propagation techniques to be used, 
explaining any differences identified.  
III. Determine the role of established IAV attachment receptors and identify novel 
targets that may have been missed by previous studies. 
IV. Investigate the mechanisms of viral uptake and release in macrophages. 
V. Determine which aspects the viral infection cycle induce innate responses in 
macrophages.  
In this thesis, the benefits of using MPI macrophages to study IAV-macrophage 
interactions are shown across a variety of aspects. The sensitivity of MPI macrophages 
to IAV, as wells as the differences viral propagation methods have on this viral 
infectivity is investigated in Chapter 3. Furthering the understanding of the different 
IAV infection mechanisms in macrophages by analysing the relevance of currently 
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identified host receptors will be determined in Chapter 4. Additionally, in this chapter 
attempts to identify novel IAV entry receptors by using MPI macrophages as a model 
for AM-IAV infection will also be performed. Moreover, variations between isolates 
ability to infect macrophages are also analysed in this chapter. Finally, the IAV-
macrophage interactions and cell PRR signalling that result in specific innate immune 
responses, leading to a variety of antiviral affects, using MPI macrophages as a model 
is detailed in Chapter 4. 
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2 Chapter Two: Materials and 
Methods 
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2.1 Materials 
2.1.1 Influenza A virus 
All influenza A strains were provided by Public Health England, Porton Down. H1N1, 
Cal/04/09 – Mouse adapted, Cal/04/09, and PR8/34 strains were propagated in MDCK 
cells. H1N1, Cal/07/09 and H3N2 Switzerland/9715293/13, Texas/50/12, 
Wuhan/359/95, and Perth/16/09 were all propagated in 9-11 day old Specific-
Pathogen-Free Embryonic Hen eggs.  Upon harvest, culture medium or allantoic fluid 
was clarified by centrifugation, aliquoted and frozen at -80oC, before quantification by 
standard plaque assay.   
2.1.2 Adenovirus  
Human replication-deficient adenoviral vector Ad5-GFP (species C) was used as a 
control for type I IFN experiments. AD5-GFP was grown in HeLa cells and purified by 
CsCl density gradient centrifugation, aliquoted and frozen at -80oC (Greber et al., 
1996). Viral particle counts were determined by UV spectrophotometry, with 
absorbance of 1AU at 260nm corresponding to 1.1x1012 particles/ml. All adenovirus 
was kindly provided by Prof. Marina Freudenberg. 
2.1.3 Lipopolysaccharide (LPS) 
S-form LPS from salmonella abortus equi was used as a control for type I IFN 
experiments. LPS was isolated by phenol/water extraction and electrodialysed to 
trimethylamine salt from, which was then dissolved in carbon-absorbed water 
(Galanos and Luderitz, 1975). LPS stocks were aliquoted and stored at -20oC. All LPS 
was kindly provided by Dr. Gyorgy Fejer. 
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2.1.4 Reagents 
Table 2.1 List of reagents and suppliers 
30% Acrylamide/Bis Sigma Aldrich (Dorset, UK) 
40% Formaldehyde Solution Sigma Aldrich (Dorset, UK) 
Acetic Acid Sigma Aldrich (Dorset, UK) 
Agar Sigma Aldrich (Dorset, UK) 
Ammonium persulfate Sigma Aldrich (Dorset, UK) 
Bovine Serum Albumin Sigma Aldrich (Dorset, UK) 
Bromophenol Blue Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Chloroform Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Crystal Violet 2.5% Sigma Aldrich (Dorset, UK) 
Dimethyl sulfoxide (DMSO) Sigma Aldrich (Dorset, UK) 
DMSO Sigma Aldrich (Dorset, UK) 
D-Sucrose (Molecular Biology) Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
EDTA Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Ethanol VWR (Leicestershire, UK) 
Glycerol Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Glycine Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Isopropanol, molecular grade Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Methanol Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
NaCl Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
non-fat milk powder Marvel (Hertfordshire, UK) 
RNase-free water Thermo Fisher Scientific (Ambion) 
(Hemel Hempstead, UK) 
SDS Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Sodium deoxycholate Sigma Aldrich (Dorset, UK) 
Sucrose Sigma Aldrich (Dorset, UK) 
TEMED Sigma Aldrich (Dorset, UK) 
Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma Aldrich (Dorset, UK) 
TPCK-treated Trypsin Sigma Aldrich (Dorset, UK) 
Tris Base Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Triton x-100 Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Trypan Blue, 0.4% Sigma Aldrich (Dorset, UK) 
Trypsin-Versene  Lonza (Slough, UK) 
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(0.5g/ltr Trypsin, 0.2g/ltr versene) 
Tween 20 Sigma Aldrich (Dorset, UK) 
Β-mercaptoethanol Sigma Aldrich (Dorset, UK) 
 
2.1.5 Disposables 
Table 2.2 List of Disposables and suppliers 
20ml syringe  Greiner Bio One 
(Stonehouse, UK) 
35mm petri dish Greiner Bio One 
(Stonehouse, UK) 
6-, 12-, 96- well plates (flat bottom, cell culture 
treated 
Greiner Bio One 
(Stonehouse, UK) 
8-well chamber slides Eppendorf (Stevenage, UK) 
96-well plates, flat bottom, high binding  Thermo Fisher Scientific 
(Hemel Hempstead, UK) 
Centrifuge tubes (15ml and 50ml) Greiner Bio One 
(Stonehouse, UK) 
Cryovials  Greiner Bio One 
(Stonehouse, UK) 
DNase and RNase free 1.5ml tubes Thermo Fisher Scientific 
(Hemel Hempstead, UK) 
MicroAmp EnduraPlat Optical 96-Well Fast Clear 
Reaction Plates 
Thermo Fisher Scientific 
(Applied Biosystems) (Hemel 
Hempstead, UK) 
Microplate sealers Greiner Bio One 
(Stonehouse, UK) 
Needle and syringe, 1ml 25GA x5/8in BD Biosciences (Berkshire, 
UK) 
Needles 0.9 x 40mm BD Biosciences (Berkshire, 
UK) 
Petri dishes (100mm x 20mm) Greiner Bio One 
(Stonehouse, UK) 
Pipet tips (filter and non-filter) Greiner Bio One 
(Stonehouse, UK) 
Protein LoBind 1.5ml tubes Eppendorf (Stevenage, UK) 
Reaction tubes (0.5-2ml) Flip and Screw Cap Greiner Bio One 
(Stonehouse, UK) 
Round bottom, 5ml tubes for FACs Greiner Bio One 
(Stonehouse, UK) 
Sampling spatula Bel-Art Products (New Jersey, 
US) 
Serological Pipets  Greiner Bio One 
(Stonehouse, UK) 
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2.1.6 Equipment 
Table 2.3 List of Equipment and suppliers 
21 Microcentrifuge Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Acrylamide gel casting kit Bio-Rad (Watford, UK) 
Acrylamide gel electrophoresis kit Bio-Rad (Watford, UK) 
AE2000 Inverted Microscope Motic (Barcelona, Spain) 
Autoclave PriorClave (London, UK) 
Bibbyjet Pro Pipette Controller PC2000 Stuart (Staffordshire, UK) 
Centrifuge 3-16KL Sigma Aldrich (Dorset, UK) 
Centrifuge 8810R Eppendorf (Stevenage, UK) 
Class II Safety Cabinet Faster BH-EN 2003 Faster S.r.l (Cornaredo, Italy) 
Class II Safety Cabinet MARS 1200 Labogene (Allerød Municipality, 
Denmark) 
CO2 incubator C150 BINDER (Tuttlingen, Germany) 
Ducted Fume Hood Premier Laboratory Systems 
(Glasgow, UK) 
FACS Aria II BD Biosciences (Berkshire, UK) 
Finnpipette F2 Pipettes, P2, P20, P200, 
P1000, MC300 
Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Fluorescent IM8 microscope Leica Microsystems (Milton Keynes, 
UK) 
FLUOstar Omega Plate reader with BMG Labtech (Bucks, UK) 
Haemocytometer Brand (Wertheim, Germany) 
Heat Block VWR (Leicestershire, UK) 
Lab Basics Pipettes, P2, P20P200, P1000, 
MC300 
Scientific Laboratory Supplies 
(Nottingham, UK) 
Nanodrop  
NanoDrop 2000/2000c Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Orbital Rocker Grant instruments (Cambridge, UK) 
Proline Plus Pipettes, P10, P100, P1000, 
MC100 
Sartorius AG (Epsom, UK) 
PXi 4 Multi-Application Gel Imaging System SynGene (Cambridge, UK) 
StepOnePlus Real-Time PCR System Thermo Fisher Scientific (Applied 
Biosystems) (Hemel Hempstead, UK) 
SW28Ti Rotor/buckets Beckman Coulter (High Wycombe, 
UK) 
Syringe Filter, hydrophobic, 0.45µm Sartorius AG (Epsom, UK) 
Tissue culture Flasks (25cm3, 75cm3, 175cm3) Greiner Bio One 
(Stonehouse, UK) 
Ultra-Clear Centrifuge Tubes SW32 Beckman Coulter (High 
Wycombe, UK) 
Ultra-Clear Centrifuge Tubes SW55 Beckman Coulter (High 
Wycombe, UK) 
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SW55Ti Rotor/buckets Beckman Coulter (High Wycombe, 
UK) 
Tube Roller VWR (Leicestershire, UK) 
Ultracentrifuge Beckman Coulter (High Wycombe, 
UK) 
Verit 96-Well Thermal Cycler Thermo Fisher Scientific (Applied 
Biosystems) (Hemel Hempstead, UK) 
Vertical gel Transfer Kit Genesee Scientific (California, US) 
Vortex Genius 3 IKA (Oxford, UK) 
Water bath VWB18 VWR (Leicestershire, UK) 
 
2.1.7 Recombinant Proteins 
Table 2.4 List of recombinant proteins and suppliers 
Recombinant Murine IFN-β Biotechne (R&D systems) (Abingdon, 
UK) 
Recombinant Murine IL-1α PeproTech (London, UK) 
Recombinant Murine IL-1β Thermo Fisher Scientific (eBioscience) 
(Hemel Hempstead, UK) 
Recombinant Murine IL-6 BD Pharmingen (Berkshire, UK) 
Recombinant Murine IP-10 PeproTech (London, UK) 
Recombinant Murine MIP-1α PeproTech (London, UK) 
Recombinant Murine MIP-2 PeproTech (London, UK) 
Recombinant Murine RANTES PeproTech (London, UK) 
Recombinant Murine TNF-α Thermo Fisher Scientific (eBioscience) 
(Hemel Hempstead, UK) 
 
2.1.8 Antibodies 
Table 2.5 List of antibodies and suppliers 
Alexa Fluor 488 conjugated goat anti-rabbit IgG Thermo Fisher Scientific 
(Hemel Hempstead, UK) 
Alexa Fluor 594 conjugated goat anti-mouse IgG Thermo Fisher Scientific 
(Hemel Hempstead, UK) 
Biotin Conjugated rabbit anti-mouse polyclonal IL-1α  PeproTech (London, UK) 
Biotin Conjugated rabbit anti-mouse polyclonal IL-1β Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
Biotin Conjugated rabbit anti-mouse polyclonal IP-10 PeproTech (London, UK) 
Biotin Conjugated rabbit anti-mouse polyclonal MIP-
1α 
PeproTech (London, UK) 
Biotin Conjugated rabbit anti-mouse polyclonal MIP-2 PeproTech (London, UK) 
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Biotin Conjugated rabbit anti-mouse polyclonal 
RANTES  
PeproTech (London, UK) 
Biotin Conjugated rat anti-mouse monoclonal IL-6  Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
Biotin Conjugated rat anti-mouse monoclonal TNF-α  Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
HRP Conjugated goat anti-rabbit IgG 
 
Cell Signalling Technologies 
(Leiden, NL) 
HRP Conjugated horse anti-mouse IgG Cell Signalling Technologies 
(Leiden, NL) 
Purified Armenian hamster anti-mouse/rat 
monoclonal IL-1β  
Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
Purified mouse anti-mouse monoclonal GAPDH ACRIS (Herford, Germany) 
Purified Mouse Monoclonal Influenza A NP [5D8] Insight Biotechnology 
(Middlesex, UK) 
Purified rabbit anti-mouse monoclonal Phospho-IRF-3 
(Ser396) 
Cell Signalling Technologies 
(Leiden, NL) 
Purified rabbit anti-mouse monoclonal Phospho-NF-
κB p65 (Ser536) 
Cell Signalling Technologies 
(Leiden, NL) 
Purified rabbit anti-mouse monoclonal Phospho-p38 
MAPK (Thr180/Tyr182) (Ser536) 
Cell Signalling Technologies 
(Leiden, NL) 
Purified rabbit anti-mouse monoclonal Phospho-
TBK1/NAK (Ser172) 
Cell Signalling Technologies 
(Leiden, NL) 
Purified rabbit anti-mouse polyclonal IL-1α  PeproTech (London, UK) 
Purified rabbit anti-mouse polyclonal IP-10 PeproTech (London, UK) 
Purified rabbit anti-mouse polyclonal MIP-1α PeproTech (London, UK) 
Purified rabbit anti-mouse polyclonal MIP-2 PeproTech (London, UK) 
Purified rabbit anti-mouse polyclonal RANTES PeproTech (London, UK) 
Purified rabbit polyclonal Influenza HA (H3) Sino Biological (Eschborn, 
Germany) 
Purified rat anti-mouse monoclonal IL-6  Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
Purified rat anti-mouse monoclonal TNF-α  Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
 
2.1.9 Molecular Reagents 
Table 2.6 List of Molecular reagents and suppliers 
Amersham Hybond P 0.45 PVDF blotting 
membrane 
GE Healthcare Life Sciences 
(Buckinghamshire, UK) 
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Avidin-HRP Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
Bicinchoninic Acid Kit for Protein Determination 
for 200-1000 μg/ml protein 
Sigma Aldrich (Dorset, UK) 
Biotinylated Protein Ladder Detection Pack Cell Signalling Technologies 
(Leiden, NL) 
Color-coded Prestained Protein Marker, Broad 
Range (11-250 kDa) 
Cell Signalling Technologies 
(Leiden, NL) 
DAPI Sigma Aldrich (Dorset, UK) 
High-Capacity cDNA Reverse Transcription Kit Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Power SYBR Green PCR Master Mix Thermo Fisher Scientific (Applied 
Biosystems) (Hemel Hempstead, 
UK) 
Protease/Phosphatase Inhibitor Cocktail (100X) Cell Signalling Technologies 
(Leiden, NL) 
QuntiBlue Invivogen (Toulouse, France) 
Shadon Immu-Mount Thermo Fisher Scientific (Hemel 
Hempstead, UK) 
Super AquaBlue Substrate Thermo Fisher Scientific 
(eBioscience) (Hemel 
Hempstead, UK) 
SuperSignal West Pico Chemiluminescent 
Substrate kit   
Themo Fisher Scientific (Hemel 
Hempstead, UK) 
T7 transcript of full-length M gene A gift from Dr Karen Gooch, PHE 
(Porton Down, UK) 
TriFast VWR (Peqlab) (Leicestershire, 
UK) 
 
2.1.10 Primers  
Table 2.7 Primer sequences 
Target 
gene 
Sequence Melting 
Temp (oC) 
IAV M-
gene - Fw 
5' - CTT CTA ACC GAG 
GTC GAA ACG TA - 3' 
60.6 
IAV M-
gene - Rv 
5' - GGT GAC AGG ATT 
GGT CTT GTC TTT A - 3' 
61.3 
 
2.1.11 Buffers and Solutions 
 
96 
 
Table 2.8 List of buffers and solutions  
0.5M Tris-HCl, pH 6.8 (100ml) 
6g Tris base  
60ml diH2O 
Adjust to pH 6.8 with HCl 
To 100ml with H2O 
 
 
1.5M Tris-HCl, pH 8.8 (150ml) 
27.23g Tris base  
80ml diH2O 
Adjust to pH 8.8 with HCl 
To 150ml with diH2O 
 
 
10% APS (1ml) 
0.1g Ammonium persulfate  
1ml diH2O 
 
 
10% SDS (100ml) 
10g SDS 
100ml diH2O 
 
 
10x D-PBS w/o Ca++ and Mg++ Lonza (Slough, UK) 
10x NTC Buffer (500ml) 
29.22g NaCl 
2.775 CaCl 
100ml 1M Tris 
400ml diH2O 
 
1M Tris-HCl, pH7.6 (100ml) 
12g Tris Base  
60ml diH2O 
Adjust to pH 6.8 with HCl 
To 100ml with diH2O 
 
 
1x D-PBS w/o Ca++ and Mg++ 
 
Lonza (Slough, UK) 
1X ELISA Wash (2ltr) 
200ml 10x D-PBS w/o Ca++ and Mg++ 
799ml diH2O 
1ml Tween 20 
 
 
30% sucrose (100ml) 
30g sucrose 
100ml diH2O 
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Bromophenol blue, 0.25%, 10ml 
25mg Bromophenol blue  
10ml diH2O 
 
 
Crystal Violet solution 1x 
40ml 2.5% crystal violet 
80ml Methanol 
300ml diH2O 
 
PBS-EDTA (1.236mM EDTA) Lonza (Slough, UK) 
RIPA Buffer (100ml) 
0.88g NaCl  
0.15g EDTA  
1ml Triton X-100  
1g Sodium deoxycholate  
0.1g SDS  
2.5ml 1M Tris-HCL, pH7.6 
96.5ml diH2O 
  
 
SDS-page Running buffer 10x – (1ltr) 
30.3g Tris base  
144.1g Glycine  
10g SDS  
1ltr diH2O 
 
 
SDS-page sample buffer 5x (10ml) 
3.75ml 0.5M Tris-HCl, pH6.8  
4.5ml Glycerol  
0.5ml 0.25% bromophenol blue  
0.5g SDS  
12.5% β-mercaptoethanol before use 
 
 
Silver ethanol wash solution (100ml) 
10ml acetic acid 
90ml diH20 
 
 
Silver stain fixing solution (100ml) 
30ml ethanol 
10ml acetic acid 
60ml diH20 
 
 
Silver stain stop solution (100ml) 
5ml acetic acid 
95ml diH20 
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Transfer buffer 10X (1ltr)  
30.3g Tris Base 
144.1g Glycine  
1ltr diH2O 
 
 
Tris-buffered saline (TBS) – 10x, (1ltr)  
24.2g Tris base (Fisher – 10376743) 
292.4g NaCl (Fisher – 10428420) 
500ml diH2O 
Adjust to pH 7.5 with HCl 
To 1ltr with diH2O 
 
 
Tween- Tris-buffered saline (TTBS) wash solution (1ltr) 
0.5ml Tween 20  
100ml 10x TBS 
To 1ltr with diH2O 
 
 
Western blot antibody buffer – 3% BSA TTBS (200ml) 
6g BSA  
200ml TTBS 
 
 
Western blot blocking Buffer – 5% non-fat milk –TBS 
(100ml) 
non-fat milk powder 
10ml 10x TBS 
90ml diH2O 
 
 
 
2.1.12 Cells 
2.1.12.1 MPI 
MPI cell line is a recently established, GM-CSF-dependent mouse primary macrophage.  
These cells originate from C57BL/6 (BL6) mice, prepared as recently described (Fejer., 
et al 2013). These cells were kept in culture for no more than 25 passages. 
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2.1.12.2 MARCO KO MPI  
MARCO KO MPI cells originate from MARCO -/- C57BL/6 (BL6) mice, prepared as 
described in Maler et al. (2017). These cells were kept in culture for no more than 25 
passages 
2.1.12.3 A549 
A549 is a human lung epithelial cell line, originating from a 58-year-old Caucasian male 
with lung carcinoma. These cells were supplied by the European collection of 
Authenticated Cell Cultures, (ECACC) (PHE, Porton Down, UK). (ECACC 86012804) 
These cells were kept in culture for no more than 25 passages. 
2.1.12.4 MDCK 
MDCK is a canine kidney cell line, origination from a Cocker Spaniel kidney in 1958, and 
is described as an epithelial-like cell type. These cells were supplied by the European 
collection of Authenticated Cell Cultures (ECACC) (PHE, Porton Down, UK). (ECACC 
85011435) These cells were kept in culture for no more than 25 passages. 
2.1.12.5 MLE-12 
MLE-12 is a murine lung epithelial transformed cell line, from a 5-month-old female 
FVB/N mouse. These cells were supplied by the American Type Culture Collection 
(ATCC) (Middlesex, UK). (ATCC CRL-2110) These cells were kept in culture for no more 
than 25 passages. 
2.1.12.6 L929 
L929 is a murine fibroblast cell line, from 100-day old male C3H/An mouse, originating 
from adipose tissue. These cells we provided by Dr Marekia Maler, University of 
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Freiburg. These cells were kept in culture for no more than 25 passages and used for 
the generation of condition media containing M-CSF. 
2.1.12.7 X-63-GM-CSF 
X63-GM-CSF is a HAT sensitive Ag8653 myeloma cell transfected with murine GM-CSF 
cDNA. These cells we provided by Dr Marekia Maler, University of Freiburg. These cells 
were kept in culture for no more than 25 passages and used for the generation of 
condition media containing GM-CSF. 
2.1.12.8 RAW-Blue ISG 
RAW-Blue ISG are murine RAW 264.7 macrophages with an interferon regulatory 
factor (IRF) inducible secreted embryonic alkaline phosphatase (SEAP) reporter 
construct, to detect bioactive murine type I IFNs. These cells were supplied by Inviogen 
(Toulouse, France) (RAW-ISG). These cells were kept in culture for no more than 25 
passages. 
2.1.13 Media and Supplements  
2.1.13.1 Media 
Table 2.9 List of cell culture medium and suppliers 
10x MEM Lonza (Slough, UK) 
DMEM high glucose Lonza (Slough, UK) 
F12 Nutrient Mix Thermo Fisher Scientific (Gibco) 
(Hemel Hempstead, UK) 
RMPI 1640 Lonza (Slough, UK) 
 
2.1.13.2 Supplements 
Table 2.10 List of cell culture supplements and suppliers 
BSA (Bovine Serum Albumin) Sigma Aldrich (Dorset, UK) 
DEAE Dextran Sigma Aldrich (Dorset, UK) 
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FBS EU Grade Origin: Brazil Thermo Fisher Scientific 
(Hemel Hempstead, UK) 
HEPES 1M Lonza (Slough, UK) 
Hydrocortisone 50µM Sigma Aldrich (Dorset, UK) 
Insulin from Bovine pancreas (cell 
culture grade) 
Sigma Aldrich (Dorset, UK) 
L-Glutamine 200mM Lonza (Slough, UK) 
Penicillin-Streptomycin 10,000U/ml Lonza (Slough, UK) 
Sodium Carbonate 7.5% Sigma Aldrich (Dorset, UK) 
Sodium Pyruvate (100mM) Lonza (Slough, UK) 
Sodium Selenite Sigma Aldrich (Dorset, UK) 
Transferrin Sigma Aldrich (Dorset, UK) 
Zeocin Invivogen (Toulouse, 
France) 
β-estradiol Sigma Aldrich (Dorset, UK) 
 
2.1.13.3 L-cell condition medium for bone marrow derived macrophages: 
L-929 fibroblasts were seeded at 1x105/ml in 175cm2 tissue culture flasks at 37oC, 5% 
CO2, humidified atmosphere in DMEM supplemented with 10% V/V FBS, 100U/ml 
penicillin, 100U/ml streptomycin, 2mM L-glutamine, 5mM HEPES. After 7 days of 
culture the supernatant was collected, clarified by centrifugation at 1000 rpm for 5 
minutes and pooled with other supernatants. The pooled supernatants were sterile 
filtered through a 0.45µm pore filter and stored in aliquots at -80oC. 
2.1.13.4 X-63 – GM-CSF condition medium for MPI cell culture:  
X-63 cells were seeded at 2.5x105/ml in 75cm2 tissue culture flasks at 37oC, 5% CO2, 
humidified atmosphere in RPMI 1640 supplemented with 10% V/V FBS, 100U/ml 
penicillin, 100U/ml streptomycin, 2mM L-glutamine. After 7 days of culture the 
supernatant was collected, clarified by centrifugation at 1000 rpm for 5 minutes and 
pooled with other supernatants. The pooled supernatants were sterile filtered through 
a 0.45µm pore filter and stored in aliquots at -80oC. 
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2.1.13.5 Plutznik-medium for bone marrow derived macrophage differentiation 
DMEM medium was supplemented with 20% V/V FBS, 20% V/V L-cell condition 
medium, 1mM sodium pyruvate, 2mM L-glutamine, 100U/ml Penicillin, and 100U/ml 
Streptomycin. 
2.1.14 Inhibitors and Blockers 
Table 2.11 List of inhibitors/blockers and suppliers 
Name Inhibits/blocks: Supplier IC-50 
Asialofetuin MGL Sigma Aldrich (Dorset, UK) N/A 
BX795 RIG-I (TBK1) Invivogen (Toulouse, France) 11nM 
Chloroquine Endosomal 
acidification 
Sigma Aldrich (Dorset, UK) H3N2 IAV 
replication - 
0.84µM 
Dynasore Dynamin Sigma Aldrich (Dorset, UK) 15µM 
EIPA Membrane ruffling Sigma Aldrich (Dorset, UK) 10.5µM 
Gefitinib NOD-2 Invivogen (Toulouse, France) 33nMM 
Isoliquiritigenin Inflammasome Invivogen (Toulouse, France) 358.9µM 
Mannan MMR Sigma Aldrich (Dorset, UK) N/A 
ODN2088 TLR-7,8,9 Invivogen (Toulouse, France) N/A 
R406 Syk Invivogen (Toulouse, France) 41nM 
SB203580 p38 Invivogen (Toulouse, France) 0.3-0.5µM 
Sialidase Sialic acid Sigma Aldrich (Dorset, UK) N/A 
SP600125 JNK Invivogen (Toulouse, France) 40-90µM 
TLR3/dsRNA 
Complex 
Inhibitor 
TLR-3 Merck Millipore (Hertfordshire, 
UK) 
3.44µM 
UO126 MEK/ERK Sigma Aldrich (Dorset, UK) 10-20µM 
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2.2 Methods 
2.2.1 Cell counting  
Haemocytometer counting was used to determine the number of cells in suspension. 
Cell suspension and 0.4% trypan blue dye mixed thoroughly at a ratio of 1:1, this 
cell/trypan blue suspension was loaded into the counting chamber of the 
haemocytometer, where the cells were counted by eye under two separated fields of 
view, excluding dead cells stained blue. An average of the two counts was taken, 
multiplied by two, for the trypan blue dilution, and converted to cell number/ml. 
2.2.2 Cell Culture 
All cells were grown in a humidified atmosphere at 37oC with 5% CO2. 
2.2.2.1 MPI (WT and MARCO KO) 
The mouse AM like MPI were grown in 75cm2 tissue culture flasks in RPMI 1640 
supplemented with 10% V/V FBS, 2mM L-glutamine, 100U/ml penicillin, 100U/ml 
streptomycin and 1% V/V X-63 – GM-CSF condition medium. Culture routine consisted 
of removing the medium containing non-adherent cells and transferring to a centrifuge 
tube and washing the flask with D-PBS, which was also transferred to the tube. The 
remaining adhered cells were detached using PBS-EDTA at 37oC for 10 minutes. Flask 
was gently tapped to ensure all cells had detached and cells were removed and pooled 
into the centrifuge tube. The cells were pelleted by centrifugation at 1000rpm for 5 
minutes, at which point the supernatant was discarded and cells were resuspended in 
fresh culture medium. Cells were reseeded at a density of 2.5x105 cells/ml. This 
procedure was performed twice weekly, with a 50% medium change halfway through. 
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2.2.2.2 A549 
The human alveolar epithelial A549 cells were grown in 75cm2 tissue culture flasks in 
DMEM supplemented with 10% V/V FBS, 2mM L-glutamine, 100U/ml penicillin, and 
100U/ml streptomycin. Culture routine consisted of discarding the medium and 
washing the flask twice with D-PBS. The remaining adhered cells were detached using 
trypsin-versene at 37oC for 5 minutes. Flask was gently tapped to ensure all cells had 
detached and trypsin-versene was inactivated using culture medium, cell suspension 
was transferred into a centrifuge tube. The cells were pelleted by centrifugation at 
1000rpm for 5 minutes, at which point the supernatant was discarded and cells were 
resuspended in fresh culture medium. Cells were reseeded at a density of 3.3x104 
cells/ml. This procedure was performed twice weekly. 
2.2.2.3 MDCK 
The canine kidney MDCK cells were grown in 75cm2 tissue culture flasks in DMEM 
supplemented with 10% V/V FBS, 2mM L-glutamine, 100U/ml penicillin, and 100U/ml 
streptomycin. Culture routine consisted of discarding the medium and washing the 
flask twice with D-PBS. The remaining adhered cells were detached using trypsin-
versene at 37oC for 5 minutes. Flask was gently tapped to ensure all cells had detached 
and trypsin-versene was inactivated using culture medium, cell suspension was 
transferred into a centrifuge tube. The cells were pelleted by centrifugation at 
1000rpm for 5 minutes, at which point the supernatant was discarded and cells were 
resuspended in fresh culture medium. Cells were reseeded at a density of 3.3x104 
cells/ml. This procedure was performed twice weekly. 
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2.2.2.4 MLE-12 
The mouse lung alveolar epithelial MLE-12 cells were grown in 75cm2 tissue culture 
flasks in F12:DMEM 50:50 mix supplemented with 2% V/V FBS,0.05mg/ml insulin, 
0.01mg/ml transferrin, 30nM sodium selenite, 10nM hydrocortisone 10nM, 10nM β-
estradiol, 10mM HEPES, 100U/ml penicillin, and 100U/ml streptomycin. Culture 
routine consisted of discarding the medium and washing the flask twice with D-PBS. 
The remaining adhered cells were detached using trypsin-versene at 37oC for 5 
minutes. Flask was gently tapped to ensure all cells had detached and trypsin-versene 
was inactivated using culture medium, cell suspension was transferred into a 
centrifuge tube. The cells were pelleted by centrifugation at 1000rpm for 5 minutes, at 
which point the supernatant was discarded and cells were resuspended in fresh 
culture medium. Cells were reseeded at a density of 3.3x104 cells/ml. This procedure 
was performed twice weekly. 
2.2.2.5 L929 
L-929 cells were grown in 75cm2 tissue culture flasks in DMEM supplemented with 10% 
V/V FBS, 2mM L-glutamine, 100U/ml penicillin, and 100U/ml streptomycin. Culture 
routine consisted of discarding the medium and washing the flask twice with D-PBS. 
The remaining adhered cells were detached using trypsin-versene at 37oC for 5 
minutes. Flask was gently tapped to ensure all cells had detached and trypsin-versene 
n was inactivated using culture medium, cell suspension was transferred into a 
centrifuge tube. The cells were pelleted by centrifugation at 1000rpm for 5 minutes, at 
which point the supernatant was discarded and cells were resuspended in fresh 
culture medium. Cells were reseeded at a density of 6.6x104 cells/ml. This procedure 
was performed twice weekly. 
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2.2.2.6 X-63 
X-63 cells were grown in 75cm2 tissue culture flasks in DMEM supplemented with 10% 
V/V FBS, 2mM L-glutamine, 100U/ml penicillin, and 100U/ml streptomycin. Culture 
routine consisted of discarding the medium and flask twice with D-PBS. The remaining 
adhered cells were detached using PBS-EDTA at 37oC for 5 minutes. Flask was gently 
tapped to ensure all cells had detached and trypsin-versene was inactivated using 
culture medium, cell suspension was transferred into a centrifuge tube. The cells were 
pelleted by centrifugation at 1000rpm for 5 minutes, at which point the supernatant 
was discarded and cells were resuspended in fresh culture medium. Cells were 
reseeded at a density of 2.5x105 cells/ml. This procedure was performed twice weekly. 
2.2.2.7 Bone marrow derived macrophages (BMDMs) 
Bone marrow was obtained from 6 to 8 week-old male and female C57/Black6/J mice. 
Mice were killed following Schedule 1 methods of exposure to CO2 gas in rising 
concentrations followed by cervical dislocation of the neck. The joints were cut at both 
ends and the bone marrow was washed out with D-PBS using a 19GA lancet inserted 
into one end. The bone marrow from several bones containing the macrophage 
precursor cells were pelleted at 1000rpm for 5 minutes. Supernatant was discarded 
and the cells were resuspended in Plutznik medium. All cells were counted and seeded 
in 75cm2 flasks at 1x106 cells/ ml of Plutznik medium. Cells were cultured for 10 days, 
with a complete medium change at day 7 to refresh medium and remove any 
remaining red blood cells. On day 10 more than 98% of the cells are macrophages, 
(Freudenberg, et al., 1986), and cells were used for experiments. The medium was 
discarded and the flask was washed twice with D-PBS. The remaining adhered cells 
were detached using trypsin-versene at 37oC for 5 minutes. Flasks was gently tapped 
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to ensure all cells had detached and trypsin-versene was inactivated using plutznik 
medium, cell suspension was transferred into a centrifuge tube. The cells were 
pelleted by centrifugation at 1000rpm for 5 minutes, at which point the supernatant 
was discarded and cells were resuspended in 5ml fresh culture medium. Cells were 
counted and seeded at required density for experiments. 
2.2.2.8 RAW-Blue ISG 
The RAW-Blue ISG cells were grown in 75cm2 tissue culture flasks in DMEM 
supplemented with 10% V/V FBS, 2mM L-glutamine, 100U/ml penicillin, and 100U/ml 
streptomycin. Culture routine consisted of discarding the medium and detaching 
adhered cells using a cell scraper. Flask was washed with D-PBS to ensure all cells were 
suspended and cell suspension was transferred into a centrifuge tube. The cells were 
pelleted by centrifugation at 1000rpm for 5 minutes, at which point the supernatant 
was discarded and cells were resuspended in fresh culture medium. Cells were 
reseeded at a density of 1x105 cells/ml with the addition of 200µg/ml of zeocin. This 
procedure was performed twice weekly. 
2.2.3 Influenza virus Propagation  
Influenza virus Strains were grown in either MDCK cells or 9 to 11-day SPF-
embryonated hen eggs, as described in Szretter, et al., 2006, with minor modifications 
regarding equipment, volumes and timings, established by Public Health England, 
Porton Down. The fully detailed protocols are described in 2.2.3.1 and 2.2.3.2. 
2.2.3.1 For Embryonic egg: 
Eggs were set at 37oC, humidified atmosphere, with the air sack pointing up; the eggs 
were then incubated while rocked for 9-11 days. Before inoculation, eggs were candled 
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to mark the position of the inoculum site, above the end of the air sack and at the 
opposite end to the embryo. Any unfertilised, cracked or dead eggs were discarded at 
this point.  A hole was placed in the egg at the marked point about 2-5mm above the 
end of the air sack, and a second another 5mm above this. Virus inoculum (100µl) 
containing 103 PFU/ml, diluted in PBS, was added by injection through the lower hole, 
with the needle fully inserted. The two holes were then sealed with multiple layers of 
glue. The infected eggs were incubated with the air sacks pointed up, at 33oC, 
humidified atmosphere, for 72hrs. During this time the eggs were not rocked. After the 
incubation period, eggs were chilled at 4oC for 4 hours to kill the embryo, after which 
the top of the egg around the air sack was cracked and removed. The membrane was 
pulled back, and the embryo and yolk sack was pushed to the side using a spatula that 
created a clear pool of fluid that was harvested. A small amount of blood was 
acceptable in the harvesting step; however, breakage of the yolk sack resulted in the 
discard of the entire egg. Fluid from multiple eggs was pooled and clarified by 
centrifugation at 3000rpm for 5 minutes, then aliquoted into 1ml volumes and frozen 
at -80oC before being quantified. 
2.2.3.2 For cell culture: 
MDCK cells were seeded in respective culture medium in tissue culture flasks at 1.6 
x105 cells/4ml. After 24hrs culture, cells were washed with D-PBS twice and inoculated 
with 1-5ml of virus inoculum (made in serum free culture medium) at 0.01 multiplicity 
of infection (MOI) or mock inoculum as a control for 1hr at 37oC, with gentle agitation 
every 15 minutes to ensure complete coverage of the cells. Virus inoculum containing 
any unabsorbed virus was removed and cells were gently washed with serum free 
medium to remove as much unabsorbed virus as possible. Fresh serum free culture 
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medium was added containing 2µg/ml TPCK-treated trypsin to facilitate virion release 
and the cells were incubated at 37oC, 5% CO2, humidified atmosphere for 72 hours. 
Supernatant were collected and pooled if using multiple flasks, then clarified by 
centrifugation at 1500rpm for 10 minutes at 4oC, split into 1 aliquot, then stored at -
80oC before being quantified. 
2.2.4 Influenza A virus quantification 
The titres of infectious Influenza virus were quantified by plaque assay on MDCK cells 
as described in Szretter, et al., 2006, with modification established by Public Health 
England, Porton Down. The fully detailed protocol is described in 2.2.4.1. 
2.2.4.1 Plaque assay: 
MDCK cells were seeded in 12 well plates, at least one day before experiment, to give 
final cell number of 1x105 cell/1ml culture medium. For majority of experiments 3 
plates were used for each sample quantification. After 24hrs at 37oC, 5% CO2, 
humidified atmosphere, culture medium was removed and the cells were washed with 
D-PBS. Virus for quantification was 10-fold serially diluted in serum free culture 
medium to give dilutions ranging from neat to 10-10, with a mock infected control. 
Inoculum (200µl) of the 10 dilutions was added in triplicate for each dilution and the 
cells were incubated at 37oC for 1 hour, with gentle agitation every 15 minutes to 
endure complete coverage of the monolayer. Virus inoculum containing any 
unabsorbed virus was removed, and 1ml of agar plaque assay overlay medium with 
2µg/ml TPCK-treated trypsin to facilitate virion release was added to each well and 
allowed to solidify. Cells were incubated at 37oC, 5% CO2, humidified atmosphere for 
72 hours, at which point the cells were fixed with 20% formaldehyde added over the 
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agar plug for 15 minutes. The agar plugs were removed using a steady stream of water 
to dislodge, and the fixed cell monolayer was stained with 0.5ml crystal violet solution 
for 5 minutes. Excess stain was removed and the cells were washed twice in water. 
Plaques were visualised as clear circles against the purple monolayer, and counted by 
eye, where an average was taken from the three replicate wells. Virus titration was 
corrected to give plaque forming units (PFU)/ml. 
2.2.5 Viral infection of cells  
All cells were seeded 1 day before infection, in normal culture medium at 37oC, 5% 
CO2, humidified atmosphere, to allow cells to attach and equilibrate back to their cell 
cycle after the detachment procedure. For Mock infected controls, egg allantoic fluid 
was used to provide proper control for the virus grown in embryonated hen eggs.  
Trying to recreate a relevant infective dose was important for these experiments. In 
order to replicate the clinical environment as closely as possible two things need to be 
considered, firstly the average AM population in the lung, and the average IAV PFU 
during a seasonal infection. Bronchial alveolar lavage (BAL) in the work of Nakata et al. 
(1999) yielded average AM numbers of 8.2x104/ml, while IAV titres of symptomatic 
patient nasal washes were found to average 5.7x104/ml (Tobita et al., 1975). With both 
of these numbers, there is a high degree of variability between individuals, but it can 
be deduced that a MOI of 0.7 is experienced for AMs during seasonal lung infection. 
For these experiments this is rounded to a MOI of 1 for ease, which is used for the 
majority of experiments. For comparison purposes 0.2 and 5 MOIs are also used to 
show low and high infectivity respectively. 
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2.2.5.1 For Cytokine, Chemokine, and type I IFN induction: 
Cells were seeded in respective culture medium in 96 well plates at 1x105 cells/200µl. 
After 24hrs culture, cells were washed with 200µl D-PBS and inoculated with 35µl of 
virus inoculum (made in serum free culture medium) at 0.2, 1, or 5 multiplicity of 
infection (MOI) or mock inoculum as a control in triplicate for 1hr at 37oC. Virus 
inoculum containing any unabsorbed virus was removed and fresh culture medium 
was added and the cells were incubated at 37oC, 5% CO2, humidified atmosphere for 
time points indicated. Supernatants were collected and stored at -80oC before cytokine 
detection. 
2.2.5.2 For viral replication: 
Cells were seeded in respective culture medium in 6 well plates at 8 x105 cells/2ml. 
After 24hrs culture, cells were washed with 2ml D-PBS and inoculated with 400µl of 
virus inoculum (made in serum free culture medium) at 0.01 multiplicity of infection 
(MOI) or mock inoculum as a control for 1hr at 37oC. Virus inoculum containing any 
unabsorbed virus was removed and cells were gently washed with serum free medium 
to remove as much unabsorbed virus as possible. Fresh serum free culture medium 
was added containing 2µg/ml TPCK-treated trypsin to facilitate multiple viral infection 
cycles and the cells were incubated at 37oC, 5% CO2, humidified atmosphere for time 
points indicated. Supernatants were collected and clarified by centrifugation at 
1500rpm for 10 minutes at 4oC then stored at -80oC before virus titration. 
2.2.5.3 For imaging  
Cells were seeded in respective culture medium in 8 well chamber slides at 1.25x105 
cells/200µl. After 24hrs culture, cells were washed with 200µl D-PBS and inoculated 
with 50µl of virus inoculum (made in serum free culture medium) at 1 multiplicity of 
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infection (MOI) or mock inoculum as a control for 1hr at 37oC. Virus inoculum 
containing any unabsorbed virus was removed and fresh culture medium was added 
and the cells were incubated at 37oC, 5% CO2, humidified atmosphere for 2 and 6hr. 
Supernatant was removed and the cells washed with D-PBS and fixed with 4% 
formaldehyde for 30 mins and stored at 4oC in PBS before staining and imaging. 
2.2.5.4 For phospho-western blots 
Cells were seeded in respective culture medium minus FBS in 12 well plates at 1x106 
cells/1ml. After 24hrs culture, cells were washed with D-PBS and inoculated with 200µl 
of virus inoculum (made in serum free culture medium) at 5 multiplicity of infection 
(MOI) or mock inoculum as a control for 1hr at 37oC. For adequate visualisation of 
phosphorylated proteins infection with MOI of 0.2 and 1 were insufficient. Virus 
inoculum containing any unabsorbed virus was removed and fresh culture medium 
minus FBS was added and the cells were incubated at 37oC, 5% CO2, humidified 
atmosphere for time points indicated. Supernatant was removed and the cells washed 
with ice-cold D-PBS, and 100µl of ice-cold RIPA buffer with 1% protease/phosphatase 
inhibitor was added. After incubation for 15mins at 4oC, cell lysate was pipetted up and 
down to ensure lysis, then removed to a protein-lo bind tube. The lysate was then 
centrifuged at 14,000G for 15min at 4oC to remove cell debris, with the supernatant 
transferred to a clean protein lo-bind tube and stored at -80oC for gel electrophoresis. 
2.2.5.5 For PCR 
Cells were seeded in respective culture medium in 12 well plates at 1x106 cells/1ml. 
After 24hrs culture, cells were washed with D-PBS and inoculated with 200µl of virus 
inoculum (made in serum free culture medium) at 1 multiplicity of infection (MOI) or 
mock inoculum as a control for 1hr at 37oC. Virus inoculum containing any unabsorbed 
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virus was removed and fresh culture medium was added and the cells were incubated 
at 37oC, 5% CO2, humidified atmosphere for time points indicated. Supernatant was 
removed and the cells washed with D-PBS, and 1ml of TriFast lysis buffer was added. 
Cell lysate was pipetted up and down to ensure lysis, then removed to an 
RNase/DNase free tube. Samples were then immediately taken for RNA extraction, see 
2.2.15.1. 
2.2.6 ELISA 
Samples were prepared as described in 2.2.5.1 
All washing performed three times using either multichannel pipet or wash bottle with 
ELISA wash solution (see Table 2.8Table 2.8 List of buffers and solutions). Each well of a 
96-well plate (Nunc, Maxisorp) was coated with 50µl of capture antibody in PBS and 
incubated at 4oC overnight. Primary antibody was removed, and the wells washed, 
each well was then blocked with 100µl 2% BSA for one hour at room temperature. The 
standard was made using 2-fold serial dilutions of the specific recombinant protein in 
RPMI, and an 8th blank of just RPMI. Any samples that needed dilutions were done in 
RPMI also. After blocking, BSA was removed and the wells washed, and 50µl of 
standards and samples were added to the plate. Plate was incubated at 4oC overnight 
or room temperature for 2 hours. Standards and samples were removed and the wells 
washed, 50µl of detection antibody in PBS was added to each well. The plate was 
incubated at room temperature for 1 hour, the detection antibody was removed and 
the wells washed. 50µl of Strep-avidin diluted 1:500 in PBS was added to each well and 
incubated at room temperature for 30 minutes, after which strep-avidin was removed 
and the wells washed. At this point the bottom of the plate was cleaned to remove 
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smudges, and 50µl of super aqua blue substrate was added to each well, and 
incubated out of direct light for 15-30 minutes, the OD was measured at 405nm using 
plate reader. Concentration in the samples was determined via the standard curve 
generated by the standards as calculated by MARS data analysis software, taking into 
account any dilutions.  Specific standard range and antibody concentrations use are 
stated below. 
Table 2.12 ELISA standard ranges and antibody concentrations 
 
 
 
 
 
2.2.7 Type I IFN Assay 
Samples were prepared as described in 2.2.5.1 
RAW-Blue ISG cells were washed and seeded in culture medium with heat inactivated 
FBS (test medium), in 96 well plates at 1 x105 cells in 180µl. The standard was made 
using 2-fold serial dilutions of recombinant IFN-β protein in test medium, and an 8th 
blank of just test medium. Samples or standard (20µl) were added to the cells and 
incubated at 37oC, 5% CO2, humidified atmosphere for 18hrs. Supernatants were 
removed and stored at -20oC before continuing. Supernatant (50µl) was added to 
150µl of QUABTI-Blue solution and incubated for 2hr at 37oC. The bottom of the plate 
was cleaned to remove smudges, the OD was measured at 620nm using plate reader. 
Antigen Standard Range Capture Antibody Detection Antibody 
IL-6 31-2000 pg/ml 2µg/ml 2µg/ml 
TNF-α 31-2000 pg/ml 3µg/ml 2µg/ml 
IL-1α 31-2000 pg/ml 0.5µg/ml 0.25µg/ml 
IL-1β 31-2000 pg/ml 2µg/ml 3µg/ml 
MIP-1α 31-2000 pg/ml 0.5µg/ml 0.25µg/ml 
MIP-2 31-2000 pg/ml 0.5µg/ml 0.25µg/ml 
RANTES 31-2000 pg/ml 0.5µg/ml 0.25µg/ml 
IP-10 31-2000 pg/ml 2µg/ml 2µg/ml 
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Figure 2.1 Standard curve obtained from recombinant IFN-b used to determine the concentration of 
Type I Interferon in samples 
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Concentration of type I IFN in the samples was determined via the standard curve 
generated by the standards (Figure 2.1) as calculated by MARS data analysis software 
V3.32 R5, taking into account any dilutions.   
 
 
 
 
 
  
 
 
 
 
2.2.8 Viral Infection Imaging  
Samples were prepared as described in 2.2.5.3. 
All washing steps were performed three times using D-PBS. Fixed samples in 8 well 
chamber slides were removed from 4oC storage, D-PBS was removed and the cells 
permeabilised with 0.01 Triton X-100 for 3 mins. Triton X-100 was removed and the 
wells were washed before being blocked with 10% BSA- D-PBS for 30 mins at room 
temp. Murine anti-IAV NP antibody was diluted 1:50 using 1.5% BSA- D-PBS. BSA was 
removed and the wells were washed before the addition of anti-IAV NP antibody for 
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1hr at room temp. Anti-Murine IgG alexafluor 594 was diluted 1:6000 in 1.5% BSA- D-
PBS.  Anti-IAV NP antibody was removed and the wells washed before the addition of 
Anti Murine IgG alexafluor 594 for 45 mins at room temp. Anti-Murine IgG alexafluor 
594 was removed and wells were washed prior to the addition of 0.5ng/ml DAPI (in D-
PBS) for 5 mins at room temp. DAPI was removed and the wells washed. The chambers 
were removed and the cell coated coverslip was mounted to a slide using aqueous 
mounting media. Slides were analysed via fluorescent microscopy using DAPI and 
Texas red filter sets for DAPI and alexafluor 594 respectively. Images of both were 
merged to provide final images.  
2.2.9 Viral Binding Assay 
2.2.9.1 In-direct FACs 
Cell suspension in serum-free culture medium were infected with purified 
concentrated IAV at 100 multiplicity of infection (MOI) to fully saturate the cell surface 
or mock inoculum as a control for 1hr at 4oC to allow binding but prevent uptake. Cells 
were then pelleted by centrifugation at 1000rpm for 5 mins at 4oC, and the 
supernatant was removed, cells were then washed twice in cold D-PBS to remove any 
non-bound virus. Cells were then fixed in 4% formaldehyde for 30mins, after which 
cells were washed twice in cold D-PBS. Rabbit anti-IAV HA H3 antibody was diluted 
1:500 using 3% BSA- D-PBS and incubated with the cells for 30 mins at room 
temperature. Antibody was removed and cells washed 3 times in D-PBS. Anti-rabbit 
IgG alexafluor 488 was diluted 1:6000 using 3% BSA- D-PBS and incubated with the 
cells for 30 mins at room temp. Antibody was removed and cells washed 3 times in D-
PBS. Cells were resuspended in D-PBS and processed via the flow cytometer with 488 
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laser, with a minimum of 10,000 events recorded. Gating for individual samples was 
set to remove low size, low fluorescent particles. 
2.2.10 Phospho-Western Blot 
Samples were prepared as described in 2.2.5.4. 
2.2.10.1 Gel casting 
Polyacrylamide gels were cast in 1.5mm glass plates, with 15 well combs. Plates were 
filled with 7ml of 12% resolving gel, allowed to polymerise, then topped up with 4% 
stacking gel, with the 15 well combs. The recipe for each gel is as follows: 
Table 2.13 Acrylamide gel recipe  
 4% Stacking 12% Resolving 
30% Acrylamide/Bis 528μl 2.8ml 
0.5M Tris-HCl pH 6.8 1008μl - 
1.5M Tris-HCl pH 8.8 - 1.75ml 
10% SDS 40μl 70μl 
diH2O 2.4ml 2.347ml 
TEMED 4μl 2μl 
10% APS 20μl 35μl 
Total Volume 4ml 7ml 
 
Gels were either used immediately or stored in washing buffer for 2 days at 4oC 
2.2.10.2 Gel electrophoresis  
Samples from -80oC were thawed on ice, 20µg of total protein (as estimated by BCA 
assay) was mixed with 5X SDS page sample buffer to yield 1X concentration. Samples 
were boiled at 95oC for 5 mins, and then centrifuged at 14,000G for 15 mins to pellet 
any debris. Casted gels were placed into running modules, with both inner and outer 
chambers filled to marked levels with 1x running buffer. Biotin conjugated and pre-
stained marker were loaded into the first wells, followed by samples. Well volumes 
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were adjusted to equal volumes with 1x loading buffer to ensure uniform running. Gels 
were run at 130v until samples had reached the bottom of the gel (45-60mins). 
2.2.10.3 Transfer 
Gels were removed from running cassettes and plates and equilibrated in 1x transfer 
buffer for 5mins. Transfer cassettes were assembled in the following order: Cathode – 
foam – filter paper- gel – membrane – filter paper – foam – anode. At each assembly 
stage, air bubbles were removed, and once gel-membrane contact was made it was 
not adjusted. A 0.45-micron PVDF- membrane was used, ensuring activation in 
methanol prior to use. Transfer cassettes were placed in transfer tank containing cold 
1x transfer buffer and were run at 30mA overnight at 4oC. 
2.2.10.4 Immuno-detection 
After removing membranes from transfer cassettes, the effectiveness of the transfer 
was determined by pre-stained marker success. All wash steps were done 3 times in 
TTBS for 5 mins under agitation, all incubation periods were also performed under 
agitation.  
Membrane was washed after transfer and incubated with blocking solution for 1hr. 
Membrane was washed and incubated in primary antibody diluted in antibody buffer 
overnight at 4oC. Membrane was washed and incubated in HRP-secondary antibody, 
and HRP-biotin marker antibody diluted in TTBS for 45mins at room temp. Membrane 
was washed and incubated in SuperSignal West Pico Chemiluminescent Substrate for 1 
min at room temperature before chemiluminescent imaging. The exposure time for 
each membrane was automatically determined by the geneSys image acquisition 
software. Antibodies and their concentrations can be found below: 
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Table 2.14 Phospho western blot antibody concentrations 
Primary 
Antibody 
Expected 
band 
size 
Dilution Secondary 
Antibody 
Dilution 
P-TBK1 84 1:50 Anti-Rabbit 
IgG- HRP 
1:2000 
P-IRF3 50-55 1:50 Anti-Rabbit 
IgG- HRP 
1:2000 
P-p38 43 1:50 Anti-Rabbit 
IgG- HRP 
1:2000 
P-NF-kB 
(P65) 
65 1:50 Anti-Rabbit 
IgG- HRP 
1:2000 
GAPDH 37 1:6000 Anti-Mouse 
IgG- HRP 
1:2000 
   anti-biotin-
HRP 
1:2000 
 
2.2.11 IAV Protein Western Blot 
Purified and concentrated IAV samples were used as described in 2.2.13, with protein 
concentration estimated via BCA assay, as described in 2.2.12. 
2.2.11.1 Gel electrophoresis  
Pre-cast gradient gels of 4-16% were used to separate viral proteins, with the gels 
being run as described in 2.2.10.2, however the protein concentration was reduced to 
1µg. 
2.2.11.2 Transfer 
Viral proteins gels for western blotting were transferred to membranes as described in 
2.2.10.3. 
2.2.11.3 Immuno-detection 
Immuno-detection for viral proteins were performed as described in 2.2.10.4, using 
the following antibodies and concentrations: 
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Table 2.15 IAV protein western blot antibody concentrations 
Primary 
Antibody 
Expected 
band size 
Dilution Secondary 
Antibody 
Dilution 
IAV H3 
HA 
HA0 – 80-85 
HA1 – 50-55 
HA2 – 25-30 
1:500 Anti-Rabbit 
IgG- HRP 
1:2000 
   anti-biotin-
HRP 
1:2000 
     
 
2.2.12 Protein quantification 
IAV protein samples were used as described in 2.2.13, and cell protein samples were 
generated as described in 2.2.5.4. 
2.2.12.1  Bicinchonic acid protein assay (BCA) 
Bicinchoninic Acid Kit for Protein Determination for 200-1000 μg/ml protein was used 
to determine protein concentration. BCA working solution of 4% copper sulphate and 
Bicinchonic acid solution was prepared at 1:50 ratio, and 200µl added per well of a 96 
well plate. BSA standards were prepared in RIPA buffer at the following concentrations 
1000µg/ml, 800µg/ml, 600µg/ml,400µg/ml, and 200µg/ml, with a final blank of just 
RIPA buffer. Samples requiring dilution, was done in RIPPA buffer also. Samples or 
standards (25µl) were added to the 200µl BCA working solution and incubated at 37oC 
for 30 min. The OD was measured at 562nm using plate reader. Concentration in the 
samples was determined via the standard curve generated by the standards as 
calculated by MARS data analysis software, taking into account any dilutions.   
2.2.13  Viral purification and Concentration 
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IAV was propagated as described in 2.2.3.Virus layered on top of a chilled 30% sucrose 
cushion inside ultra-clear ultracentrifuge tubes. Virions were pelleted through the 
sucrose via ultra-centrifugation at 112,000G for 90mins at 4oC. Supernatant was 
removed and virus pellet was resuspended in 1x NTC buffer, before a second ultra-
centrifugation at 154,000G for 60mins at 4oC to remove residual sucrose. Pellet was 
resuspended in 1x NTC buffer, aliquoted and frozen at -80oC. 
2.2.14 UV Inactivation of IAV 
IAV was propagated as described in 2.2.3. IAV (1ml) was spread over a 35mm petri dish 
and kept on ice to prevent overheating. IAV was exposed to UV light in the spectrum of 
250-270nm for 30mins. The light source was kept as close to the sample as possible 
during inactivation to prevent loss intensity. After this UV-IAV was stored at -80oC and 
infectivity was tested via plaque assay as described in 2.2.4.1. 
2.2.15 Measurement of Viral RNA replication by q-RT PCR 
Samples were generated as described in 2.2.5.5 
2.2.15.1 RNA extraction  
Lysis samples (1ml) were kept at room temp for 5 minutes before the addition of 200µl 
chloroform and shaken vigorously for 15s before incubated at room temp for 15mins. 
Samples were then centrifuged for 12,000G for 5 mins, with the clear upper aqueous 
phase containing RNA was removed to a fresh RNase free tube. Isopropanol (500µl) 
was added and incubated at 4oC for 15 mins, at which point centrifugation at 12,000G 
for 10 mins at 4oC pelleted the RNA precipitate. Supernatant was removed and the 
RNA pellet was washed twice with 75% ethanol and re-pelleted. The pellet was 
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allowed to air dry and resuspended in RNase-free water. RNA quantity and purity were 
assessed via nanodrop before progressing. 
2.2.15.2 Reverse transcription 
RNA (0.5µg total) was diluted in RNase free water into thin walled PCR tubes and was 
reverse transcribed to cDNA using high capacity RNA to cDNA reverse transcriptase kit. 
A Standard was generated of known copy number synthetic T7 transcript of full-length 
M gene, vRNA-sense at using 10-fold serial dilutions ranging from 107-101. Each 
sample/standard and non-template control (ntc) (2µl) was added to wells of a 96 well 
reaction plate. For each sample, the following Master Mix was made: 
 
Table 2.16 Reverse transcription master mix recipe 
Master Mix Component Volume (µl) 
RT buffer 2 
25x dNTP mix  0.8 
10x RT random primers 2 
MultiScribe Reverse Transcriptase 1 
RNase Inhibitor 1 
RNAase free water 3.2 
Total 10 
 
Master mix (10µl) was added to each well with sample/standard, or ntc and the plate 
was sealed and briefly centrifuged. The reverse transcription was run under the 
following conditions: 37oC for 1 hr, stopped by heating at 95oC for 5 min, and then the 
run was held at 4oC using a 96 well thermal cycler machine. Samples were then stored 
at -20oC until q-PCR. 
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2.2.15.3 q-PCR 
The cDNA generated from RT (2.2.15.2) was amplified using Power SYBR Green kit. 
1.2µl of RT reaction was added to the wells of 96 well reaction plate. The following 
master mix was made for each sample: 
Table 2.17 q-PCR master mix recipe 
 
 
 
 
Master mix (10.8µl) was added to each well and the plate was sealed and briefly 
centrifuged. qPRC was run under the following conditions: 95oC for 10 minutes for the 
holding stage, then 40 cycles of denaturation at 95oC for 15s, annealing and extension 
at 60oC for 60s. M-gene copy number of the samples was determined via the standard 
curve generated by the standards as calculated by StepOne Plus software, taking into 
account any dilutions.   
2.2.16 MTT assay 
Samples were prepared as described as in 2.2.5.1. However instead of IAV infection 
cells were exposed to PRR inhibitors. The infected cells were resuspended in 180µl of 
warmed culture medium, to which 20µl of 5mg/ml MTT reagent is added. Plate was 
then incubated for 2hrs at 37oC, 5% CO2, after which medium is removed and 200µl 
DMSO was added to the cells, pipetted up and down to ensure a good mix. The OD was 
Master Mix Component Volume (µl) 
2x Power SYBR Green PCR master mix 6 
Fw Primer (20pmol/µl) 0.12 
Rv Primer (20pmol/µl) 0.12 
RNase free water 4.56 
Total 10.8 
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measured at 540nm using plate reader, with cell viability determined by fold change 
compared to non-treated control. 
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2.3 Software  
2.3.1 Data Analysis and Statistics 
2.3.1.1  GraphPad Prism V6.0 (GraphPad Software. California, US) 
Creating of majority of graphs and performed statistical analysis. 
2.3.1.2  MARS Data analysis software V3.32 R5 (BMG Labtech. Bucks, UK) 
Generated standard curves for absorbance assays, and extrapolated concentrations of 
unknowns from this curve. 
2.3.1.3  ImageJ V1.46r (National Institutes of Health, Maryland, US) 
Merge multiple fluorescent fields into a single image and calculate relative band 
intensity for western blots. 
2.3.1.4  Flowjo V9 (BD Biosciences. Berkshire, UK) 
Merge multiple flow cytometry histograms into one graph 
2.3.1.5  FACSDiva V6.1.3 (BD Biosciences. Berkshire, UK) 
Set gating of cell populations during FACs analysis. 
2.3.1.6  GeneSys image acquisition software V 1.7.2 (SynGene. Cambridge, UK) 
Capture chemiluminescent images, and automatically determined exposure time. 
2.3.1.7  StepOne Plus software v2.3 (Thermo Fisher Scientific. Hemel Hempstead, 
UK) 
Running q-PCR and generating standard curves to extrapolate unknown gene copy 
number from. 
2.3.2 Other software 
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2.3.2.1  Microsoft Office 2016 (Microsoft. Washington, US) 
Microsoft word was used for document production and writing of thesis. Microsoft 
excel was used for data manipulation and storage. Microsoft PowerPoint was used for 
poster and oral presentations.  
2.3.2.2  Biorender.com (BioRender. Ontario, Canada) 
Biorender was used to create artistic diagrams and figures for the thesis. 
2.3.2.3  Endnote X8.2 (Clarivate Analytics. Pennsylvania, US) 
Endnote was used as a referencing and bibliography complier during the thesis write 
up. 
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3 Chapter Three: Propagation Method 
of Influenza A Affects Viral Entry 
and Immune Response 
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3.1 Introduction 
One of the limiting factors in studying innate immune responses to IAV is the 
availability of primary cells in large enough numbers to investigate fully all the factors 
involved. Many studies tend to perform the majority of experiments on imperfect 
models, with a small number of confirmatory experiments conducted on primary cells. 
The issue with this methodology is the overlooking of results in the initial experiments 
that are not taken forward to study in the primary models. Several studies have found 
differences between cell line macrophages and primary AM’s, the work of Marvin et al. 
(2017) has shown differences in the cytotoxicity caused by IAV infection in macrophage 
cell lines and primary macrophages. Moreover the work of Londrigan et al. (2015) 
showed there was an initial period of productive replication in cell line macrophages 
but not primary cells. 
Furthermore, it is now generally accepted that there is variation in both the receptor 
distribution and cytokine production between separate macrophage types, making it 
essential to match the macrophage type to the pathogen involved. In the case of 
respiratory infections, AMs present the scavenger receptor MARCO on their surface 
and produce the cytokine IL-1α, whereas RAW264.7 macrophages do not (Fejer et al., 
2013; Maler et al., 2017). MPI macrophages have already been shown to produce 
innate immune responses that mimic those seen in AMs, (Fejer et al., 2013). One of 
the key aims of this chapter is to establish if MPI macrophages can be used as a 
superior model to study early IAV innate immunity, compared to these non-specific 
macrophage models such as BMDMs. 
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Because of the abundance and variation of IAV strains available, it is essential that a 
high and low immune inducing strain be selected in order to fully study the virus-host 
interactions in the later chapters. One of the issues with propagation of the virus is the 
choice of embryonated hen eggs or cell culture using MDCK cells, both of which can be 
used to different levels of success (Szretter et al., 2006). Generally the choice of 
method comes down to ease, with some strains of H3N2 IAV unable to be isolated and 
grown directly in eggs, (Donis et al., 2014) and tends to result in only one of these 
methods used for a strain’s entire passage history. Due to differences in the host 
species of the virus during propagation, it is possible that this may modify the daughter 
virions produced in such a way to alter the immune response in MPI macrophages. It 
has been well documented that IAV undergoes host adaptation during the isolation 
and propagation processes (Choi et al., 2020; Xue et al., 2016). Therefore, the optimal 
method should be identified and then used for both selected virus strains to enable 
better comparisons in later studies. If there are any differences between the produced 
viruses induced immune response in MPI macrophages, the secondary aim of this 
chapter is to attempt to identify and explain why this effect occurs.  
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3.2 Results  
3.2.1 Influenza A Strain Selection and Comparison to Established Models 
The inflammatory response of MPI macrophages to different isolates of IAV H1N1 and 
H3N2 strains was established, to aid strain selection for subsequent investigations. The 
inflammatory response was determined by secreted IL-6 and TNF-α as shown in Figure 
3.1. Generally, the H1N1 strain induced lower responses than the H3N2 strain. At the 
time of study the predominant circulating strain was H3N2 (Public Health England, 
2015), thus this strain was chosen for further study. Within this strain there were also 
large variations in the response to different isolates. A strain giving strong induction of 
IL-6 (p=0.008) and TNF-α (p=0.0112), Perth/16/09 and a strain giving weak induction of 
IL-6 (p=0.079) and TNF-α (p=0.234), Texas/50/12 were selected for continued 
investigation.  
 
 
 
 
 
 
Figure 3.1 H3N2 IAV strains generally induced higher levels of IL-6 and TNF-α than H1N1 when infecting 
MPI macrophages.  Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the 
absence of FBS, after which inoculum was removed and the cells were incubated in medium containing 
10% FBS. MA shows mouse adapted strains. At 16hrs, post-infection supernatants were collected and 
(A) IL-6, (B) TNF-α, were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01). Non-
significant values are indicated with n.s.. 
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To assess MPI macrophages as a relevant model of Influenza A – Macrophage 
interactions, comparisons were made with established models of macrophages, such 
as BMDM’s (Figure 3.2, Figure 3.3, and Figure 3.4.). In these experiments the 
Perth/16/09 was used alone rather than with the Texas/50/12 due to the inability if 
the later to induced significant levels of pro-inflammatory cytokines.  
BMDM’s did not produce any significant levels of cytokines in response to the doses 
used, other than IL-6 (MOI 1 p=0.0011), however at lower doses, this production was 
not significant (p=0.941). MPI macrophages produced significant cytokine responses at 
all doses, with the exception of IL-1α at the MOI of 0.2 (p=0.131) (Figure 3.2). 
Comparison of the IAV induction of cytokines by the two macrophages is therefore 
only possible with IL-6 (where both MPI and BMDMs produced significant levels). Here 
MPI macrophages produced 90-fold (MOI 1) and 14-fold (MOI 5) levels of IL-6 than the 
BMDMs 
This was also the case with type I IFN, with IAV infection in BMDMs at any MOI yielding 
no significant production compared to mock infected cells (p=0.153). Yet in MPI 
macrophages IAV infection at a MOI of 5 resulted in a 5.5-fold increase in type I IFN 
(p=0.003) Interestingly, the baseline production of type I IFN in non-infected cells was 
higher in BMDM than in MPI macrophages. (Figure 3.4) In this figure the production of 
type I IFN from MPI cells was lower than the lowest concentration of standard 
(30pg/ml) however from curve extrapolation, a value for sample concentrations was 
provided.  
In contrast, significant chemokine production was seen in both MPI macrophages 
BMDMs, however in BMDMs lower doses of infection (MOI 0.2) did not produce 
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significant values (RANTES – p=0.108) (IP-10 – p=0.522) (MIP-1α- p=0.698) (MIP-2 – 
p=0.066) (Figure 3.3). Yet even where BMDMs did produce significant levels of 
chemokines (MOI 5), they were still drastically reduced than in MPI macrophages. 
RANTES production was 6.7-fold lower, IP-10 was 5.2-fold lower, MIP-1α was 35.2 
lower, and MIP-2 was 85.5 lower in BMDMs than in MPI macrophages Figure 3.3.  
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.2 MPI macrophages produced higher levels of cytokines than BMDM when challenged with 
increasing doses of Influenza A strain Perth/16/09.  Cells were inoculated with virus for 1hr at 37oC in 
the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-
1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment) ± S.E.M. Significance was calculated using unpaired t-test, significant 
values, compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-
significant values are indicated with n.s. 
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Figure 3.3 MPI macrophages produced higher levels of chemokines than BMDM when challenged with 
increasing doses of Influenza A strain Perth/16/09.  Cells were inoculated with virus for 1hr at 37oC in 
the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. At 16hrs, post-infection supernatants were collected and (A) RANTES, (B) IP-10, (C) 
MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 
0.001). Non-significant values are indicated with n.s. 
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Figure 3.4 MPI macrophages produced higher levels of type-I IFN than BMDM when challenged with 
increasing doses of Influenza A strain Perth/16/09. cells were inoculated with virus for 1hr at 37oC in the 
absence of FBS, after which inoculum was removed and the cells were incubated in medium containing 
10% FBS. Unless stated otherwise, at 16hrs post-infection supernatants were collected and Type I 
Interferon was analysed using reporter cell line assay.  Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. Significance was calculated using unpaired t-
test, significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05) Non-significant 
values are indicated with n.s. 
 
 
135 
 
Several previous studies have shown that seasonal IAV strains replicate poorly in 
macrophages and do not produce infectious virions (Bedi et al., 2018; Londrigan et al., 
2015; Rodgers and Mims, 1982). MPIs were similar in this regard, with both 
Perth/16/09 (23.6 reduction in 72hrs) and Texas/50/12 (60-fold reduction in 72hrs) 
able to produce infections virions in these macrophages. Perth.16/09 and Texas/50/12 
successful replication still occurred in the IAV propagation cell line MDCK cells (105 
increase for Perth/16/09 and 103 increase for Texas/50/12 in 72hrs)and in murine lung 
epithelial cells (MLE-12) (104 increase for Perth/16/09 and 106 increase for 
Texas/50/12 in 72hrs) (Figure 3.5). 
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Figure 3.5 MPI macrophages show abortive IAV replication, while epithelial cells show productive IAV 
replication. Cells were inoculated with 0.01 MOI of (A) Perth/16/0, (B) Texas/50/12 for 1hr at 37oC in 
the absence of FBS, after which inoculum was removed and the cells were incubated in serum deficient 
medium containing 2µg/ml TPCK-trypsin. At indicated time points post-infection supernatants were 
collected and virus was quantified via standard plaque assay. Points represent the mean from 3 
individual experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Linear Regression performed 
to identify t & p values. 
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3.2.2 Effect of propagation technique on Influenza A – Host interactions  
IAV propagated using embryonated hen eggs, or cell lines, gives contrasting levels of 
immune response, as measured by IL-6 production. IAV strain Perth/16/09 was 
propagated in 10-day old embryonated hen eggs or indicated cells lines, as previously 
described in Materials and Methods, the produced virions were then used to infect 
MPI macrophages. As shown in Figure 3.6A only the egg grown virus was able to 
facilitate IL-6 production (p=0.0002), whereas cell culture grown virus induced no 
significant IL-6 production. Due to the need for the addition of a protease during the 
growth of IAV in cell culture, IAV was grown using different concentrations of TPCK-
Trypsin to analyse any inadvertent effects. This was performed in MDCK cells due to 
their optimal virus production as seen in Figure 3.5. Apart from 20 and 2 ng/ml, where 
no virus was produced (as measured by plaque assay), differing concentrations of the 
protease still produced no significant IL-6 (2000ng/ml – p=0.085) (200ng/ml – p=0.094) 
(Figure 3.6B). 
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Figure 3.6 Perth/16/09 propagated in eggs results in greater IL-6 production upon infecting MPI 
macrophages than Perth/16/09 propagated via cell culture. Cells were inoculated with 1 PFU per cell 
(MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells 
were incubated in medium containing 10% FBS. At 16hrs, post-infection supernatants were collected 
and IL-6 was measured by ELISA. (A) Immune response when virus grown using different epithelial cell 
lines. (B) Immune response when virus grown using variable concentrations of TPCK Trypsin for 
Hemagglutinin cleavage.  Bars represent the mean from 3 individual experiments (3 replicate samples 
per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (***= P ≤0.001). Non-significant values are indicated with 
n.s. 
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To investigate the reason behind this lack of immune response, the ability of the virus 
to infect macrophages and epithelial cells was analysed by fluorescent microscopy, 
infected cells were determined by the detection of the IAV Nuclear Protein. In MDCK 
epithelial cells (Figure 3.7) egg grown virus gave a mean infectivity of 34% by 6hr post-
infection, whereas MDCK cell grown virus with 2000ng/ml TPCK Trypsin only gave 
5.6%, a reduction of 6-fold. (p=0.002) When further reducing TPCK Trypsin 
concentration to 200ng/ml the % infectivity was completely abolished. 
This effect is also seen in macrophages, both MPI (Figure 3.8) and BMDM (Figure 3.9), 
where cell culture grown virus, results in smaller percentages of infected cells. In MPI 
macrophages egg grown virus yielded a 39% infectivity by 6hr post infection. This 
dropped 6.6-fold (p=<0.001) to 5.9% when the virus was grown in MDCK cells with 
2000ng/ml TPCK Trypsin and was completely abolished with 200ng/ml TPCK Trypsin. 
With BMDMs, egg grown virus had a 50.8% infectivity at 6hrs, and was reduced 8-fold 
(p=0.0012) to 6.4% infection which was non-significant to the mock infected control 
(p=0.093). 
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Figure 3.7 Perth/16/09 propagated in eggs results in higher percentage infection of MDCK cells than 
Perth/16/09 propagated via cell culture. Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 
1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in 
medium containing 10% FBS. At indicated time point’s cells were fixed and stained for IAV nuclear 
protein (red), counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective 
lens magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicates per experiment) 
± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, compared to Mock 
are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01). Non-significant values are indicated with n.s. 
Comparison of infectivity of MDCK grown virus to egg grown virus was performed using unpaired t-test, 
significant differences are indicated by red asterisk (**= P ≤ 0.01). 
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Figure 3.8 Perth/16/09 propagated in eggs results in higher percentage infection of MPI macrophages 
than Perth/16/09 propagated via cell culture. Cells were inoculated with 1 PFU per cell (MOI 1) of virus 
for 1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in 
medium containing 10% FBS. At indicated time point’s cells were fixed and stained for IAV nuclear 
protein (red), counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective 
lens magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicates per experiment) 
± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, compared to Mock 
are indicated by asterisk (*= P < 0.05, ***= P ≤ 0.001). Non-significant values are indicated with n.s. 
Comparison of infectivity of MDCK grown virus to egg grown virus was performed using unpaired t-test, 
significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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Figure 3.9 Perth/16/09 propagated in eggs results in higher percentage infection of BMDMs than 
Perth/16/09 propagated via cell culture. Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 
1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in 
medium containing 10% FBS. At indicated time point’s cells were fixed and stained for IAV nuclear 
protein (red), counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective 
lens magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicates per experiment) 
± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, compared to Mock 
are indicated by asterisk (***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of 
infectivity of MDCK grown virus to egg grown virus was performed using unpaired t-test, significant 
differences are indicated by red asterisk (**= P ≤ 0.01, ***= P ≤ 0.001).  
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Due to the lack of infectivity of the cell culture grown virus, it appeared that the virus 
hemagglutinin may be affected by the propagation technique. Sucrose purified 
influenza from eggs, cell culture, and virus passaged though cell culture then eggs, 
were lysed and the viral proteins separated via acrylamide electrophoresis. Western 
blot analysis of the hemagglutinin protein (Figure 3.10B) between the three samples 
shows why there is a lack of infectivity of the cell culture grown virus. The cleavage of 
the inactive HA0 form to the Infectious HA1 and HA2 forms is much less efficient when 
cell culture propagation is used, compared to eggs, with 8-fold (p=0.0014) reduction in 
the HA1 protein (Figure 3.10). This reduction was able to be restored to original egg 
grown levels when the virus was passaged back through eggs (p=0.38).   
Whether TPCK Trypsin would have any additive effects on IAV propagated in 
embryonated hen eggs was investigated by treatment of egg grown IAV with TPCK 
Trypsin (Figure 3.11). This additional protease treatment did not significantly alter the 
expression of HA1, with only a 1.3 fold increase (p=0.0106), (Figure 3.11B) as expected 
this did not alter the induction of the pro-inflammatory cytokine IL-6 (p=0.294) (Figure 
3.11C). 
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Figure 3.10 Cleavage of viral HA0 to HA1 and HA2 is more efficient if propagation occurs in eggs than via 
cell culture Perth/16/09 was propagated in the allantoic cavities of 10-day old embryonated hen eggs or 
MDCK cells for 3 days. After harvest virus was purified using a 30% sucrose cushion and lysed using lysis 
buffer. Proteins were separated by 8-16% acrylamide gel electrophoresis for analysis (A) Western 
blotting using anti-hemagglutinin antibody, (B) Measurement of the relative intensity of the western 
blot.   Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values are indicated by asterisk (**= P ≤ 0.01). Non-significant values 
are indicated with n.s. 
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Figure 3.11 Addition of TPCK-Trypsin to virus propagated in eggs increases the cleavage of HA0 to HA1, 
but does not result in a change in IL-6 production when infecting MPI macrophages.  Perth/16/09 was 
propagated in the allantoic cavities of 10-day old embryonated hen eggs. After harvest virus was 
purified using a 30% sucrose cushion and either treated with 2mg/ml TPCK Trypsin or Sterile Water for 
30 minutes at room temperature after which virus was lysed using lysis buffer. Proteins were separated 
by 8-16% acrylamide gel electrophoresis for analysis (A) Western blotting using anti-hemagglutinin 
antibody, (B) Measurement of the relative intensity of the western blot, (C) IL-6 response induced by 
Perth/16/09 for 16hrs, with and without TPCK-Trypsin incubation. Bars represent the mean from 3 
individual experiments ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant 
values compared to Mock are indicated by asterisk (*= P ≤ 0.05, ***= P ≤ 0.001). Non-significant values 
are indicated with n.s. Comparison of egg grown + TPCK-Trypsin to egg grown virus was performed using 
unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05). Non-significant values 
are indicated with red n.s. 
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3.3 Discussion 
Before any major investigations could occur, it was imperative to ensure this study 
identified which strains would be beneficial in exploring IAV infections in an alveolar-
like macrophage model. There are 144 possible different subtypes of IAV (Tong et al., 
2013), however currently only two circulate seasonally in humans; H1N1 and H3N2 
(Beare and Webster, 1991). The initial step to start to identify which strains were 
worthy for further study was to test the ability of different strains to cause an immune 
response in the model used for this investigation, MPI macrophages. Eight different 
stains were procured from the National Collection of Pathogenic Viruses, four of H3N2 
and four H1N1, with two of the H1N1 viruses being mouse adapted viruses via serial 
passage in mouse lungs. 
It was clearly evident that in MPI macrophages, the H3N2 strains were generally more 
virulent than H1N1 counterparts (Figure 3.1). This is consistent with several other 
studies on macrophages using these two strains of IAV, (Cheung et al., 2002; Geiler et 
al., 2011; Tate et al., 2011c) where H3N2 strains induced greater immune responses in 
both human and murine macrophages. However in contrast, studies that focus on 
whole lung models, (Wu et al., 2010) tend to find comparable immune response 
between the two strains. This suggests that while there were differences in induced 
immunity between the H1N1 and H3N2 in macrophages, ultimately this has no effect 
on the overall progression of disease in the lung. It is also worth noting that the mouse 
adapted H1N1 strain PR8/34 (PR8), was unable to cause an immune response in the 
MPI macrophages, something that has been seen in a variety of other mouse 
macrophages by several studies (Londrigan et al., 2015; Reading et al., 2007; Tate et 
al., 2010). This lack of a response has been attributed to a complete lack of 
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glycosylation of the PR8 HA molecule (Caton et al., 1982) and therefore is unable to 
efficiently bind to and enter macrophages (Londrigan et al., 2015).  
Due to the more virulent nature of the H3N2 strains seen in this study, in addition to 
H3N2 being the predominant seasonal influenza the year this study commenced 
(Public Health England, 2015), this subtype was chosen for continued investigation. To 
further reduce the complexity of strains, only two of the four H3N2 strains were 
selected to continue with. Perth/16/09 was a clear option, due to it inducing the 
highest immune response, Texas/50/12 in contrast, induced no detectible immune 
response, but this strain was chosen to provide contrasting data, when looking at 
different host-virus interactions. 
With these two strains, the next logical step was to expand the investigation of the 
innate immune response by looking at an increased number of secreted inflammatory 
proteins, at different levels of virus titre, in comparison to an ‘imperfect’ established 
model (BMDMs). BMDMs lack the expression of certain AM specific receptors and are 
unable to produce IL-1α (Table 1.4,  
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, and Figure 1.11).  This would confirm that the MPI macrophages would be a good 
model to continue investigating, therefore only the ‘high immune yielding’ 
Perth/16/09 was used. There are two categories that these secreted proteins fall into, 
the first is pro-inflammatory cytokines, here the secreted proteins have a greater 
effect on the surrounding tissue and cells, modulating the immune response. The 
second category, termed chemokines, includes those proteins that have a greater 
functionality in cellular recruitment. While this study differentiates the measured 
proteins into these two sub-groups, it must be made clear, that the parameters are not 
all-defining, and there is some overlap between groups with several proteins.  
 MPI macrophages produced pro-inflammatory cytokines at all levels of virus titre 
used, with the exception of IL-1α at the lowest titre, where there was no significant 
production. BMDMs, on the other hand, only produced IL-6 at the mid and high levels 
of virus titre however these levels were 14-fold lower than the MPI macrophages. With 
chemokines, MPI macrophages produced all of those measured at all three virus doses 
used, yet BMDM’s only produced chemokines at the highest level of virus used, with 
the one exception of IP-10, where the mid-level of virus had a chemokine response. 
Similarly, to the chemokines these levels were much less than the MPI macrophages 
with levels ranging from 9 to 85-fold reduction of the MPI response. IAV infection was 
able to induce the production of type I IFN in MPI macrophages (except with the 
lowest MOI), however, type I IFN induction did not occur upon IAV infection in 
BMDMs.  
 
149 
 
This suggests that MPI macrophages are very sensitive to IAV, a characteristic that has 
also been seen in other inflammatory ligands such as LPS, FSL-1, murine Tuberculosis, 
and Adenovirus (Fejer et al., 2013). Moreover the high levels of cytokines, chemokines, 
and type-I IFNs, produced by MPIs compared to BMDMs, reinforces the idea that the 
AMs residing in the lung are crucial for the recruitment of lymphocytes to the site of 
infection, as wells inducing the early antiviral state (Hoeve et al., 2012; Kim et al., 
2008).  
One key characteristic of both human and murine macrophages when infected with 
seasonal IAV is abortive replication of virus, and thus no production of infectious 
virions (Rodgers and Mims, 1981; Rodgers and Mims, 1982). In order to test whether 
MPI macrophages would also exhibit this characteristic it was necessary to measure 
infectious virions at multiple time points post infection (Figure 3.5). From this, it is 
clear to see that with either strain, there is no production of infectious virions from 
MPI macrophages, unlike the two types of epithelial cells. This is hugely important 
when using MPI macrophages as a model for AMs and proving that the two cell types 
respond in similar ways goes a long way in establishing MPI macrophages as a viable 
model for IAV – Macrophage interaction.  
The reasons behind this abortive replication of seasonal influenza is not wholly 
understood, but it is known that certain highly pathogenic IAV, such as H5N1 (Cline et 
al., 2013) and the H1N1 strain WSN/33 (Cline et al., 2017) are actually able to replicate 
productively in macrophages. This would imply that macrophages have the ‘machinery’ 
needed by the virus to productively replicate itself. This ‘machinery’, ranges from 
factors for attachment, internalisation, endosomal trafficking, fusion, uncoating, 
nuclear import/export, transcription/translation, packaging, and budding (Edinger et 
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al., 2014; Matsuoka et al., 2013). In fact, the more likely explanation is cellular 
inhibition of the virus replication cycle. Several of these inhibitions have been 
identified in previous studies, and each block the virus replication at a different stage, 
thus strains that are able to evade or inhibit these are able to replicate productively. 
The first barrier IAV must overcome to successfully replicate in macrophages is 
attachment and internalisation, where certain hemagglutinin forms are unable to 
recognise attachment receptors on the macrophage surface. This could be due 
differences in the glycosylation of the hemagglutinin receptor or different preferences 
for α2,3 or α2,6 linked sialic acid (Londrigan et al., 2015). Following successful binding 
and entry the next barrier is the escape of the endosome, where different strains, as a 
result of slight point mutations, require different endosome pH levels to facilitate 
fusion and escape. If strains are unable to reach their individually required pH then the 
endosome is able to progress to the lysosome and the virus is destroyed (Marvin et al., 
2017). These first two post nuclear-restriction points on the IAV replication cycle have 
so far only be confirmed in murine macrophages, and do not appear to be present in 
human macrophages. 
The first post nuclear barrier occurs prior to protein translation, thus preventing 
production of viral proteins, however the mechanisms behind this are not understood 
(Cline et al., 2013; Marvin et al., 2017). The last mechanism, which a successfully 
replicating virus must overcome is a block in the viral protein assembly at the 
macrophage surface, in preparation for ‘budding’.(Londrigan et al., 2015) Here the 
association of viral HA and M2 transmembrane proteins is suppressed by actin 
polymerisation, increasing the segregation of HA and M2 concentrated regions of the 
macrophage membrane, thereby preventing accumulation of viral proteins for 
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‘budding’ (Bedi et al., 2018).  These two post-nuclear blocks in IAV replication are seen 
in both murine and human macrophages, but why some blocks are only found in  
murine macrophages is unclear.  
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Figure 3.12 Summary of IAV Replication blocks in macrophages based on current knowledge. 1. 
Inefficient attachment and entry – results from specific HA forms recognising host SA, and different 
preferences of sialic acid linkages (α-2,3 & α 2,6) related to HA glycosylation. 2. Improper endosomal 
acidification and escape – pH levels required by different strains to facilitate fusion and thus escape. 3. 
Protein translation blocked – mechanisms not understood. 4. Defective assembly and budding – 
Prevention of HA and M2 viral proteins accumulating in sufficient levels via host actin polymerisation. 
Blocks 1 and 2 have currently only been identified in mice, while blocks 3 and 4 have been identified in 
both humans and mice. 
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Current methods for IAV propagation utilise both embryonated hen eggs and cell lines 
to yield high titres of virus for experimentation, which one is often dependent on how 
that particular strain has been propagated previously (Szretter et al., 2006). Both of 
the strains selected could be grown in both eggs and cells, however it soon became 
clear that IAV grown in cells behaved very differently than that grown in eggs. Only IAV 
grown in eggs was able to induce an immune response in MPI macrophages, whereas 
virus of the same passage grown in cells had no detectable response (Figure 3.6A). 
There have been several other studies that have used this specific IAV strain for 
immune studies, however it appears that this study is the first to use it in an ex vivo 
macrophage model, and all current have used embryonated hen eggs as the source of 
the virus stocks (Ayegbusi et al., 2019; Fejer et al., 2017; Ilyushina et al., 2014; Music et 
al., 2016). 
One of the key differences in cell culture method of IAV propagation compared to 
embryonated hen eggs is the need to artificially add protease to the culture media in 
order to facilitate entry of the virus into host cells (Zuhairi et al., 2012). This is done by 
TPCK-treated trypsin in order to activate the virus for infection by cleaving 
hemagglutinin (Klenk et al., 1975) while in the egg there is host protease, blood 
clotting factor Xa that performs a similar role (Gotoh et al., 1990). The first conclusion 
was that the addition of TPCK-treated trypsin was somehow affecting the virus 
produced in cells, it was unlikely that the virus was lysed as it was able to be quantified 
by plaque assay and therefore was viable. The most likely hypothesis was that as an 
additional effect TPCK-trypsin was modifying the hemagglutinin in such a way that 
there was inefficient entry of the virus. To investigate, lowering concentrations of 
TPCK-trypsin were used to grow the virus to see if any effect was dose dependent, 
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however at any concentration that yielded viable virus there was still no immune 
response (Figure 3.6B). From this, even at the lowest TPCK-trypsin dose able to yield 
virus, there is still a lack in a measurable immune response.  
To confirm that this effect was due to a lack of viral infectivity, the amount of IAV able 
to infect cells was measured by immunofluorescence in both macrophages and 
epithelial cells.  In line with the immune response data, cell grown IAV had a much 
lower infectivity, 6.6-fold decrease, than the egg grown in MPI macrophages (Figure 
3.8). This was also confirmed in a different macrophage model, BMDM’s, where there 
was an 8-fold decrease in infectivity with cell culture grown virus (Figure 3.9). 
Surprisingly this reduced infectivity with cell culture grown IAV was also visualised in 
MDCK cells, with a 6-fold reduction in infectivity compared to the egg grown virus 
(Figure 3.7). This was rather surprising considering that the cell culture grown virus 
used in this experiment was quantified via plaque assay on MDCK cells, meaning that 
they were able to be infected (data not shown). Therefore, if given longer periods of 
time, MDCK cells are able to be infected by the cell culture grown IAV.  
While there is a dose-dependent relationship with viral infectivity and TPCK-treated 
trypsin in all cells, the relationship is inverse to what was hypothesised. It was assumed 
that TPCK-treated trypsin was modifying the hemagglutinin of the virus, in such a way 
to inhibit effective entry, thus it would be a logical assumption that higher TPCK-
treated trypsin concentrations would have a lower viral infectivity. However this was 
the opposite case, with higher concentrations of TPCK-treated trypsin yielding higher 
viral infectivity in all cells tested on, MPI (Figure 3.8), BMDM (Figure 3.9), and MDCK 
(Figure 3.7). This initial hypothesis was based on previous studies suggesting the level 
of glycosylation of the hemagglutinin affects the ability of the virus to enter the 
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macrophage (Londrigan et al., 2011; Tate et al., 2011a; Tate et al., 2014). In these 
studies, a loss of glycosylation resulted in a lack or reduction of macrophage infection, 
thus it was conceivable that TPCK-Trypsin may have unintended effect of removing N-
linked glycan’s via its protease activity. 
This was already unlikely to be the case here, with the dose-dependent nature 
identified via immunofluorescence, but in order to gain a better understanding of what 
was different between the egg and cell culture virus hemagglutinin, the two proteins 
needed to be compared. Previous studies have detected IAV proteins using SDS page 
electrophoresis, and even been able to identify levels of glycosylation based on the 
migration of the NP through the gel (Jin et al., 1997; Shaw et al., 2008). However upon 
investigation it appeared that IAV grown in eggs or in MDCK had the same levels of HA 
glycosylation as there was no difference in the migration of the HA protein for either 
sample (Figure 3.10), as was observed in Shaw et al. (2008). However, what was seen 
was a much less efficient cleavage of the HA protein from the precursor HA0 molecule 
to the HA1 and HA2 molecules that allow for virus fusion with the host cell. The 
intensity of the HA1 molecule was eight times lower in IAV grown in MDCK cells than 
that grown in eggs, which arguably explains the lack of infectivity in this virus.  
To investigate further this cleavage effect, it was hypothesised that the addition of 
TPCK-Trypsin to the egg grown virus would further enhance the immune response by 
enhancing the cleavage of HA0 even further. As seen in Figure 3.10A, while there was 
cleavage of the HA0 form, there were still detectable amounts of the un-cleaved  HA0 
form present, suggesting the ability of further cleavage. When egg grown virus was 
exposed the TPCK-Trypsin, the amount of HA1 present increased 1.3 fold, when 
compared to the original egg grown virus (Figure 3.11A,B). Whether this small increase 
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is relevant is up for debate, from a biological view this increase in cleavage did not 
result in a change in the cytokine production by MPI macrophages (Figure 3.11C). 
More effective HA cleavage in eggs has been shown been identified before, with 
Arcangeletti et al. (2008) identifying egg grow IAV having complete HA0 cleavage, 
whereas MDCK (trypsin) IAV had residual HA0 remaining. In spite of this host adaption 
of viral strains using MDCK cells, has shown to be slightly more beneficial for vaccine 
production, giving a better representation of the clinical isolate, (Robertson et al., 
1995) and immunogenic vaccine (Shin et al., 2015). However, none of these studies 
look at the downstream innate immune aspects of egg or cell isolates like has been 
performed in this study.  
The virulence of IAV is associated with the virus’s ability to infect cells and  effective 
cleavage of the hemagglutinin precursor HA0 to the HA1 and HA2 fragments is 
required for infection (Klenk et al., 1977; Lazarowitz and Choppin, 1975). In fact one of 
the key aspects in the pathogenicity of IAV is mutation in the HA cleavage site, that 
enables cleavage by multiple proteases instead of the trypsin-like proteases that 
cleave low-pathogenic IAV (Sun et al., 2010). This is found to be the case for the 1918 
H1N1 pandemic IAV, which has a much broader protease susceptibility than the 2009 
H1N1 IAV, which goes some way to explaining the extreme virulence of this 1918 virus 
(Laporte et al., 2019). 
 In this chapter, it is clearly shown that cell culture propagation of IAV severely limits 
this cleavage using currently established methods, and thus effectively diminishes the 
virus’s ability to infect host cells. This finding is of course limited by the cells and virus 
strains used here and should of course be replicated on a variety of strains and cells 
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before being fully believed, however it does bring into question previous studies with 
IAV infection, and how the propagation methods used affected the outcomes.  
There are many more avenues of research into the findings of this chapter, to better 
identify viral host isolation adaption and the mechanisms involved. New isolation cell 
lines being developed, such as the humanised MDCK cell line, (Takada et al., 2019) and 
MDCK cells expressing the human proteases, thus not requiring TPCK-treated trypsin 
(Wen et al., 2015) will help in these studies. The aims of this research included several 
innate immune investigations in macrophages and therefore not all the effects of TPCK 
Trypsin could not be explored. Because of this, the findings here contribute to the 
immunological investigations of this thesis only using IAV strains that have been 
propagated using embryonated hen eggs. Further studies should use strains where the 
host adaptations and propagation methods play no role in the immunological 
interactions of the macrophage and virus. This would allow the results from such 
studies on the entry mechanisms and innate immune responses in this new model of 
murine AM’s to have an impact on the current understanding.  
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4 Chapter Four: Influenza A entry 
mechanisms in Macrophages 
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4.1 Introduction 
The mechanisms of IAV infection have been studied extensively in non-immune 
epithelial cells. The current understanding is that viral HA binds to cell surface sialic 
acid on host proteins, which then mediates attachment (Lai and Tamm, 2007; Reading 
et al., 2000; Skehel and Wiley, 2000), and is followed by endosomal uptake via both 
clathrin-mediated endocytosis and macropinocytosis (de Vries et al., 2011). Finally 
fusion of the IAV and endosomal membranes occurs to allow release of the viral 
nuclear material into the cytoplasm (Cady et al., 2009; Schnell and Chou, 2008). The 
understanding of these mechanisms has provided excellent targets for treatments, 
such as M2 targeting adamantanes preventing endosomal release and NA inhibitors to 
prevent virion release. However better understanding of the interactions between 
macrophages and IAV may heavily influence future treatments and therapies.  
Macrophages, specifically AM’s are also readily infected by IAV, but seasonal strains 
are unable to replicate productively, unlike in epithelial cells (Lai and Tamm, 2007; 
Londrigan et al., 2015; Marvin et al., 2017). This infers a difference in the way IAV 
infects macrophages compared to epithelial cells, but there is an incomplete picture on 
macrophage infection. It is generally believed that sialic acid dependent infection is 
less crucial in macrophages, and several other receptors play a role, such as the 
macrophage mannose receptor and macrophage galactose type lectin (Reading et al., 
2000; Upham et al., 2010). Details of the mechanisms of uptake for IAV in 
macrophages, are lacking, with much of the knowledge based on work using epithelial 
cell lines (de Vries et al., 2011). 
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The lack of available, representative models of AM’s is probably the limiting factor in 
advancing the understanding of IAV entry mechanisms. MPI macrophages which are 
available in vast quantities and represent AM’s in both surface marker expression and 
immune responses, will be used in this chapter. Using this model should provide not 
only confirmation of current models of IAV infection, but possibly shed light on 
previously unexplored aspects which could be used as the basis for future treatment 
targets. 
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4.2 Results 
4.2.1 Perth/16/09 vs Texas/50/12 
The ability of the two different H3N2 strains to infect macrophages and epithelial cells 
was analysed. First the binding ability of the strains was analysed by FACs to determine 
the quantity of virus bound to the cell surface when virus uptake was inhibited by 
incubation at 4oC (Figure 4.1 and Figure 4.3). Quantification of this bound virus was 
determined as the mean fluorescence across the population measured. Second the 
internalisation of the virus was analysed using fluorescent microscopy to determine 
the efficiency of infection (Figure 4.2, Figure 4.4, Figure 4.5). This infection was 
determined as a percentage, based on positively or negatively infected cells, rather 
than grading system of the infection.  
In MPI macrophages, Perth/16/09 bound to the cell surface with 2-fold greater 
efficiency than Texas/50/12 (p=0.04) (Figure 4.1B). This was mirrored in the infectivity 
where the Perth/16/09 strain yielded a 2.5-fold increase in percentage of positively 
infected cells than the Texas/50/12 by 6hrs post infection (p=<0.001) (Figure 4.2B). 
This contrast in infectivity was replicated in BMDMs (Figure 4.5B). With again the 
Perth/16/09 strain resulting in a 2.3-fold increase in percentage of infected cells, when 
compared to the Texas/50/12 strain by 6hrs post infection (p=0.0173). 
For comparison, both strains were analysed in MDCK epithelial cells, and in the 
macrophages, the Perth/16/09 strain had 1.5-fold greater cell surface binding than the 
Texas/50/12 strain (p=0.038) (Figure 4.3B). However, in contrast, the infection of the 
epithelial cells was stronger for the Texas/50/12 strain compared to the Perth/16/09 
by 2.2-fold (p=0.0006) (Figure 4.4B). 
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Figure 4.1 IAV strain Perth/16/09 binds to the surface of MPI macrophages more efficiently than 
Texas/50/12. Cells in suspension were inoculated with 100 PFU per cell (MOI 100) of virus for 1hr at 4oC 
in the absence of FBS, after which inoculum was removed and the cells were washed and fixed. Infected 
cells were stained for viral hemagglutinin. (A) Representative overlaid Histogram of fluorescent peaks.  
(B) Mean fluorescence intensity of sample population. -/-/- =Unstained Uninfected, -/+/- = Unstained 
Uninfected, +/-/- = Mock, +/+/- = Perth/16/09, +/-/+ = Texas/50/12.  (C) Representative size and 
granularity scatter plots of samples to show how gating was performed. Bars represent the mean from 
3 individual experiments (3 technical replicates per experiment) ± S.E.M. (N=3) Significance was 
calculated using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 
0.05, **= P ≤ 0.01). Comparison of Perth/16/09 and Texas/50/12 virus was performed using unpaired t-
test, significant differences are indicated by red asterisk (*= P < 0.05). 
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Figure 4.2 IAV strain Perth/16/09 infects MPI macrophages more efficiently than Texas/50/12. Cells 
were inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated time 
point’s cells were fixed and stained for IAV nuclear protein (red), counter stained with DAPI (blue). (A) 
Visual representation of IAV infected cells, objective lens magnification 40x. Images shown are the best 
representative of % infectivity’s from multiple experiments. (B) Percentage infectivity of cells, data is 
taken at four separate fields of view of the sample. Bars represent the mean from 3 individual 
experiments (4 technical replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 0.05, ***= P 
≤ 0.001). Non-significant values are indicated with n.s. Comparison of groups was performed using two-
way Anova, with Tukeys multiple comparisons, significant differences are indicated by red asterisk (***= 
P ≤ 0.001).  
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Figure 4.3 IAV strain Perth/16/09 binds to the surface of MDCK cells more efficiently than Texas/50/12. . 
Cells in suspension were inoculated with 100 PFU per cell (MOI 100) of virus for 1hr at 4oC in the 
absence of FBS, after which inoculum was removed and the cells were washed and fixed. Infected cells 
were stained for viral hemagglutinin. (A) Representative overlaid Histogram of fluorescent peaks.  (B) 
Mean fluorescence intensity of sample population. -/-/- =Unstained Uninfected, -/+/- = Unstained 
Uninfected, +/-/- = Mock, +/+/- = Perth/16/09, +/-/+ = Texas/50/12. (C) Representative size and 
granularity scatter plots of samples to show how gating was performed. Bars represent the mean from 3 
individual experiments (3 technical replicates per experiment) ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 0.05, ***= P 
≤ 0.001). Comparison of Perth/16/09 and Texas/50/12 virus was performed using unpaired t-test, 
significant differences are indicated by red asterisk (*= P < 0.05). 
 
(A) Representative overlaid Histogram of fluorescent peaks.  (B) Mean fluorescence 
intensity of sample population. -/-/- =Unstained Uninfected, -/+/- = Unstained 
Uninfected, +/-/- = Mock, +/+/- = Perth/16/09, +/-/+ = Texas/50/12.  (C) Representative 
size and granularity scatter plots of samples to show how gating was performed. Bars 
represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance was 
calculated using unpaired t-test, significant values, compared to Mock are indicated by 
asterisk (*= P ≤ 0.05, **= P ≤ 0.01). 
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Figure 4.4 IAV strain Texas/50/12 infects MDCK cells more efficiently than Perth/16/09.  Cells were 
inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated time 
point’s cells were fixed and stained for IAV nuclear protein (red), counter stained with DAPI (blue). (A) 
Visual representation of IAV infected cells, objective lens magnification 40x. Images shown are the best 
representative of % infectivity’s from multiple experiments. (B) Percentage infectivity of cells, data is 
taken at four separate fields of view of the sample. Bars represent the mean from 3 individual 
experiments (4 technical replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock are indicated by asterisk (**= P ≤ 0.01, ***= 
P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of groups was performed using 
two-way Anova, with Tukeys multiple comparisons, significant differences are indicated by red asterisk 
(***= P ≤ 0.001).  
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Figure 4.5 IAV strain Perth/16/09 infects BMDMs more efficiently than Texas/50/12.  Cells were 
inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated time 
point’s cells were fixed and stained for IAV nuclear protein (red), counter stained with DAPI (blue). (A) 
Visual representation of IAV infected cells, objective lens magnification 40x. Images shown are the best 
representative of % infectivity’s from multiple experiments. (B) Percentage infectivity of cells, data is 
taken at four separate fields of view of the sample. Bars represent the mean from 3 individual 
experiments (4 technical replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 0.05, ***= P 
≤ 0.001). Non-significant values are indicated with n.s. Comparison of groups was performed using two-
way Anova, with Tukeys multiple comparisons, significant differences are indicated by red asterisk (*= P 
< 0.05).  
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4.2.2 Sialic Acid  
Sialic acid plays a crucial role in facilitating IAV entry into both epithelial cells and 
macrophages, (Reading et al., 2000) and the extent of its effect can be determined by 
removal using the enzyme sialidase to cleave the sialic acid glyosidic linkages prior to 
infection. In MPI macrophages (Figure 4.6), pre-treatment with sialidase, significantly 
reduced the infection percentage by 5-fold after 6 hrs post infection when compared 
to non-treated cells (p=<0.0001). However, this treatment did not completely remove 
the ability of the virus to infect MPI macrophages, as at 6hr post-infection there 
remained 7.8% positively infected cells, after sialidase treatment, was significantly 
greater than the mock infected control (p=0.0019). 
This result was mirrored in MDCK epithelial cells (Figure 4.7) with sialidase treatment 
also reducing the infection percentage of the cells, compared to the non-treatment by 
3.4-fold after 6hrs post infection (p=<0.0001). The same lack of a complete inhibition 
of viral infection was also observed, as again at 6hr post-infection there remained 10% 
positively infected cells when compared to mock-infected controls (p=0.008). 
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Figure 4.6 Removal of cell surface sialic acid reduces IAV infection of MPI macrophages. Cells were pre-
treated with 100mU Sialidase for 30 mins at 37oC to remove sialic acid on the cell surface prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), 
counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens 
magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant 
values are indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys 
multiple comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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Figure 4.7 Removal of cell surface sialic acid reduces IAV infection of MPI macrophages. Cells were pre-
treated with 100mU Sialidase for 30 mins at 37oC to remove sialic acid on the cell surface prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), 
counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens 
magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are 
indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys multiple 
comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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4.2.3 Macrophage Mannose Receptor 
The role of the macrophage mannose receptor (MMR) in IAV infection of MPI 
macrophages was determined by blocking the receptor using the polysaccharide 
mannan (Pontow et al., 1992; Reading et al., 2000; Upham et al., 2010). MPI 
macrophages pre-treated with mannan to block MMR (Figure 4.8) resulted in a 1.7-
fold lower infectivity when compared to non-treated cells at 6hrs post infection 
(p=<0.0001). Similar to sialic acid, the blocking of MMR did not inhibit IAV infection 
completely, with a 22.5% of cells remaining infected, even after mannan treatment 
(p=<0.0001). 
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Figure 4.8 Blocking the Macrophage Mannose Receptor (MMR) slightly reduces IAV of MPI 
macrophages. Cells were pre-treated with 5mg/ml Mannan for 30 mins at 37oC to block the Mannose 
receptor prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of 
FBS, after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear 
protein (red), counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective 
lens magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (*= P < 0.05, ***= P ≤ 0.001). Non-significant values are 
indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys multiple 
comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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4.2.4 Macrophage Galactose-type Lectin 
The macrophage galactose-type lectin (MGL), is another macrophage transmembrane 
protein to be implicated in IAV entry into macrophages. MGL can be blocked using 
asialofetuin glycopeptide (Ng et al., 2014; Upham et al., 2010). MPI macrophages were 
pre-treated with asialofetuin to block MGL (Figure 4.9) which resulted in a 2.3-fold 
reduction in IAV infection compared to the non-treated cells after 6hrs post infection 
(p=0.0001). However, similar to sialic acid and MMR, the blocking of MGL did not 
inhibit IAV infection completely, as there was still 16.8% of MPI macrophages infected 
after treatment with asialofetuin at 6hrs post infection (p=0.008). 
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Figure 4.9 Blocking the Macrophage Galactose-type Lectin (MGL) slightly reduces IAV of MPI 
macrophages. Cells were pre-treated with 5mg/ml Asialofetuin for 30 mins at 37oC to block MGL prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), 
counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens 
magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant 
values are indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys 
multiple comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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4.2.5 Scavenger Receptor MARCO 
To investigate the role of MARCO in IAV infection of macrophages, MARCO knockout 
MPI macrophages were used similarly to previous studies investigating the role of this 
receptor in adenovirus infections (Maler et al., 2017; Stichling et al., 2018). First the 
ability of the virus to bind to the MPI surface, with and without MARCO was assessed 
by FACs analyses after IAV infection at 4oC to inhibit endocytosis (Figure 4.10). The 
absence of MARCO on the MPI surface did not hinder the IAV binding to the cell 
surface, reducing it only 1.2-fold and was not deemed significantly different 
(p=0.4788).  
Next, the infection of cells deficient in MARCO was analysed using fluorescent 
microscopy, including use of a blocking antibody for confirmation of results.  (Figure 
4.11)  
MPI lacking MARCO had a 4.5-fold lower IAV infection compared to wild-type MPI 
macrophages expressing the receptor. However, loss of MARCO did not inhibit IAV 
infection completely, as there was still 8.6% of residual infectivity at 6hr (p=0.014. This 
effect was confirmed when the MARCO receptor was blocked using a specific antibody, 
also resulting in a 3.2-fold reduction in percentage of IAV infected cells. As a final 
investigation, the MARCO deficient macrophages were treated with sialidase to 
remove sialic acid residues to see if the remaining infectivity could be completely 
inhibited. This appeared to be the case as MARCO and sialic acid deficient MPI 
macrophages had a 5.6-fold reduction in percentage infectivity compared to WT MPI 
cells with sialic acid. This reduced the percentage infectivity to a point which it was no 
longer significant compared to the Mock infected control (p=0.053).  
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Figure 4.10 The scavenger receptor MARCO is not involved in IAV surface binding on MPI macrophages. 
Cells in suspension were inoculated with 100 PFU per cell (MOI 100) of Perth/16/09 for 1hr at 4oC in the 
absence of FBS, after which inoculum was removed and the cells were washed and fixed. Infected cells 
were stained for viral hemagglutinin. (A) Representative overlaid Histogram of fluorescent peaks. (B) 
Mean fluorescence intensity of sample population. -/-/- =Unstained Uninfected, -/+/- = Unstained 
Uninfected, +/-/- = Mock, +/+/- = MPI Perth/16/09, +/-/+ = MARCO KO Perth/16/09.  (C) Representative 
size and granularity scatter plots of samples to show how gating was performed. Bars represent the 
mean from 3 individual experiments (3 technical replicates per experiment) ± S.E.M. (N=3) Significance 
was calculated using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= 
P < 0.05). Non-significant values are indicated with n.s. Comparison of Perth/16/09 and Texas/50/12 
virus was performed using unpaired t-test. Non-significant values are indicated with red n.s. 
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Figure 4.11 The scavenger receptor MARCO is required of successful IAV infection in MPI macrophages. 
Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after 
which inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated 
time point’s cells were fixed and stained for IAV nuclear protein (red), counter stained with DAPI (blue). 
(A) Visual representation of IAV infected cells, objective lens magnification 40x. Images shown are the 
best representative of % infectivity’s from multiple experiments. (B) Percentage infectivity of cells, data 
is taken at four separate fields of view of the sample. Bars represent the mean from 3 individual 
experiments (4 technical replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 0.05, **= P 
≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. 
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4.2.6 Endosomal formation and Escape 
For analysing IAV entry into the endosome, MPI macrophages were pre-treated with 
two different inhibitors to test for separate mechanisms. First dynamin-dependent 
endocytosis was inhibited using the specific inhibitor Dynasore prior to MPI 
macrophages being infected with IAV (Figure 4.12). Previous work of de Vries et al. 
(2011) has shown that a concentration of 80µM prevented IAV entry in MDCK cells. 
This resulted in a 4.9-fold reduction in the percentage of infected MPI macrophages 
compared to those not treated with Dynasore by 6hrs post infection (p=0.0001). 
However, even with dynamin-dependent endocytosis inhibition 8% of infected cells 
remained at 6hr post-infection, compared to the mock infected control (p=0.008). 
A second possible mechanism of IAV uptake in macrophages is macropinocytosis, 
which can be investigated using the specific inhibitor EIPA prior to IAV infection of MPI 
macrophages (Figure 4.13). Previous work of de Vries et al. (2011) has shown that a 
concentration of 80µM prevented IAV entry in MDCK cells. EIPA reduced the infection 
of MPI macrophages by 65-fold by 6hrs post infection (p=<0.0001). This reduction was 
so great that the remaining 0.6% of infected cells at 6hrs was deemed not significant, 
compared to the mock infected control (p=0.3506).  
Escape from the endosome is also necessary for successful infection of IAV in host 
cells, which is achieved via the acidification of the endosome (Akole and Warner, 
2019). Here this acidification was prevented via the pre-treatment of MPI 
macrophages with Chloroquine before IAV infection (Figure 4.14). Previous work of Ooi 
et al. (2006) has shown that a concentration of 2.5µM resulted in a 90% reduction in 
H3N2 replication. Inhibition of endosomal acidification reduced the percentage of 
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infected MPI macrophages compared to those not pre-treated with Chloroquine by 
3.8-fold (p=<0.0001). At 6hr post-infection 10% of infected MPI macrophages 
remained despite the inhibition of endosomal acidification with Chloroquine (p=0.022). 
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Figure 4.12 IAV infection of MPI macrophages utilises dynamin dependent endocytosis as a viral entry 
mechanism. Cells were pre-treated with 80µM Dynasore for 30 mins at 37oC to inhibit dynamin prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), 
counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens 
magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant 
values are indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys 
multiple comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001).  
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Figure 4.13 IAV infection of MPI macrophages utilises macropinocytosis as a viral entry mechanism. Cells 
were pre-treated with 80µM EIPA for 30 mins at 37oC to inhibit membrane ruffling prior to inoculation 
with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum 
was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was present at all 
points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), counter 
stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens magnification 40x. 
Images shown are the best representative of % infectivity’s from multiple experiments. (B) Percentage 
infectivity of cells, data is taken at four separate fields of view of the sample. Bars represent the mean 
from 3 individual experiments (4 technical replicate samples per experiment) ± S.E.M. (N=3) Significance 
was calculated using unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= 
P < 0.05, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of groups was 
performed using two-way Anova, with Tukeys multiple comparisons, significant differences are 
indicated by red asterisk (***= P ≤ 0.001).  
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Figure 4.14 Successful endosomal acidification is essential for IAV infection of MPI macrophages. Cells 
were pre-treated with 2.5µM chloroquine for 30 mins at 37oC to inhibit endosomal acidification prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At indicated time point’s cells were fixed and stained for IAV nuclear protein (red), 
counter stained with DAPI (blue). (A) Visual representation of IAV infected cells, objective lens 
magnification 40x. Images shown are the best representative of % infectivity’s from multiple 
experiments. (B) Percentage infectivity of cells, data is taken at four separate fields of view of the 
sample. Bars represent the mean from 3 individual experiments (4 technical replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock are indicated by asterisk (*= P < 0.05, ***= P ≤ 0.001). Non-significant values are 
indicated with n.s. Comparison of groups was performed using two-way Anova, with Tukeys multiple 
comparisons, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
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4.3 Discussion 
One of the key aims in this thesis was to evaluate the role of currently identified IAV 
entry mechanisms in MPI macrophages, and possibly identify novel mechanisms not 
previously recognised. The main technique used in this investigation was fluorescent 
microscopy with a specific antibody for the IAV nuclear protein (NP). Detection of this 
protein within the infected cells requires the occurrence of viral attachment, entry, 
and replication. To specifically look at the attachment of IAV to macrophages, FACs 
analysis was performed using a specific antibody for the IAV hemagglutinin HA. MPI 
macrophages infected at 4oC to prevent endocytosis (Nichols et al., 1993; Pohl and 
Stertz, 2015; Rinkenberger and Schoggins, 2018) would enable the detection of the 
virus bound to the cell surface via detection of the HA protein.  
Based on findings in Chapter 3, there were differences in the tested immune 
responses, (Figure 3.1) with Perth/16/09 yielding a high IL-6 and TNF-α response and 
Texas/50/12 inducing no signification production of either. The hypothesised 
difference between the two was a lack or reduction in the infectivity of Texas/50/12 in 
MPI macrophages. There was indeed a reduction in the infection of MPI macrophages 
for Texas/50/12 vs Perth/16/09, with the binding of the virus to the cell surface 2 fold 
lower (Figure 4.1) and the percentage of infected cells at 6hr, 2.5 fold lower (Figure 
4.2). This effect was mirrored in other macrophages with BMDMs infected, with 
Texas/50/12  also showing 2.3 fold reduction in infection at 6 hours post infection, 
when compared to those infected with Perth/16/09 (Figure 4.5). Contrary to this effect 
in macrophages, in epithelial cells the infectivity of Texas/50/12 was 2.2-fold greater 
than that of Perth/16/09 (Figure 4.4). Yet this wasn’t matched with an increase in cell 
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surface binding, in fact the Perth/16/09 strain remained the slightly more efficient at 
binding to the cell surface (Figure 4.3). 
Overall this would suggest that the Perth/16/09 strain has a much higher binding 
capacity for cell surface sialic acid on both macrophages and epithelial cells, than the 
Texas/50/12 strain. Both AM’s and MDCK cells have proportionally lower expression 
levels of sialic acids than what is found in type II alveolar epithelial cells (Lin et al., 
2017; Yu et al., 2011) which may explain this. With lower levels of sialic acid expressed 
on the cells surface, lower affinity hemagglutinin (Texas/50/12) may have limited 
surface binding. However, to truly confirm this hypothesis, the virus binding to type II 
alveolar epithelial cells such as MLE-12 cell line would need to be investigated. 
The infectivity of the two strains differed between cell types, with Perth/16/09 being 
better at infecting macrophage, and Texas/50/12 being better at infecting epithelial 
cells. This was unexpected based on the cell binding data, where in both cell types 
Perth/16/09 was expected to be the more infective strain. The percentage infectivity 
of Perth/16/09 across MPI, BMDM, and MDCK was quite similar, and therefore it 
appears that Texas/50/12 is much less efficient at macrophage infection than epithelial 
cells. This differential infectivity of macrophages and epithelial cells between strains is 
not unusual. The work of Tate et al. (2011c) found the H3N2 BJx109 strain better 
infected macrophages over epithelial cells, whereas the PR8 strain yielded better 
epithelial infection. The theory behind the less efficient PR8 infectivity in macrophages 
is a lack of glycosylation on the HA (Londrigan et al., 2015; Tate et al., 2010), which 
may also be the explanation for Texas/50/12’s poor macrophage infectivity. However, 
based on results discussed later in this chapter this seems unlikely (Figure 4.15). 
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Sialic acid has long been known to be the key receptor on the cell surface (Weis et al., 
1988), however in both epithelial cells (Stray et al., 2000; Thompson et al., 2006) and 
macrophages (Reading et al., 2000; Upham et al., 2010), limited infection has been 
seen to occur independent of sialic acid. In this chapter the effects of sialic acid 
removal on epithelial cells were able to be replicated, with sialidase treatment of 
MDCK cells causing a 4.4-fold reduction in 6hr percentage infectivity, but not 
completely abolishing the infection (Figure 4.7)(Table 4.1). MPI macrophages also 
acted as expected from these previous studies, again with sialidase treatment resulting 
in a 5-fold reduction in infectivity at 6hrs, but with a small percentage of cells 
remaining (Figure 4.6). 
It is quite clear from these experiments and the literature, that there must be other 
receptors involved, either directly or in-directly.  C-Type Lectins may be these 
receptors, with several studies having looked at two in particular, Macrophage 
Mannose Receptor (MMR) (Reading et al., 2000; Upham et al., 2010) and Macrophage 
Galactose-type Lectin (MGL) (Ng et al., 2014; Sato et al., 2005; Upham et al., 2010). 
The role that these two C-Type Lectins in IAV infection of MPI macrophages was 
determined by similar methods as these studies, using blocking molecules specific to 
each receptor, mannan (MMR) and asialofetuin (MGL). MPI macrophages treated with 
mannan, prior to IAV infection yielded a 1.7 fold reduction in 6hr infectivity, but did 
not completely abolish it (Figure 4.8)(Table 4.1). While this follows the trend set in 
previous studies (Reading et al., 2000; Upham et al., 2010), the infection suppression 
was much weaker in MPI macrophages than in those studies. This is where the MPI 
macrophages show advantages over conventional models. The surface marker 
similarities to AMs and abundant cell numbers enable more relevant investigations 
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into the role MMR plays in IAV infection, specifically in AM’s. Previous work of Upham 
et al. (2010) and Reading et al. (2000) both investigated the role of MMR in non-
alveolar macrophages, using peritoneal macrophages and the J774 macrophage cell 
line respectively. It would appear that the role of MMR in IAV entry is less crucial in 
alveolar like macrophages than other macrophages, based on what is seen using the 
MPI model. 
MGL appeared to have a greater impact than MMR in MPI macrophages, with pre-
treatment of asialofetuin to block MGL, producing a 2.3 fold reduction in 6hr 
infectivity, but again not entirely removing the infection (Figure 4.9)(Table 4.1). This 
trend followed what has been seen in peritoneal macrophages, where similar levels of 
inhibition were seen, (Ng et al., 2014) however in cell line macrophages (RAW264 and 
J774) the inhibitory effect on infection was much greater.  
As mentioned before, the role of these two receptors in IAV infection in macrophages 
has been shown in the literature for several years. These studies have gone into far 
greater detail on the exact interactions between these receptors and IAV than could be 
done within the scope of this chapter. The work of Reading et al. (2000) and Upham et 
al. (2010) both showed that IAV can not only bind directly to MMR via viral 
glycoproteins, independently of sialic acid, but can also bind sialic acid on MMR. IAV 
also is able to bind MGL directly, independently of sialic acid. (Ng et al., 2014; Upham 
et al., 2010) However even though MGL is sialylated, IAV is unable to bind to this sialic 
acid possibly due to the type of sialic acid on the receptor (Upham et al., 2010).  
It was hoped to investigate the binding of IAV to these two receptors, as well as the 
interactions with sialic acid, on MPI macrophages using the same FACs method used 
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previously in this chapter. However, pre-treatment of the cells with sialidase, mannan, 
and asialofetuin resulted in the appearance of clumped cells and high levels of auto 
fluorescence in the flow cytometer. Therefore, the conclusions on the role of these 
receptors in MPI macrophages, specifically binding to IAV, have been formed using the 
data presented supplemented with knowledge from the literature. It appears that 
MMR and MGL act as secondary co-receptors for sialic acid, with sialic acid 
concentrating the virus on the cell surface, allowing MMR and MGL to bind to the viral 
glycoproteins on the HA stalk, which possibly may facilitate a different type of viral 
uptake then what is seen in epithelial cells. This is further reinforced by the lack of PR8 
infectivity in macrophages, because the PR8 HA completely lacks glycosylation 
(Londrigan et al., 2015) it would mean that MMR and MGL would not be able to bind 
the IAV and facilitate entry. As mentioned earlier this may also explain the poor 
infectivity of the Texas/50/12 strain if it was poorly glycosylated, thus was unable to 
bind MMR and MGL, hindering macrophage infection. However, it appears that while 
Perth/16/09 has 11 predicted glycosylation sites, Texas/50/12 has 12 and which are at 
comparable positions to each other (Figure 4.15).  
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Figure 4.15 Amino acid sequences of Perth/16/09 and Texas/50/12, with predicted Glycosylation sites of. Predicted Glycosylation sites were determined using HA amino acid 
sequences (CY081428 – Perth/16/09) (KC892952 – Texas/50/12) via HCV sequence database. Red underlined amino acids denote predicted glycosylation. Perth/16/09 sites = 11, 
Texas/50/12 sites = 12 
 
 
 
 
 
 
 
 
 
 Amino Acid Sequence Amino Acid 
Number 
Number of 
Predicted 
Glycosylation 
site 
 
 
 
 
Perth/16/09 HA (GenBank 
Source Sequence Accession: 
CY081428) 
YILCLVFAQK LPGNDNSTAT LCLGHHAVPN GTIVKTITND QIEVTNATEL  
VQSSSTGEIC DSPHQILDGK NCTLIDALLG DPQCDGFQNK KWDLFVERSK   
AYSNCYPYDV PDYASLRSLV ASSGTLEFNN ESFNWTGVTQ NGTSSACIRR   
SKNSFFSRLN WLTHLNFKYP ALNVTMPNNE QFDKLYIWGV LHPGTDKDQI  
FLYAQASGRI TVSTKRSQQT VSPNIGSRPR VRNIPSRISI YWTIVKPGDI   
LLINSTGNLI APRGYFKIRS GKSSIMRSDA PIGKCNSECI TPNGSIPNDK   
PFQNVNRITY GACPRYVKQN TLKLATGMRN VPEKQTRGIX GAIAGFIENG   
WEGMVDGWYG FRHQNSEGRG QAADLKSTQA AIDQINGKLN RLIGKTNEKF   
HQIEKEFSEV EGRIQDLEKY VEDTKIDLWS YNAELLVALE NQHTIDLTDS   
EMNKLFEKTK KQLRENAEDM GNGCFKIYHK CDNACIGSIR NGTYDHDVYR  
DEALNNRFQI KGVELKSGYK DWILWISFAI SCFLLCVALL GFIMWACQKG   
NIRC      
50 
100 
150 
200 
250 
300 
350 
400 
450 
500 
550 
554 
 
 
 
 
11 
 
 
 
 
Texas/50/12 HA (GenBank 
Source Sequence Accession: 
KC892952) 
MKTIIALSYI LCLVFAQKLP GNDNSTATLC LGHHAVPNGT IVKTITNDRI  
EVTNATELVQ NSSIGEICDS PHQILDGENC TLIDALLGDP QCDGFQNKKW  
DLFVERSKAY SNCYPYDVPD YASLRSLVAS SGTLEFNNES FNWNGVTQNG  
TSSACIRRSN NSFFSRLNWL THLNFKYPAL NVTMPNNEQF DKLYIWGVHH  
PGTDKDQIFL YAQPSGRITV STKRSQQAVI PNIGSRPRIR NIPSRISIYW  
TIVKPGDILL INSTGNLIAP RGYFKIRSGK SSIMRSDAPI GKCKSECITP  
NGSIPNDKPF QNVNRITYGA CPRYVKQSTL KLATGMRNVP EKQTRGIFGA  
IAGFIENGWE GMVDGWYGFR HQNSEGRGQA ADLKSTQAAI DQINGKLNRL   
IGKTNEKFHQ IEKEFSEVEG RIQDLEKYVE DTKIDLWSYN AELLVALENQ  
HTIDLTDSEM NKLFEKTKKQ LRENAEDMGN GCFKIYHKCD NACIGSIRNG  
TYDHDVYRDE ALNNRFQIKG VELKSGYKDW ILWISFAISC FLLCVALLGF   
IMWACQKGNI RCNICI 
50 
100 
150 
200 
250 
300 
350 
400 
450 
500 
550 
566 
 
 
 
 
12 
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This hypothesised co-receptor role of MMR and MGL led to the conceivable theory 
that there were other receptors on the macrophage surface that acted in similar ways. 
One such possible receptor is the scavenger receptor MARCO, this was of interest due 
to being expressed constitutively only on subsets of macrophages but not all, (Bowdish 
and Gordon, 2009) this includes AM’s (Arredouani et al., 2004). MARCO has previously 
been shown to play a role in IAV induced innate immune responses, but did not affect 
the infectivity of the virus (Ghosh et al., 2011). However because these studies used 
the PR8 IAV strain, which poorly infects macrophages anyway, and MARCO has 
recently been implicated in adenovirus entry (Maler et al., 2017; Stichling et al., 2018) 
using the MPI model, it was likely that MPI’s could be used to better investigate if 
MARCO played a role in IAV entry into macrophages. 
MARCO KO MPI macrophages showed no difference in IAV binding to the cell surface 
(Figure 4.10). Which suggests that IAV binding can occur independently of MARCO. 
This does not mean that IAV does not bind to either MARCO directly, or sialic acid on 
MARCO, which may still occur, but with the redundancy in place from the C-type lectin 
receptors and sialic acid, the loss of MARCO does not affect cell surface binding of IAV 
in MPI macrophages. Conversely MARCO KO MPI macrophages had a 4.5 fold 
reduction in 6hr percentage infectivity of IAV, when compared to WT MPI, which was 
also mirrored with MARCO specific antibody blocking that also gave a reduced 
infectivity of about 3.3 fold (Figure 4.11)(Table 4.1).  
Neither receptor-deficient nor receptor-blocked MPI macrophages had a complete loss 
of IAV infectivity at 6hrs, similarly to what is seen with MMR and MGL (Table 4.1). 
Because of the use of KO macrophages, sialidase treatment was able to be used to look 
at the interactions with MARCO and sialic acid for the IAV infection. A lack of MARCO 
189 
 
Figure 4.16 Visualisation of the three hypothesised roles of MARCO in IAV binding and entry in MPI 
macrophages. 
and sialic acid on MPI macrophages resulted in a statistically insignificant percentage 
of infected cells, whereas sialidase treatment of WT MPI macrophages still left 
percentage residual infection. Statistical comparison of these two results showed that 
they could not be separated significantly, inferring that additional loss of MARCO 
following sialic acid removal has a marginal effect on the viral infectivity.  
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There were three hypothesised mechanisms by which MARCO facilitated infection, 
based on the mechanisms seen with MMR (Indirect, Direct, and Secondary) and MGL 
(Direct and Secondary) (Figure 4.16). Based on findings here, indirect (1) and direct (2) 
binding of MARCO by IAV does not occur in MPI macrophages, and the most likely 
mechanism is that of a secondary co-receptor (3) for sialic acid. This appears the first 
time that MARCO has specifically been shown to be involved with IAV infection in 
macrophages, and very clearly demonstrates the importance of using models that 
better represent AM’s for in vivo studies of IAV induced innate immune responses.  
 
Table 4.1 Results summary of investigated IAV receptors on MPI macrophages at 6hrs 
 
Once bound to the cell surface, the internalisation process of the virus, is still not fully 
understood, with much of the current work being performed using epithelial cells. Two 
mechanisms have been identified in these cells, macropinocytosis and clathrin- 
mediated endocytosis. Interestingly in epithelial cells both of these mechanisms 
appear to work redundantly of one another where if one is blocked, viral entry will 
occur via the other and remain unaffected (de Vries et al., 2011; Sun et al., 2013). In 
order to demine the mechanism of viral uptake in MPI macrophages the inhibitors 
Dynasore and EIPA were used to analyse clathrin-mediated endocytosis and 
macropinocytosis respectively.  
Receptor Effect on IAV Infection Remaining Residual % infection 
Sialic Acid 5-fold reduction 7.8% 
MMR 1.8-fold reduction 22.5% 
MGL 2.3-fold reduction 16.8% 
MARCO 4.5-fold reduction 8.6% 
MARCO & Sialic Acid 5.6-fold Reduction 6.9% (Not significant to control) 
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Figure 4.17 Mechanisms of action for EIPA and Dynasore, which inhibit Macropinocytosis and Clathrin-
dependent endocytosis respectively. EIPA inhibits NA+/H+ exchange to prevent membrane ruffling and 
subsequent membrane protrusion. Dynasore inhibits dynamin to prevent ‘pinching of’ of the vesicle. 
Red squared off dashed lines show the effect of inhibitors. 
 
Dynasore selectively inhibits dynamin involved in clathrin-mediated endocytosis 
(Figure 4.17), which reduced the IAV 6hr infectivity of MPI macrophages 4.9 fold, but 
did not completely abolish it (Figure 4.12). EIPA which inhibits Na+/H+ exchange 
preventing membrane ruffling (Figure 4.17), resulted in a 65.4 fold reduction in 
percentage infectivity at 6hrs and completely inhibited the viral infection.  While 
Na+/H+ exchange is involved in a variety of cellular functions, this method of 
Macropinocytosis inhibition by EIPA is considered the most effective and selective (Lin 
et al., 2018).  
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This was in contrast with previous literature, where viral uptake was only prevented 
when both pathways were blocked (de Vries et al., 2011; Sun et al., 2013), admittedly 
it is likely that the mechanisms in macrophages would differ from those in epithelial 
cells. It has been suggested that IAV virions are pleomorphic and have both spherical 
virions and filamentous virions (Rossman et al., 2012). This study found that clathrin-
mediated endocytosis was used for the spherical virions, with the filamentous virions 
internalised by macropinocytosis. It appears that both pathways are important in IAV 
entry in MPI macrophages when the H3N2 Perth/16/09 strain was used and does not 
have the redundancy seen in epithelial cells. However, macropinocytosis seems to be 
the more crucial mechanism as without this process infection of MPI macrophages 
could not occur. 
The final aspect for successful IAV infection is the escape from the endosome before 
destruction of the virus in the late lysosome. Acidification of the endosome facilitates 
conformal changes in the HA of the virus, allowing fusion to the endosome membrane 
(Cline et al., 2017). This acidification can be blocked using chloroquine, which builds up 
in the endosome, inhibiting enzymes and raising the pH to prevent fusion (Figure 4.18) 
(Steinman et al., 1983). MPI macrophages pre-treated with chloroquine to inhibit this 
acidification showed a 3.8-fold reduction in 6hr infectivity of the virus, however 
surprisingly chloroquine treatment did not abolish it (Figure 4.14). 
This may be due to the endosomal pH threshold being specific to the HA of the virus 
(Marvin et al., 2017) where certain IAV strains can facilitate HA fusion to the 
endosomal membrane at higher or lower pH. In this case some of the virions could 
escape the endosome if the endosome starting pH was sufficient to facilitate fusion. 
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Figure 4.18 Chloroquine blocks endosomal escape by preventing endosomal acidification. 1. Viral 
uptake. 2. Endosomal and virion acidification. 3. Fusion and vRNA escape. Chloroquine accumulates 
within the endosome, preventing the lowering of pH. This blocks the conformal change of the virus HA 
protein and prevents fusion to the endosome, allowing vRNA escape. Squared off dashed line shows 
inhibition effect of chloroquine.  
Ideally the pH of endosomes could be measured using pHrodo green dextran as used 
in the work of Marvin et al. (2017) to comparatively determine the endosomal pH of 
AM’s, macrophage cell lines and epithelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Overall, this chapter shows the benefits of using a representative model of AMs to 
study IAV entry mechanisms such as MPI macrophages, and the variation in how 
different strains infect either macrophages or epithelial cells. The complexity of these 
identified using MPI as a model shows that there is not one clear receptor of IAV or 
mechanism, but rather multiple macrophage receptors working in conjunction with 
sialic acid to facilitate uptake (Table 4.1). The identification of MARCO as a co-receptor 
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of IAV in macrophages has previously been unseen, and it is likely that there are 
several unknown receptors that also aid in IAV uptake. The IAV uptake mechanisms in 
macrophages, appears to be different from epithelial cells. In MPI macrophages there 
is no redundancy between the two described mechanisms of macropinocytosis and 
clathrin-dependent endocytosis. The effect these complex interconnecting 
mechanisms have on the immune response against IAV may deepen the understanding 
IAV-AM interactions, and lead to the development of novel treatments that target 
these. 
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5 Chapter Five: Influenza A Induced 
Immune Reponses in Macrophages 
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5.1 Introduction 
This chapter primarily focuses on the inflammatory responses in MPI macrophages 
upon infection with IAV via the mechanisms established in Chapter 4, looking at how 
MARCO, and endosomal entry and escape affect the innate immune response. 
Moreover it expands on some of those already measured in Chapter 3, going into 
greater depth comparing the differing innate immune responses induced by H3N2 IAV 
strains Perth/16/09 and Texas/50/12.  AM’s which reside in the alveolar air spaces are 
the first cells to come into contact with respiratory pathogens and therefore play a key 
role in early IAV innate immunity (Rubins, 2003). By using MPI macrophages as a 
model of AMs a greater understanding of this immune response can be achieved due 
to the greater availability of cell numbers over that of primary AM’s (Fejer et al., 2013). 
There are several key aims in this chapter, with the first being the expanded analysis of 
the response driven by IAV strains Perth/16/09 and Texas/50/12, and how these relate 
to the difference of infectivity observed in Chapter 4. The timings of the induction of 
the innate immune response against IAV are also to be analysed in an attempt to 
distinguish how the viral infection cycle tailors the innate response to the virus. In a 
hope to identify key aspects of treatment targets or future studies. Some studies 
(Kleinerman et al., 1976; Wang et al., 2012) have looked at non-RNA replicating IAV’s 
ability to induce innate immune responses, however the use of the PR8 IAV strain, 
which poorly infected macrophages (Londrigan et al., 2015) has limited their 
effectiveness. Hopefully MPI macrophages and a good infective strain (Perth/16/09) 
can yield a better understanding.  
The main output to study the innate immune response here will be the measurement 
of secreted inflammatory proteins upon infection. These will be divided between; pro-
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inflammatory cytokines (1.3.3.1), chemotactic chemokines (1.3.3.2), and type I 
interferons (1.3.3.3), each having their own role in the immune response. Confirmatory 
experiments will be done, where available, on the activation of signalling pathways, to 
further the understanding of host-virus interactions leading to the innate response. 
Novel findings will provide excellent knowledge for therapeutic targets, as well as 
show the benefits of MPI macrophages as a model to study IAV induced innate 
immune responses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
5.2  Results 
5.2.1 Comparisons of Innate Immune Responses Induced by Perth/16/09 and 
Texas/50/12 Strains 
This section shows the expanded analysis of the induction of immune responses in MPI 
macrophages by strains Perth/16/09 and Texas/50/12, from those in 3.2.1. A greater 
range of secreted cytokines are tested, split between pro-inflammatory cytokines and 
chemokines, both in a dose and time-dependent nature.  
For IL-6, both strains were able to induce significant levels in MPI macrophages when 
compared to the mock control (Figure 5.1A). However there a significantly less IL-6 
produced upon Texas/50/12 infection, with the greatest effect occurring at the MOI 5, 
with a 2.7-fold reduction (p=0.0015). TNF-α was only inducible by Perth/16/09, while 
infection at any MOI of 0.2 (p=0.363), 1 (p=0.085), and 5 (p=0.175) of Texas/50/12 was 
unable to induced significant levels (Figure 5.1B). IL-1α and IL-1β had very similar 
results, with both induced strongly by Perth/16/09, where concentrations of 698pg/ml 
(p=0.002) and 1432pg/ml (p=0.0012) respectively were detected (Figure 5.1C and 
Figure 5.1D). However, with Texas/50/12 only a MOI of 5 was able to induce IL-1α 
(p=0.02) and IL-1β (p=0.04) to significant levels. Both of these values were much lower 
than those induced by Perth/16/09, with IL-1α showing a 3.7-fold reduction (p=0.005) 
and IL-1β showing a 3.4-fold reduction (p=0.003) 
Chemokine induction was more comparable for the two strains (Figure 5.2), with both 
strains producing significant levels of RANTES, IP-10, MIP-1α, and MIP-2. The only 
detectable difference between Perth/16/09 and Texas/50/12 induction of chemokines 
was observed with IP-10 at a MOI of 5 (Figure 5.2B). Here there was a 1.4-fold increase 
in production with Texas/50/12 when compared with Perth/16/09 (p=0.03). 
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Continuing the investigation, the time kinetics of cytokines and chemokines induction 
were measured over time, using a MOI of 1 (Figure 5.3 and Figure 5.4). With 
Perth/16/09 the kinetics differed greatly between the individually secreted proteins 
and was not specific to the category of cytokine and chemokine. IL-6 (p=0.003), TNF-α 
(p=<0.0001), IL-1α (p=0.04), (Figure 5.3) IP-10 (p=0.005), MIP-1α (p=0.01), and MIP-
2(p=<0.0001) (Figure 5.4) all showed significant levels as early as 2hr post infection, 
with TNF-α actually having the peak of 706pg/ml at this time. In contrast, IL-1β 
(p=0.025) (Figure 5.3D) and RANTES (p=0.012) (Figure 5.4A) were not significant until 
after 8hr post infection. Texas/50/12 infection also showed unexpected induction of IL-
1α at 0.5 (p=0.037) and 1hr (p=0.02) post infection, but with no induction at the later 
16 (p=0.39) and 24hrs (p=0.91). (Figure 5.3C) 
Type I interferons are a hallmark of viral infection in macrophages. To measure them a 
bioassay was performed using the reporter cell line RAW-Blue ISG for bioactive murine 
type I interferons, as described in 2.2.7. To obtain a quantitative measurement, rather 
than just a fold-change comparison, biologically active recombinant murine IFN-β was 
used to develop a standard curve (Figure 2.1). Type I interferon was only induced 
significantly at 16hrs (p=0.009) and not 0.5hrs (p=>0.99) or 2hrs (p=0.35) post-infection 
with Perth/16/09, whereas Texas /16/09 was unable to induce type I interferon at any 
of the 0.5hr (p=0.347), 2hr (p=0.346), or 16hr (p=0.169) time points (Figure 5.5A).  
Furthermore, the MOI of the virus affected type I interferon production, with MOIs of 
1 (p=0.009) and 5 (p=0.003) producing significant levels of type I interferon, but a MOI 
of 0.2 (p=0.169) yielding non- significant values, in response with Perth/16/09. With 
Texas/50/12 significant type I interferon was not induced until a MOI of 5 (p=0.038), 
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however while this was 1.6-fold lower than the induction seen with Perth/16/09 it was 
deemed not to be a significant difference (p=0.305) (Figure 5.5B). 
IAV induced type I IFN was seen as relatively low, MPI macrophages are capable of 
producing ‘high levels’ of type I interferon using high MOIs of Adenovirus, such as 
10,000 MOI producing 93pg/ml of type-I IFN (p=<0.0001).  LPS on the other hand as a 
poor inducer of IFN (Fejer et al., 2013), requires high concentrations of 100ng/ml to 
induce significant level of 5.7pg/ml (p=0.008) (Figure 5.5C). In Figure 5.5 the 
production of type I IFN by IAV and LPS was lower than the lowest concentration of 
standard (30pg/ml) however from curve extrapolation, a value for sample 
concentrations was provided. 
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5.2.1.1 Cytokine and Chemokine Response Relative to Viral infection Load  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Perth/16/09 induces higher levels of cytokines than Texas/50/12 in MPI macrophages in a 
dose dependent manner. Cells were inoculated with virus for 1hr at 37oC in the absence of FBS, after 
which inoculum was removed and the cells were incubated in medium containing 10% FBS. At 16hrs, 
post-infection supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-1α, (D) IL-1β were measured by 
ELISA. Bars represent the mean from 3 individual experiments (3 replicate samples per experiment) ± 
S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, compared to Mock 
Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are 
indicated with n.s. Comparison between Perth/16/09 and Texas/50/12 at each MOI was performed 
using unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01, ***= 
P ≤ 0.001). Non-significant values are indicated with red n.s. 
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Figure 5.2 Similar levels of chemokines produced by MPI macrophages when challenged with increasing 
doses of Influenza A strains Perth/16/09 and Texas/50/12. Cells were inoculated with virus for 1hr at 
37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. At 16hrs, post-infection supernatants were collected and (A) RANTES, (B) IP-10, (C) 
MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P 
≤ 0.001). Non-significant values are indicated with n.s. Comparison between Perth/16/09 and 
Texas/50/12 at each MOI was performed using unpaired t-test, significant differences are indicated by 
red asterisk (*= P < 0.05). Non-significant values are indicated with red n.s. 
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5.2.1.2  Cytokine and Chemokine Response Relative to Viral infection Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 IAV induction of IL-6, TNF-α, and IL-1α cytokine responses occur as early as 2hrs post infection  
in MPI macrophages, while IL-1β does not occur until 8hrs post infection. Cells were inoculated with 1 
PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which inoculum was removed 
and the cells were incubated in medium containing 10% FBS. At varying time points post-infection 
supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-1α, (D) IL-1β, were measured by ELISA. Bars 
represent the mean from 3 individual experiments (3 replicate samples per experiment) ± S.E.M. (N=3) 
Significance was calculated using unpaired t-test, significant values compared to Mock Infected are 
indicated by asterisk. (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated 
with n.s. Black lines and asterisks represent Perth/16/09 and Grey lines and asterisks represent 
Texas/50/12. 
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Figure 5.4 IAV induction of IP-10, MIP-1α, and MIP-2 chemokine responses occur as early as 2hrs post 
infection  in MPI macrophages, while RANTES does not occur until 8hrs post infection. Cells were 
inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. At varying time 
points post-infection supernatants were collected and (A) RANTES, (B) IP-10, (C) MIP-1α, (D) MIP-2, were 
measured by ELISA. Bars represent the mean from 3 individual experiments (3 replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values 
compared to Mock Infected are indicated by asterisk. (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-
significant values are indicated with n.s. Black lines and asterisks represent Perth/16/09 and Grey lines 
and asterisks represent Texas/50/12. 
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5.2.1.3 Type I IFN Response Relative to Viral infection Load, and Infection Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 IAV is able to induce type-I IFN production in MPI macrophages, but at relatively low levels. 
Production of type-I IFN occurred after 16hrs post infection, with Texas/50/12 requiring a higher 
infective dose than Perth/16/09 to induce a response. Unless stated otherwise cells were inoculated 
with 1 PFU/cell (MOI1) virus for 1hr at 37oC in the absence of FBS, after which inoculum was removed 
and the cells were incubated in medium containing 10% FBS. Unless stated otherwise, at 16hrs post-
infection supernatants were collected and Type I Interferon was analysed using reporter cell line assay. 
(A) Time point analysis of Type I Interferon produced by Influenza A strains Perth/16/09 and 
Texas/50/12 in MPI macrophages. (B) Dose analysis of Type I Interferon produced by Influenza A strains 
Perth/16/09 and Texas/50/12 in MPI macrophages. (C) Type I Interferon production by LPS and 
Adenovirus in MPI macrophages. Bars represent the mean from 3 individual experiments (3 replicate 
samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant 
values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). 
Non-significant values are indicated with n.s. Comparison between Perth/16/09 and Texas/50/12 at 
each MOI was performed using unpaired t-test, significant differences are indicated by red asterisk 
(***= P ≤ 0.001). Non-significant values are indicated with red n.s. 
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5.2.2 Role of the Scavenger Receptor MARCO in Immune Activation 
The immune responses in MARCO KO MPI were also measured using the same process 
as described in 5.2.1, both in a dose and time-dependent nature. Only the IAV strain 
Perth/16/09 was used in these experiments due to its uniform induction of both 
cytokines and chemokines in 5.2.1. 
 In MARCO deficient macrophages, the IL-6 (Figure 5.6A), IL-1β (Figure 5.6D), IP-10 
(Figure 5.7B), MIP-1α (Figure 5.7C), and MIP-2 (Figure 5.7D) responses all were 
reduced, so that the lowest MOI of 0.2 no longer gave a significant production of these 
proteins. At higher MOI’s (IL-6 and IL-1β – MOI 5) (IP-10, MIP-1α, and MIP-2 – MOI 1) 
while there was significant production, it was still significantly lower than that 
observed in the WT MPI macrophages.  
IL-6 (Figure 5.6A) production was drastically reduced in MARCO KO MPI macrophages, 
with only a MOI of 5 producing a significant value of 143pg/ml (p= <0.0001). However, 
this was a 33-fold reduction from the WT MPI IL-6 production (p=<0.0001). TNF-α 
(Figure 5.6B) production was no different in MARCO KO MPI macrophages compared 
to WT at any of the tested MOIs of 0.2 (=p=0.985), 1 (p=0.3), 5 (p=0.398). IL-1α (Figure 
5.6C)  induction in MARCO KO macrophages was quite strange, at MOIs of 0.2 (p=>0.9.) 
and 1 (p=0.089), there was no significant production, yet at the MOI of 5 the IL-1α was 
no different to that produced in the WT MPIs (p=0.175). IL-1β (Figure 5.6D) was very 
similar to that of IL-6 with only a MOI of 5 producing a significant value of 193pg/ml 
(p= <0.037). This was a 7.4-fold reduction from the WT MPI IL-1β production 
(p=0.0003).  
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RANTES (Figure 5.7A) was not induced in MARCO KO MPI macrophages at any of the 
used MOIs of 0.2 (p=0.83), 1 (p=0.166) , and 5 (p=0.064). IP-10 (Figure 5.7B) production 
was reduced in MARCO KO MPI macrophages, although an MOI of 1 was able to 
produce a significant value of 573pg/ml (p= <0.0001). However, this was a 10-fold 
reduction from the WT MPI IP-10 production (p=<0.0001). MIP-1α (Figure 5.7C) 
production was reduced in MARCO KO MPI macrophages, although an MOI of 1 was 
able to produce a significant value of 86pg/ml (p= <0.003). However, this was a 53-fold 
reduction from the WT MPI MIP-1α production (p=0.005).  MIP-2 (Figure 5.7D) 
production was reduced in MARCO KO MPI macrophages, although an MOI of 1 was 
able to produce a significant value of 637pg/ml (p= 0.02). However, this was an 8.5-
fold reduction from the WT MPI MIP-2 production (p=0.009). 
The kinetics of these cytokines and chemokines are shown in Figure 5.9 and Figure 
5.10. IL-6 (Figure 5.9A), IL-1α (Figure 5.9C), and IL-1β (Figure 5.9D), were not induced 
at any timepoint in MARCO KO MPI macrophages. TNF-α production (Figure 5.9B) 
maintained the same kinetics in both WT and MARCO KO MPI, where induction 
occurred as early as 0.5hrs post-infection (p=0.007). In MARCO KO MPI macrophages, 
TNF-α production was greater at 4hr (1.9-fold) and 8hr (1.9-fold) post infection than in 
the WT MPI.  
MIP-1α production (Figure 5.10C), occurred significantly earlier in MARCO KO MPI, at 
0.5hr (p=0.0012) post-infection, than in WT MPI at 1hr (p=0.04). IP-10 and MIP-2 in 
MARCO KO MPI showed significant levels at later time points than the WT MPI 
counterparts.  Significant IP-10 in WT MPI occurred at 2hr (p=0.004) post-infection, 
whereas in MARCO deficient MPI this was pushed back to 8hr (p=0.025) post-infection 
(Figure 5.10B). MIP-2 showed significant levels in MPI macrophages at 0.5hr (p=0.006) 
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post-infection, yet with MARCO KO MPI significant levels occurred at 2hr (p=0.017) 
post-infection. 
The scavenger receptor MARCO was also involved in the type I interferon response, 
where MARCO KO MPI macrophages produced detectable levels upon infection with 
Perth/16/9 at MOIs of 0.2, 1, and 5 (Figure 5.8). While WT MPI macrophages produced 
14pg/ml at MOI of 1, MARCO KO MPIs produced 0pg/ml, a significant reduction 
(p=0.0002). In this figure the production of type I IFN by WT MPI was lower than the 
lowest concentration of standard (30pg/ml) however from curve extrapolation, a value 
for sample concentrations was provided. 
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5.2.2.1 Cytokine and Chemokine Response Relative to Viral infection Load  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Lack of MARCO on MPI macrophages reduces IL-6, IL-1β, and IL-1α (except MOI of 5) 
production but has no effect on TNF-α with Perth/16/09 infection. Cells were inoculated with virus for 
1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in 
medium containing 10% FBS. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-
α, (C) IL-1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual experiments 
(3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P 
≤ 0.001). Non-significant values are indicated with n.s. Comparison between MPI and MARCO KO at 
each MOI was performed using unpaired t-test, significant differences are indicated by red asterisk (*= P 
< 0.05, ***= P ≤ 0.001). Non-significant values are indicated with red n.s. 
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Figure 5.7 Lack of MARCO on MPI macrophages reduces chemokine production with Perth/16/09 
infection. Cells were inoculated with virus for 1hr at 37oC in the absence of FBS, after which inoculum 
was removed and the cells were incubated in medium containing 10% FBS. At 16hrs, post-infection 
supernatants were collected and (A) RANTES, (B) IP-10 (C) MIP-1α, (D) MIP-2 were measured by ELISA. 
Bars represent the mean from 3 individual experiments (3 replicate samples per experiment) ± S.E.M. 
(N=3) Significance was calculated using unpaired t-test, significant values, compared to Mock Infected 
are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated 
with n.s. Comparison between MPI and MARCO KO at each MOI was performed using unpaired t-test, 
significant differences are indicated by red asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values 
are indicated with red n.s. 
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Figure 5.8 Type I interferon production from IAV infection of MPI macrophages requires MARCO. Cells 
were inoculated with Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was 
removed and the cells were incubated in medium containing 10% FBS. At 16hrs post-infection 
supernatants were collected and Type I Interferon was analysed using reporter cell line assay. (A) 
Standard curve obtained from recombinant IFN-b used to determine the concentration of Type I 
Interferon in samples. (B) Comparison of Type I Interferon induced by Influenza A strain Perth/16/09 in 
WT MPI and MARCO KO MPI. Bars represent the mean from 3 individual experiments (3 replicate 
samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant 
values, compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01). Non-significant values are 
indicated with n.s. Comparison between MPI and MARCO KO at each MOI was performed using 
unpaired t-test, significant differences are indicated by red asterisk (***= P ≤ 0.001). Non-significant 
values are indicated with red n.s. 
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5.2.2.2  Cytokine and Chemokine Response Relative to Viral infection Time 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Lack of MARCO in MPI macrophages enhances the TNF-α response to IAV infection, 
prolonging the production. Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 37oC in 
the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. At varying time points post-infection supernatants were collected and (A) IL-6, (B) 
TNF-α, (C) IL-1α, (D) IL-1β, were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values compared with Mock Infected are indicated by asterisk (*= P < 0.05, 
**= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Black lines and asterisks 
represent WT MPI and Grey lines and asterisks represent MARCO KO MPI. 
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Figure 5.10 Lack of MARCO in MPI macrophages delays the IP-10 and MIP-2 responses to IAV infection, 
but advances the MIP-1α response. Cells were inoculated with 1 PFU per cell (MOI 1) of virus for 1hr at 
37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. At varying time points post-infection supernatants were collected and (A) RANTES, 
(B) IP-10, (C) MIP-1α, (D) MIP-2, were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= 
P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Black lines and asterisks 
represent WT MPI and Grey lines and asterisks represent MARCO KO MPI. 
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5.2.3 Influenza A Induced Signalling Pathways 
5.2.3.1 Phosphorylation of Transcription Factors and Kinases by IAV 
The innate immune response to IAV is trigged by viral sensing via PRRs, leading to the 
activation of different signalling pathways via phosphorylation. In this study this was 
detected using western blotting to measure the activation of several key kinases and 
transcription factors in the different pathways. The levels of phosphorylation were 
quantified by measured band intensity, normalised to the loading control band 
intensity.  
Phosphorylation of TBK1 (Figure 5.11B) by Perth/16/09 did not reach significant levels 
until 6hrs post infection where a 25-fold increase was observed (p=0.035). The earlier 
timepoints of 0.5hr and 2hr while both showing slight increases of 2.2-fold (p=0.02) 
and 1.1-fold (p=0.676) respectively in phosphorylation, were deemed non-significant. 
Texas/50/12 infection also did not significantly phosphorylate TBK1 at 0.5hr (3.2-fold – 
p=0.06) or 2hr (1.9-fold – p=0.23) but did at 6hr (8.7-fold – p=0.013). The activation of 
TBK1 by the two different strains was comparatively non-significant at 6hrs, as while 
there was a 2.8-fold reduction with Texas/50/12, it was determined to be not 
statistically significant (0=0.509).   
NF-kB phosphorylation (Figure 5.11C) occurred at all timepoints with Perth/16/09, 
with a 3.2-fold increase at 0.5hr (p=0.011), a 2.6-fold increase at 2hr (p=0.025), and 
2.6-fold increase at 6hr (p=0.04). Infection with Texas/50/12 only produced significant 
phosphorylation at 0.5hr with a 3.2-fold increase (p=0.0197), but not 2hr (2.1-fold – 
p=0.24) or 6hr (2-fold – p=0.19). However direct comparison between the two strains 
showed no statistical difference at any time-point of 0.5hr (same value – p=0.978), 2hr 
(1.3-fold – p=0.881), or 6hr (1.3-fold- p=0.876). 
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p38 activation with Perth/16/09 was significant at all time-points of 0.5hr (2-fold – 
p=0.017), 2hr (2.6-fold – p=0.008), and 6hr (6.6-fold – p=0.001). On the other hand, 
Texas/50/12 did not activate p38 until 6hr where a 2.3-fold increase was observed 
(p=0.0004). However, this phosphorylation was 2.8-fold less than that of induced by 
Perth/16/09 (p=0.018). 
Perth/16/09 was unable to phosphorylate IRF-3 at 0.5hr (2-fold – p=0.23) but did 
induce significant phosphorylation by 2hr (1.7-fold – p=0.027) and resulted in the 
highest levels at 6hr (11.7-fold – p=0.0008). Texas/50/12 however did not result in any 
IRF-3 activation at any of the measured time-points of 0.5hr (p=0.95), 2hr (p=0.19), or 
6hr (p=0.39). 
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Figure 5.11 TBK1, IRF-3 and p38 activation is stronger with Perth/16/09 compared to Texas/60/12 
infection of MPI macrophages. Moreover NF-κB and p38 activation occurs at early time points post 
infection, while TBK1 and IRF3 activation occurs at later timepoints. Cells were inoculated with 5 PFU 
per cell (MOI 5) of virus for 1hr at 37oC in the absence of FBS, after which inoculum was removed and 
the cells were incubated in medium containing 10% FBS. At indicated time-points, post-infection cells 
were washed and lysed. (A) Western blot analysis of P-TBK1, P-NF-kB (P65), P-p38, and P-IRF-3. Bands 
were quantified by relative expression, normalised to GAPDH (B) P-TBK1, (C) P-NF-kB (P65), (D) P-p38, 
and (E) P-IRF-3. Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance was 
calculated using unpaired t-test, significant values, compared to 0hr are indicated by asterisk (*= P < 
0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison between 
Perth/16/09 and Texas/50/12 at each timepoint was performed using unpaired t-test, significant 
differences are indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01). Non-significant values are indicated 
with red n.s. 
 
 
217 
 
5.2.3.2 Role of MAP Kinases in ‘Early’ and ‘Late’ IAV Induced Immune Responses 
Based on the role of the MAP kinase p38 in both the ‘early’ and ‘late’ response in IAV 
infection the role of MAP kinase in the IAV induced immune response was 
investigated. The IAV strain Perth/16/09 was used due to its good induction of 
cytokines and chemokines (Figure 5.1 and Figure 5.2). Specific inhibitors were used to 
block specific MAP kinases; UO126 (MEK/ERK), SB203580 (P38), and SP600125 (JNK) 
with the effect on cytokine and chemokine production measured by ELISA. All three of 
these inhibitors were used at 15µM concentration, with a 15 minutes pre-treatment of 
cells. This methodology worked successfully for Ad infection of BMDMs in the work of 
Fejer et al. (2008). Both an early (2hr) and (16hr) response was taken to gauge an early 
and late effect of the pathway after infection with Perth/16/09. This measurement of 
response at both early and late timings was necessary to explore and explain how 
different cytokines and chemokines were upregulated at different times (Figure 5.3 
and Figure 5.4). 
MEK/ERK inhibition significantly reduced IL-6 1.4-fold (p=<0.0001) (Figure 5.12A), IL-1α 
2.1-fold (p=0.003) (Figure 5.12C), and IL-1β  5.8-fold (p=0.015) (Figure 5.12D) at 16hr. 
MIP-1α (Figure 5.13) was significantly reduced at both the early 2hr (2.6-fold – 
p=<0.0001) and the late 16hr (1.7-fold -p=<0.0001) time. MIP-2 (Figure 5.13) was also 
significantly reduced at both the early 2hr (2.5-fold – p=0.0009) and the late 16hr (3.8-
fold -p=<0.0001) time. RANTES (Figure 5.13A) and IP-10 (Figure 5.13B) both remained 
unaffected by MEK/ERK inhibition, at both time points. The TNF-α (Figure 5.12B) 
response was completely abolished with MEK/ERK inhibition, with no detectable TNF-α 
production at 2hr and 16hr. 
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p38 inhibition had no effect on IL-1β at 2hr (same value) and 16hr (p=0.197), (Figure 
5.14D) RANTES at 2hr (p=0.92) or 16hr (p=0.77) (Figure 5.15A) and IP-10 at 2hr 
(p=0.61) or 16hr (p=0.34) (Figure 5.15B). With IL-1α (p=0.2) (Figure 5.14C) and MIP-2 
(p=0.335) (Figure 5.15D) p38 inhibition had no effect on the early 2hr, however the 
inhibition caused an increase in the late 16hr response. For IL-1α there was a 1.4-fold 
increase in production at 16hrs when p38 was inhibited (p=0.002). MIP-2 production 
was increased by 1.9-fold at 16hrs when p38 was inhibited (p=0.005). MIP-1α (Figure 
5.15C) on the other hand was reduced  1.6-fold with p38 inhibition for the early 2hr 
time point (p=0.0002), but not at the later 16hr (p=0.167). The early 2hr IL-6 (Figure 
5.14A) response was increased 2-fold with p38 inhibition (p=0.002), while the later 
16hr response was reduced 2.8-fold (p=<0.0001). p38 inhibition was able to reduce 
TNF-α (Figure 5.14B) production by 2-fold 2hr (p=0.0003) and 5-fold at 16hr (p=0.012), 
when compared to non-inhibitor treated cells. 
Inhibition of JNK, had no effect on IL-1β (2hr no production, 16hr p=0.636) (Figure 
5.16D), RANTES (2hr p=0.4, 16hr p=0.9) (Figure 5.17A), IP-10 (2hr p=0.55, 16hr p=0.25) 
(Figure 5.17B), and MIP-2 (2hr p=0.84, 16hr p=0.167) (Figure 5.17D) production at both 
2hr and 16hr post-infection, when compared to non-inhibitor samples. MIP-1α (Figure 
5.17C) production was unaffected at 16hrs (p=0.1733) after JNK inhibition but was 
reduced 1.3-fold at the early 2hr response (p=0.015). IL-1α production (Figure 5.16) 
was unaffected by JNK inhibition at 16hr (p=0.86), but was increased by 1.5-fold at 2hr 
(p=0.047), when compared to non-treated MPIs. JNK inhibition increased IL-6 
production 2.3-fold (Figure 5.16) at 2hrs (p=0.0015) but reduced the production 1.2-
fold at 16hrs (0.036). TNF-α (Figure 5.16) was unaffected by JNK inhibition at 2hr 
(p=0.218), but was completely inhibited at 16hrs, reducing TNF-α 82-fold, compared to 
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non-inhibited cells (p=0.003). This inhibition of TNF-α was so complete that there were 
no levels of TNF-α detected there was not considered significant compared to the 
mock infected control (p=0.357). 
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Figure 5.12 MEK/ERK activation is crucial in TNF-α, IL-1α, and IL-1β production in MPI macrophages 
infected with IAV.  Cells were pre-treated with 15µM U0126 for 15 mins at 37oC to inhibit MEK/ERK 
prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, 
after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) 
TNF-α, (C) IL-1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= 
P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of MEK/ERK 
inhibitor to no inhibitor was performed using unpaired t-test, significant differences are indicated by red 
asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant differences are indicated with red 
n.s. 
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Figure 5.13 MEK/ERK activation is required for optimal MIP-1α and MIP-2 production in MPI 
macrophages infected with IAV. Cells were pre-treated with 15µM U0126 for 15 mins at 37oC to inhibit 
MEK/ERK prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence 
of FBS, after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) RANTES 
(B) IP-10, (C) MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (***= P ≤ 0.001). 
Non-significant values are indicated with n.s. Comparison of MEK/ERK inhibitor to no inhibitor was 
performed using unpaired t-test, significant differences are indicated by red asterisk (***= P ≤ 0.001). 
Non-significant differences are indicated with red n.s. 
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Figure 5.14 P38 activation is required for optimal IL-6 and TNF-α production in the late phase of MPI 
macrophage infection with IAV. Cells were pre-treated with 15µM SB203580 for 15 mins at 37oC to 
inhibit p38 prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence 
of FBS, after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) 
TNF-α (C) IL-1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= 
P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of P38 MAPK 
inhibitor to no inhibitor was performed using unpaired t-test, significant differences are indicated by red 
asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant differences are indicated with red 
n.s. 
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Figure 5.15 P38 activation aids in the early MIP-1α response, and regulating the late MIP-2 response in 
MPI macrophages infected with IAV. Cells were pre-treated with 15µM SB203580 for 15 mins at 37oC to 
inhibit P38 prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence 
of FBS, after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) RANTES 
(B) IP-10, (C) MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01, 
***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of P38 MAPK inhibitor to no 
inhibitor was performed using unpaired t-test, significant differences are indicated by red asterisk (**= P 
≤ 0.01, ***= P ≤ 0.001). Non-significant differences are indicated with red n.s. 
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Figure 5.16 JNK activation is crucial in the late TNF-α production in MPI macrophages infected with IAV. 
Cells were pre-treated with 15µM SP600125 for 15 mins at 37oC to inhibit JNK prior to inoculation with 1 
PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was 
removed and the cells were incubated in medium containing 10% FBS. Inhibitor was present at all 
points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-1α, (D) IL-1β 
were measured by ELISA. Bars represent the mean from 3 individual experiments (3 replicate samples 
per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-
significant values are indicated with n.s. Comparison of JNK inhibitor to no inhibitor was performed 
using unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01,). 
Non-significant differences are indicated with red n.s. 
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Figure 5.17 JNK activation is not required for the chemokine response in MPI macrophages when 
infected with IAV. Cells were pre-treated with 15µM SP600125 for 15 mins at 37oC to inhibit JNK prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At 16hrs, post-infection supernatants were collected A) RANTES (B) IP-10, (C) MIP-
1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). 
Non-significant values are indicated with n.s. Comparison of JNK inhibitor to no inhibitor was performed 
using unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05). Non-significant 
differences are indicated with red n.s. 
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5.2.4 Endosomal Role in the Immune Response 
5.2.4.1 Release of Viral RNA from the Endosome 
To inhibit the acidification of the endosome and prevent viral release, cells were pre-
treated with chloroquine prior to Perth/16/09 infection. Previous work of Ooi et al. 
(2006) has shown that a concentration of 2.5µM resulted in a 90% reduction in H3N2 
replication. Chloroquine remained present for the whole infection, with the effect on 
secreted cytokines and chemokines measured by ELISA. Both an early (2hr) and late 
(16hr) response was measured to gauge the early and late effect of viral endosome 
escape on the immune response.  
Chloroquine treatment did not significantly alter the production of TNF-α (2hr p=0.89, 
16hr p=0.5) (Figure 5.18B), IP-10 (2hr p=0.32, 16hr p=0.24) (Figure 5.19B), MIP-1α (2hr 
p=0.64, 16hr p=0.24) (Figure 5.19C), or MIP-2(2hr p=0.2, 16hr p=0.15)  (Figure 5.19D) 
at either time point of 2hr or 6hr. Chloroquine treatment did increase the early 2hr 
response IL-1α by 2.6-fold (p=0.0016) (Figure 5.18C) and RANTES by 1.5-fold 
(p=0.0002) (Figure 5.19A), but did not significantly alter the later 16hr response in 
either IL-1α (p=0.09) or RANTES (0.91). IL-6 response (Figure 5.18A) was increased at 
the early 2hr time point by 3.7-fold (p=<0.0001), but was reduced at the later 16hr 
time point by 1.5-fold (p=<0.0001) with the addition of chloroquine. With IL-1β (Figure 
5.18D) there was no significant early 2hr response to be inhibited, but chloroquine 
treatment did reduce the late 16hr response 3.6-fold (p=0.026). Chloroquine 
treatment reduced the IL-1β production to a level of 74pg/ml where it was not 
considered significant when compared to the mock infected control (p=0.758). 
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Figure 5.18 Endosomal escape by IAV is crucial in IL-1β production in MPI macrophages. Moreover, 
endosomal escape also prevents over production of IL-6 in the early phase of infection. Cells were pre-
treated with 2.5µM chloroquine for 30 mins at 37oC to inhibit endosomal acidification prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-
1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual experiments (3 
replicate samples per experiment)  ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P 
≤ 0.001). Non-significant values are indicated with n.s. Comparison of Perth/16/09 + Chloroquine to 
Perth/16/09 was performed using unpaired t-test, significant differences are indicated by red asterisk 
(*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant differences are indicated with red n.s. 
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Figure 5.19 Endosomal escape by IAV is not require for the chemokine response in MPI macrophages.  
Cells were pre-treated with 2.5µM chloroquine for 30 mins at 37oC to inhibit endosomal acidification 
prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, 
after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) RANTES 
(B) IP-10, (C) MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01, 
***= P ≤ 0.001). Comparison of Perth/16/09 + Chloroquine to Perth/16/09 was performed using 
unpaired t-test, significant differences are indicated by red asterisk (***= P ≤ 0.001). Non-significant 
differences are indicated with red n.s. 
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5.2.4.2 Endosomal Formation 
Dynamin-dependent endocytosis of IAV into the endosome was blocked via the use of 
the specific inhibitor Dynasore, and the resulting cytokines and chemokines produced 
were measured at 2hr and 16hr post-infection. Previous work of de Vries et al. (2011) 
has shown that a concentration of 80µM prevented IAV entry in MDCK cells.  
With Dynasore treatment, IP-10 (Figure 5.21B) was reduced by 1.3-fold at 2hrs 
(p=<0.0001) and 19-fold at 16hrs (p=<0.0001). MIP-1α (Figure 5.21C) was by 2.3-fold at 
2hrs (p=0.038) and by 20-fold at 16hrs (p=<0.0001) with Dynasore treatment. MIP-2 
(Figure 5.21D) was reduced by 3.2-fold at 2hrs (p=0.0006) and 311-fold by 16hrs 
(p=<0.0001) when Dynasore was present during the IAV infection. Dynasore treatment 
RANTES production (Figure 5.21A) at 16hrs by 31-fold (p=<0.0001) but did not 
significantly change the 2hr response (p=0.078). IL-1α production (Figure 5.20C) at 
16hrs was not affected by Dynasore treatment (p=0.057), but the early 2hr response 
was significantly increased by 1.8-fold (p=0.002). IL-6 (p=0.25) (Figure 5.20A) and IL-1β 
(p=0.75) (Figure 5.20D) production were both completely inhibited at 16hrs, with no 
significant values detected, but the 2hr response was not present in the Perth/16/09 
only infection to abolish. The TNF-α response (Figure 5.20B) was completely abolished 
at both 2hr (p=0.36) and 16hr (p=0.35), with no significant TNF-α production detected 
with Dynasore treatment.  
Macropinocytosis of IAV into the endosome was blocked using EIPA and the resulting 
cytokines and chemokines produced were measured at 2hr and 16hr post-infection. 
Previous work of de Vries et al. (2011) has shown that a concentration of 80µM 
prevented IAV entry in MDCK cells.   
230 
 
IP-10 (Figure 5.23B) production was reduced by 1.7-fold at 2hrs (p=<0.0001) and 24-
fold at 16hrs (p=<0.0001) with EIPA treatment. EIPA treatment also reduced the IAV 
induction of MIP-1α (Figure 5.23C) at 2hrs by 3.1-fold (p=<0.0001) and 16hrs by 4.2-
fold (p=<0.0001). MIP-2 (Figure 5.23D) induction by IAV was also reduced by 51-fold at 
2hrs (p=<0.0001) and by 183-fold by 16hrs (p=<0.0001) with EIPA treatment. EIPA 
treatment also completely abolished the IL-1β (Figure 5.22D) late 16hr response 
(p=0.249), but there was no 2hr response to inhibit. TNF-α responses (Figure 5.22B) at 
both 2hr (p=0.363) and 16hr (p=0.112) were completely inhibited upon EIPA 
treatment, with neither time point producing any significant value. IL-6 (Figure 5.22A) 
induced by IAV at 2hrs was increased by 1.9-fold (p=0.011), yet at 16hrs the response 
was completely abolished (p=0.844). RANTES (Figure 5.23A) response after EIPA 
treatment was significantly increased at the early 2hr time by 1.5-fold (p=<0.0001), but 
were completely abolished at the 16hr measurement (p=0.077). EIPA treatment did 
not affect IL-1α production (Figure 5.22C) at 16hrs (p=0.444) but did cause an increase 
at 2hrs of 2.4-fold (p=<0.0001). 
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Figure 5.20 Dynamin dependent endocytosis is necessary for the cytokine response in MPI cells infected 
with IAV, with the exception of IL-1α. Cells were pre-treated with 80µM Dynasore for 30 mins at 37oC to 
inhibit dynamin prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the 
absence of FBS, after which inoculum was removed and the cells were incubated in medium containing 
10% FBS. Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and 
(A) IL-6, (B) TNF-α, (C) IL-1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 
individual experiments (3 replicate samples per experiment)  ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (*= P < 
0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of 
Perth/16/09 + Dynasore to Perth/16/09 was performed using unpaired t-test, significant differences are 
indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant differences are 
indicated with red n.s. 
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Figure 5.21 Dynamin dependent endocytosis is required for the late chemokine response in MPI 
macrophages infected with IAV, is not required for the early RANTES and MIP-1α production. Cells were 
pre-treated with 80µM Dynasore for 30 mins at 37oC to inhibit dynamin prior to inoculation with 1 PFU 
per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was removed 
and the cells were incubated in medium containing 10% FBS. Inhibitor was present at all points. At 
16hrs, post-infection supernatants were collected and (A) RANTES (B) IP-10, (C) MIP-1α, (D) MIP-2 were 
measured by ELISA. Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance 
was calculated using unpaired t-test, significant values, compared to Mock Infected are indicated by 
asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of 
Perth/16/09 + Dynasore to Perth/16/09 was performed using unpaired t-test, significant differences are 
indicated by red asterisk (*= P < 0.05, ***= P ≤ 0.001). Non-significant differences are indicated with red 
n.s. 
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Figure 5.22 Macropinocytosis is required for the cytokine response in MPI macrophages infected with 
IAV, except for IL-1α. Cells were pre-treated with 80µM EIPA for 30 mins at 37oC to inhibit membrane 
ruffling prior to inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of 
FBS, after which inoculum was removed and the cells were incubated in medium containing 10% FBS. 
Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and (A) IL-6 (B) 
TNF-α, (C) IL-1α, (D) IL-1β were measured by ELISA. Bars represent the mean from 3 individual 
experiments (3 replicate samples per experiment)  ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= 
P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison of Perth/16/09 + 
EIPA to Perth/16/09 was performed using unpaired t-test, significant differences are indicated by red 
asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant differences are indicated with red 
n.s. 
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Figure 5.23 Macropinocytosis is required for the chemokine response in MPI macrophages infected with 
IAV.  Cells were pre-treated with 80µM EIPA for 30 mins at 37oC to inhibit membrane ruffling prior to 
inoculation with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. Inhibitor was 
present at all points. At 16hrs, post-infection supernatants were collected and (A) RANTES, (B) IP-10, (C) 
MIP-1α, (D) MIP-2 were measured by ELISA. Bars represent the mean from 3 individual experiments ± 
S.E.M. (3 replicate samples per experiment) (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). 
Non-significant values are indicated with n.s. Comparison of Perth/16/09 + EIPA to Perth/16/09 was 
performed using unpaired t-test, significant differences are indicated by red asterisk (**= P ≤ 0.01, ***= 
P ≤ 0.001).  
235 
 
5.2.5 Effect of UV inactivation of Influenza  
5.2.5.1 Infectivity in MPI Macrophages 
IAV was exposed to UV radiation to destroy the viral RNA to prevent successful RNA 
replication within MPI macrophages but leaving the virion intact.  The UV treatment of 
Perth/16/09 completely reduced the % infection of MPI macrophages by 6.4-fold at 
16hrs (p=<0.0001) (Figure 5.24). This remaining 6.2% infectivity with UV-Perth/16/09 
at 16hrs, was not deemed to be of significance, compared to the mock infected control 
(p=0.083).  
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Figure 5.24 UV radiation of IAV successfully prevents infection in MPI macrophages. Cells were 
inoculated with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which 
inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated time 
point’s cells were fixed and stained for IAV nuclear protein (red), counter stained with DAPI (blue). (A) 
Visual representation of IAV infected cells, objective magnification 40x. Images shown are the best 
representative of % infectivity’s from multiple experiments.  (B) Percentage infectivity of cells, data is 
taken at four separate fields of view of the sample. Bars represent the mean from 3 individual 
experiments (4 technical replicates per experiment) ± S.E.M. (N=3) Significance was calculated using 
unpaired t-test, significant values, compared to Mock are indicated by asterisk (*= P < 0.05, ***= P ≤ 
0.001). Non-significant values are indicated with n.s. Comparison of Perth/16/09 to UV- Perth/16/09 
was performed using unpaired t-test, significant differences are indicated by red asterisk (***= P ≤ 
0.001). Non-significant differences are indicated with red n.s. 
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5.2.5.2 Secreted Innate Immune Response in MPI Macrophages 
The secreted immune response with UV exposed Perth/16/09 was measured at both 
2hr and 16hr to examine the effect viral RNA replication has on both an early and late 
immune response.  
TNF-α (Figure 5.25B) was significantly increased at 2hr by 8.9-fold (p=<0.0001) and 
16hr by 10.7-fold (p=<0.0001) with UV- IAV infection compared to IAV infection. MIP-2 
(Figure 5.26D)  production was also increased by 4.5-fold at 2hr (p=<0.0001) and by 
2.2-fold at 16hr (p=0.006) with UV- IAV infection, compared to IAV infection. IL-1α 
(p=0.106) (Figure 5.25C), RANTES (p=0.157) (Figure 5.26A), and IP-10 (p=0.6815) 
(Figure 5.26B) responses were unaffected by UV-IAV at the 2hr time point. However, 
by 16hrs IL-1α was reduced 2.2-fold (p=0.0002), RANTES was reduced 2.4-fold 
(p=<0.0001), and IP-10 was reduced 2.3-fold (p=<0.0001) with UV-Perth/16/09 
infection compared to Perth/16/09.  
UV inactivation of IAV, caused a 2.6-fold reduction in the 2hr (p=0.0009), but a 3.5-fold 
increase in the 16hr (p=<0.0001) IL-6 response (Figure 5.25A) IL-1β (Figure 5.25), while 
not produced at 2hrs with IAV infection, the 16hr response was reduced 5.4-fold 
(p=0.019). The remaining 49pg/ml of IL-1β produced with UV-Perth/16/09 infection 
was determined to not be significant when compared to the mock infected control 
(p=0.87). UV-IAV stimulation of MPI macrophages had no effect on the late 16hr MIP-
1α response (p=0.146) but did significantly increase the early 2hr response by 2.3-fold 
(p=<0.0001) (Figure 5.26C). 
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Figure 5.25 IAV replication is required for optimal IL-6, IL-1α and IL-1β production, but actually inhibits 
TNF-α production in MPI macrophages. Cells were inoculated with 1 PFU per cell (MOI 1) of either 
Perth/16/09 or UV-treated Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was 
removed and the cells were incubated in medium containing 10% FBS. Inhibitor was present at all 
points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-α, (C) IL-1α, (D) IL-1β 
were measured by ELISA. Bars represent the mean from 3 individual experiments (3 replicate samples 
per experiment)  ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock Infected are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-
significant values are indicated with n.s. Comparison of Perth/16/09 to UV Perth/16/09 was performed 
using unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05, ***= P ≤ 0.001). 
Non-significant values are indicated with red n.s. 
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Figure 5.26 IAV replication is required for optimal RANTES and IP-10 production, but not MIP-1α 
production and actually inhibits MIP-2 production in MPI macrophages. Cells were inoculated with 1 
PFU per cell (MOI 1) of Perth/16/09 or UV-treated Perth/16/09 for 1hr at 37oC in the absence of FBS, 
after which inoculum was removed and the cells were incubated in medium containing 10% FBS. At 
16hrs, post-infection supernatants were collected and (A) RANTES, (B) IP-10, (C) MIP-1α, (D) MIP-2 were 
measured by ELISA. Bars represent the mean from 3 individual experiments (3 replicate samples per 
experiment) ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values, 
compared to Mock Infected are indicated by asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). Non-significant 
values are indicated with n.s. Comparison of Perth/16/09 to UV Perth/16/09 was performed using 
unpaired t-test, significant differences are indicated by red asterisk (**= P ≤ 0.01, ***= P ≤ 0.001). Non-
significant values are indicated with red n.s. 
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5.2.5.3 Phosphorylation of Transcription Factors and Kinases 
The phosphorylation of transcription factors and kinases caused by UV-IAV infection 
were compared to that of IAV infection via western blotting, with the relative intensity 
of bands normalised to the loading control.  
TBK-1 (Figure 5.27B) was significantly phosphorylated by IAV at 6hr post infections 
with a 25-fold increase from the 0hr (p=0.035). On the other hand UV-Perth/16/09 
infection gave no significant phosphorylation at this 6hr time point compared to the 
0hr control (same value).  
NF-kB phosphorylation (Figure 5.27C) with Perth/16/09 occurred significantly at 0.5hr 
with a 3.2 fold increase from 0hr (p=0.011), and remained for the 2hr (2.7-fold – 
p=0.025) and 6hr (2.6-fold – p=0.04) time points. UV-Perth/16/09, phosphorylation still 
occurred at 0.5hr but was reduced 1.7-fold from the Perth/16.09 infection, although 
this was not considered significant (p=0.157). By 2hr NF-κB phosphorylation had 
dropped to 1.2-fold from the 0hr control and was no longer considered significant 
(p=0.458).  
Perth/16 infection resulted in significant p38 phosphorylation (Figure 5.27D) at 0.5hr 
with a 2-fold increase from 0hr (p=0.017) and was most significantly induced at 6hr 
post infection, showing a 6.6-fold increase from 0hr (p=0.0013). With UV-Perth/16/09 
however the 0.5hr induction (2.5-fold – p=0.0011) remained and was not significantly 
different from the Perth/16/09 infection (p=0.648). By 2hr the induction had dropped 
to 1.04-fold 0hr control and was not considered significant (p=0.937).  
IRF-3 phosphorylation (Figure 5.27E) by Perth/16/09 was increased by 1.8-fold at 2hr 
(p=0.027) and increased to 11.8-fold by 6hr (p=0.0008). UV-Perth/16/09 was unable to 
241 
 
induced significant levels at any of the 0.5hr (same value), 2hr (p=0.26) and 6hr 
(p=0.0507) time points measured.  
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Figure 5.27 IAV replication is a requirement for TBK1 and IRF-3 activation and the late activation of NF-
κB and p38 in MPI macrophages. Cells were inoculated with 5 PFU per cell (MOI 5) of Perth/16/09 or 
UV-treated Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was removed and 
the cells were incubated in medium containing 10% FBS. At indicated time-points, post-infection cells 
were washed and lysed. (A) Western blot analysis of P-TBK1, P-NF-kB (P65), P-p38, and P-IRF-3. Bands 
were quantified by relative expression, normalised to GAPDH (B) P-TBK1, (C) P-NF-kB (P65), (D) P-p38, 
and (E) P-IRF-3. Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance was 
calculated using unpaired t-test, significant values, compared to 0hr are indicated by asterisk (*= P < 
0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparison between 
Perth/16/09 and UV-Perth/16/09 at each timepoint was performed using unpaired t-test, significant 
differences are indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant 
values are indicated with red n.s. 
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5.2.6 Viral RNA replication in MPI Macrophages 
The replication of IAV RNA in MPI macrophages was measured using q-PCR for the viral 
M gene in whole infected MPI lysate. Quantification of the gene copy number was 
determined by an M gene containing plasmid with a known copy number to generate a 
standard curve (Figure 5.28A).  The significance threshold for copy number change was 
set at 2-fold, and if this was met a student’s t-test was performed to obtain a p-value.  
M gene copy number was not significantly changed from 0.5hr to 2hr post-infection 
(1.4-fold change) but had increased significantly from 2hr to 8hr (21.7-fold change – 
p=<0.0001). Finally, the M gene copy number as then significantly reduced from 8hr to 
24hr (9.7-fold change – p=<0.0001) (Figure 5.28B).   
 
 
 
 
 
 
 
 
Figure 5.28 IAV replication within MPI macrophages peaks at 8hrs, after which it begins to subside. Cells 
were inoculated with 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after 
which inoculum was removed and the cells were incubated in medium containing 10% FBS. At indicated 
time points post-infection total RNA was isolated and viral replication was measured using q-PCR for the 
viral M-gene. (A) M-gene standard from Synthetic T7 transcript of full-length M gene, vRNA-sense. (B) 
Copy numbers of M-gene presents in MPI macrophages over time.  Points represent the mean from 3 
individual experiments (3 replicate samples per experiment) ± S.E.M. (N=3) Significant changes were 
calculated using unpaired t-test, significant values, compared to previous timepoint are indicated by 
asterisk (***= P ≤ 0.001). Non-significant values are indicated with n.s. 
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5.2.7 Pattern Recognition Receptors Involved in Influenza A Sensing 
5.2.7.1 Optimisation of inhibitor concentration based on cell viability and 
activation 
Investigating the role of several of the key PRR’s associated with IAV and their role in 
the immune response profile in MPI macrophages was done using specific inhibitors 
for either the receptors or downstream signalling molecules. Firstly in Figure 5.29a 
maximum concentration of each inhibitor that was not cytotoxic in MPI macrophages 
was determined by MTT assay. In combination with this, in Figure 5.30 the IL-6 
response to the inhibitors at the varying concentrations was measured to determine a 
concentration that would not activate the MPIs.  
For the RIG-I inhibitor (BX795) at concentration of 10nM, was chosen due to there 
being no significant change in cell viability as measured by MTT (p=0.189) (Figure 
5.29A), and only weakly induced 166pg/ml IL-6 (p=0.015) (Figure 5.30A).  
The NOD-2 inhibitor (Gefitinib) had a concentration of 2µM chosen as it caused no 
significant change to the MTT determined cell viability (p=0.488) (Figure 5.29B), and 
only weakly induced 256pg/ml of IL-6 (p=0.043) (Figure 5.30B).   
 For the NLRP3 Inflammasome inhibitor (Isoliquiritigenin) a concentration of 30µM was 
optimal, as it caused no significant change to the cell viability as measured by MTT 
absorbance (p=0.825) (Figure 5.29C). Moreover, it only induced 125pg/ml of IL-6, 
which was deemed not significant from the control cells with no inhibitor (p=0.152) 
(Figure 5.30C). 
A concentration of 30µM for the TLR-3 Inhibitor (TLR3/dsRNA Complex Inhibitor) was 
chosen as it caused no significant change to the cell viability measured by the MTT 
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assay (p=0.5) (Figure 5.29D). IL-6 production at this concentration was at 75pg/ml and 
was not a significantly increased from the control cells not treated with the inhibitor 
(p=0.88) (Figure 5.30D). 
For theTLR-7,8,9 inhibitor (ODN2088) a concentration of 1000nM was chosen as there 
was no significant loss in cell viability as measured by the MTT assay (p=0.56) (Figure 
5.29E). Additionally, the IL-6 production of 101pg/ml as a result of cells treated with 
the inhibitor was not considered to be significant from the control cells that were not 
treated with it (p=0.6) (Figure 5.30E). 
A concentration of 1µM was chosen for the Syk inhibitor (R406), at this concentration 
there was no change to the MTT measured cell viability (p=0.09) (Figure 5.29F), and 
the 101pg/ml of IL-6 induced was not significant from the untreated controls (p=0.59) 
(Figure 5.30F). 
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Figure 5.29 Optimisation of PRR inhibitor concentrations based on the effect on cell viability of MPI 
macrophages as, measured  by MTT assay.  Cells were incubated with indicated concentrations in 
medium containing 10% FBS. At 16hrs medium was removed and cells were incubated in MTT reagent 
for 2hrs, formazan crystals produced were solubilised in DMSO, and absorbance measured. (A) RIG-I 
inhibitor (BX795), (B) NOD-2 inhibitor (Gefitinib), (C) NLRP3 Inflammasome inhibitor (Isoliquiritigenin), 
(D) TLR-3 Inhibitor (TLR3/dsRNA Complex Inhibitor), (E) TLR-7,8,9 inhibitor (ODN2088), (F) Syk inhibitor 
(R406) Bars represent the mean from 3 individual experiments (3 replicate samples per experiment)  ± 
S.E.M. (N=3) Significance was calculated using unpaired t-test, significant values compared to control are 
indicated by asterisk (*= P < 0.05, ***= P ≤ 0.001). Non-significant values are indicated with n.s. 
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Figure 5.30 Optimisation of PRR inhibitor concentration based on activation of MPI macrophages, as 
measured by IL-6 production. Cells were incubated with indicated concentrations in medium containing 
10% FBS. At 16hrs supernatants were collected and IL-6 was measured by ELISA. (A) RIG-I inhibitor 
(BX795), (B) NOD-2 inhibitor (Gefitinib), (C) NLRP3 Inflammasome inhibitor (Isoliquiritigenin), (D) TLR-3 
Inhibitor (TLR3/dsRNA Complex Inhibitor), (E) TLR-7,8,9 inhibitor (ODN2088), (F) Syk inhibitor (R406) 
Bars represent the mean from 3 individual experiments (3 replicate samples per experiment)  ± S.E.M. 
(N=3) Significance was calculated using unpaired t-test, significant values compared to control are 
indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with 
n.s. 
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5.2.7.2 Measurement of cytokines induced by IAV with PRR inhibitors 
From the data seen in Error! Reference source not found. optimised concentrations of e
ach inhibitor were then used to inhibit the specific PPR during IAV infection, with a 
receptor specific PAMP as a positive control. In the majority of these experiments 
sufficient PRR inhibition was not achieved as seen with the specific PAMP control.  
For RIG-I investigation using BX795, there was no significant reduction in either IAV 
induced cytokines or polyIC/lyovec induced cytokines (Figure 5.31). For IL-1β, shown to 
require IAV replication and thus RIG-sensing (Figure 5.25D) use of BX795 increased the 
IAV response by 5.5-fold (p=0.003). Additionally, there was 4377pg/ml of L-1β 
produced with the inhibitor alone (p=0.01). 
Analysing NOD-2 in IAV sensing and immune response using Gefitinib there was also 
no significant reduction in cytokines with both IAV and peptidoglycan (PGN) (Figure 
5.32). With NOD-2 signalling eventually activating NF-κB (Figure 1.8) IL-6 should have 
been reduced with NOD-2 inhibition, however with both PGN (p=0.83) and 
Perth/16/09 (p=0.87) there was no change in IL-6 production. 
The NRLRP3 Inflammasome inhibitor Isoliquiritigenin was able to reduce the 
production of IL-1β both the positive control of LPS/ATP and also IAV. LPS/ATP induced 
IL-1β was reduced -fold (p=0.3) with Isoliquiritigenin, while Perth/16/09 induced IL-1β 
was reduced -fold (p=0.2). However as expected IAV induced IL-6 (p=0.98), TNF-α 
(p=0.86), and IL-1α (p=0.72) all remained unchanged with inflammasome inhibition 
(Figure 5.33).  
Inhibition of TLR-3 using the TLR-3/dsRNA complex inhibitor was unable to significantly 
reduced any measured cytokines induced by both IAV and the positive control of 
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PolyIC (Figure 5.34). With PolyIC IL-6 (p=0.42), TNF-α (p=0.097 IL-1α (p=0.09), and IL-1β 
(p=0.84) all remained unchanged with the TLR-3 inhibitor, compared to PolyIC 
treatment without it. 
TLR-7,8,9 inhibition using ODN2088 was able to significantly reduced the production of 
TNF-α by 2.2-fold (p=0.004) when using the positive control of R848, however this 
same effect was not mimicked when using IAV (p=0.35) (Figure 5.35). Moreover IL-6 
(p=0.11), IL-1α (p=0.9), and IL-1β (p=0.58), production by R848 all remained unaffected 
by TLR-7,8,9 inhibition.(Figure 5.35).  
Finally, inhibition of C-type lectins using R406 had varying results across the 4 
measured cytokines. For IL-6 (p=0.57) and TNF-α (p=0.52) there was no significant 
reduction when using the positive control of β-glucan. However, when using IAV IL-6 
was reduced by 1.8-fold (p=0.002) and TNF-α was reduced by 4.2-fold (p=0.021) 
(Figure 5.36 A&B). R406 was able to reduce IL-1α production by 3-fold (p=0.012) upon 
β-glucan stimulation, but not IAV (p=0.23) (Figure 5.36C). With IL-1β C-type R406 did 
not reduced production with either IAV or the positive control, but in fact resulted in a 
significant increase for both stimulants. With Perth/16/09 IL-1β was increased 1.7-fold 
(p=0.047) and with β-glucan IL-1β was increased 3-fold (p=0.0004). (Figure 5.36D). 
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Figure 5.31 BX795 was unable to block RIG signalling upon IAV and PolyIC/lyovec challenge in MPI 
macrophages  Cells were pre-treated with 10nM BX795 for 15 mins at 37oC to inhibit TBK1 signalling 
prior to inoculation with 2.5µg/ml PolyIC/lyovec or 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC 
in the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. Inhibitor was present at all points. At 16hrs, post-infection supernatants were 
collected and (A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b were measured by ELISA. Bars represent the mean 
from 3 individual experiments ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected (-/-/-) are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, 
***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparisons of Perth/16/09 (-/+/-) to 
RIG-I inhibitor + Perth/16/09 (+/+/-) and polyIC/lyovec to RIG-I inhibitor + polyIC/lyovec (+/-/+) was 
performed using unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05, **= P 
≤ 0.01). Non-significant values are indicated with red n.s. 
in 
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Figure 5.32 Gefitinib was unable to block NOD2 signalling upon IAV and PGN challenge in MPI 
macrophages.  Cells were pre-treated with 2µM Gefitinib for 15 mins at 37oC to inhibit RIP2 signalling 
prior to inoculation with 10µg/ml PGN or 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the 
absence of FBS, after which inoculum was removed and the cells were incubated in medium containing 
10% FBS. Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and 
(A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b were measured by ELISA. Bars represent the mean from 3 
individual experiments ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant 
values, compared to Mock Infected (-/-/-) are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 
0.001). Non-significant values are indicated with n.s. Comparisons of Perth/16/09 (-/+/-) to NOD2 
inhibitor + Perth/16/09 (+/+/-) and PGN (-/-/+) to NOD2 inhibitor + PGN (+/-/+) was performed using 
unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05,). Non-significant values 
are indicated with red n.s. 
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Figure 5.33 Isoliquiritigenin blocked inflammasome signalling upon IAV and LPS/ATP challenge in MPI 
macrophages  Cells were pre-treated with 30µM Isoliquiritigenin for 15 mins at 37oC to inhibit NLRP3 
Inflammasome activation prior to inoculation with 10ng/ml LPS and 5mM ATP or 1 PFU per cell (MOI 1) 
of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was removed and the cells 
were incubated in medium containing 10% FBS. Inhibitor was present at all points. At 16hrs, post-
infection supernatants were collected and (A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b were measured by 
ELISA. Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) Significance was calculated 
using unpaired t-test, significant values, compared to Mock Infected (-/-/-)  are indicated by asterisk (*= 
P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparisons of 
Perth/16/09 (-/+/-) to Inflammasome inhibitor + Perth/16/09 (+/+/-) and LPS/ATP (-/-/+) to 
Inflammasome inhibitor + LPS/ATP (+/-/+) was performed using unpaired t-test, significant differences 
are indicated by red asterisk (*= P < 0.05). Non-significant values are indicated with red n.s. 
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Figure 5.34 TLR3/dsRNA complex inhibitor was unable to block TLR-3 signalling upon IAV and PolyIC 
challenge in MPI macrophages.  Cells were pre-treated with 30µM TLR3/dsRNA Complex Inhibitor for 15 
mins at 37oC to inhibit NLRP3 Inflammasome activation prior to inoculation with 2.5µg/ml PolyIC or 1 
PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the absence of FBS, after which inoculum was 
removed and the cells were incubated in medium containing 10% FBS. Inhibitor was present at all 
points. At 16hrs, post-infection supernatants were collected and (A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b 
were measured by ELISA. Bars represent the mean from 3 individual experiments ± S.E.M. (N=3) 
Significance was calculated using unpaired t-test, significant values, compared to Mock Infected (-/-/-)  
are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 0.001). Non-significant values are indicated 
with n.s. Comparisons of Perth/16/09 (-/+/-) to TLR-3 inhibitor + Perth/16/09 (+/+/-) and PolyIC(-/-/+) to 
TLR-3 inhibitor + PolyIC (+/-/+) was performed using unpaired t-test, significant differences are indicated 
by red asterisk. Non-significant values are indicated with red n.s. 
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Figure 5.35 ODN2088 was unable to block TLR-7,8,9 signalling upon IAV and R848 challenge in MPI 
macrophages Cells were pre-treated with 1µM ODN2088 for 15 mins at 37oC to inhibit TLR-7, 8, 9 
signalling prior to inoculation with 10µg/ml R848 or 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 
37oC in the absence of FBS, after which inoculum was removed and the cells were incubated in medium 
containing 10% FBS. Inhibitor was present at all points. At 16hrs, post-infection supernatants were 
collected and (A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b were measured by ELISA. Bars represent the mean 
from 3 individual experiments ± S.E.M. (N=3) Significance was calculated using unpaired t-test, 
significant values, compared to Mock Infected (-/-/-) are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, 
***= P ≤ 0.001). Non-significant values are indicated with n.s. Comparisons of Perth/16/09 (-/+/-) to TLR-
7,8,9 inhibitor + Perth/16/09 (+/+/-) and R848 (-/-/+) to TLR-7,8,9 inhibitor + R848 (+/-/+) was performed 
using unpaired t-test, significant differences are indicated by red asterisk (**= P ≤ 0.01). Non-significant 
values are indicated with red n.s. 
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Figure 5.36 R406 was only able to block C-type lectin signalling for IL-1α (β-glucan) and IL-6 and TNF-α 
(IAV) in MPI macrophages.  Cells were pre-treated with 1µM R406 for 15 mins at 37oC to inhibit Syk prior 
to inoculation with 1mg/ml β-Glucan or 1 PFU per cell (MOI 1) of Perth/16/09 for 1hr at 37oC in the 
absence of FBS, after which inoculum was removed and the cells were incubated in medium containing 
10% FBS. Inhibitor was present at all points. At 16hrs, post-infection supernatants were collected and 
(A) IL-6, (B) TNF-a, (C) IL-1a, (D) IL-1b were measured by ELISA. Bars represent the mean from 3 
individual experiments ± S.E.M. (N=3) Significance was calculated using unpaired t-test, significant 
values, compared to Mock Infected (-/-/-) are indicated by asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 
0.001). Non-significant values are indicated with n.s. Comparisons of Perth/16/09 (-/+/-) to Syk inhibitor 
+ Perth/16/09 (+/+/-) and β-Glucan (-/-/+) to Syk inhibitor + β-Glucan (+/-/+) was performed using 
unpaired t-test, significant differences are indicated by red asterisk (*= P < 0.05, **= P ≤ 0.01, ***= P ≤ 
0.001). Non-significant values are indicated with red n.s. 
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5.3 Discussion 
Examining the immune response induced by IAV in MPI macrophages, as well as viral 
and macrophage intentions, is central to our understanding of IAV infection and thus 
developing effective therapies. The key measurement of the immune response was the 
secretion of variable inflammation-associated proteins by ELISA after viral infection 
and in some cases the activation of transcription factors by western blot. Aspects of 
viral infection cycle, or the immune pathways were blocked or removed in order to 
assess their impact on the innate immune response.  
It has already been established in Chapter 4 that the Perth/16/09 strain infects MPI 
macrophages more efficiently than Texas/50/12, and it was expected that the immune 
response induced would be lower in Texas/50/12. This was the case with cytokine and 
type I IFN secretion (Figure 5.1, Figure 5.3, and Figure 5.5) where Texas/50/12 infection 
induced lower levels of all measured proteins than Perth/16/09 in both a dose and 
time dependent manner. Chemokine production was slightly different, where RANTES 
and IP-10 production in both strains were similar in both a dose and time dependent 
nature. On the other hand, MIP-1α and MIP-2 induction required greater Texas/50/12 
MOI to be induced and in a time dependent nature, both were reduced at later time 
points, but only MIP-2 was reduced at early time points. A full summary of the changes 
in cytokine, chemokine and type I IFN responses from both strains can be found in 
Table 5.1. 
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Table 5.1 Summary of cytokine, chemokine, and type I IFN changes in MPI macrophages infected with 
strain Perth/16/09 compared to Texas/50/12. 
 Early Response (2hr) vs 
Perth/16/09 
Late Response (16hr) vs WT 
 Up Down No Change Up Down No Change 
Texas/50/12  IL-6, 
TNF-α, 
MIP-2 
IL-1α*, 
IL-1β*, 
RANTES*, 
IP-10, 
MIP-1α, 
type I IFN* 
 IL-6, 
TNF-α, 
IL-1α, 
IL-1β, 
MIP-1α, 
MIP-2, 
type I 
IFN 
 
RANTES, 
IP-10 
 
* No significant production in Perth/16/09 or Texas/50/12 
 
The two most interesting results from these experiments were the comparative 
RANTES and IP-10 induction by Perth/16/09 and Texas/50/12, despite a much lower 
infectivity of Texas/50/12. This would suggest that the induction of these two 
chemokines does not relate to the ability of the virus to replicate, something 
confirmed with IP-10 previously.(Wang et al., 2012) RANTES has not been shown to be 
induced this way before, and with these experiments was only induced at later 
measured time points. Previous studies have found RANTES induction to be TLR-3 
dependent (Le Goffic et al., 2006) and a crucial inhibitor for HIV (Cocchi et al., 1995). 
Arguably IAV induction of RANTES therefore occurs in the endosome, explaining the 
later production, and may act as an inhibitor of IAV in a similar way to HIV, with low 
levels of virus sufficient to induce a ‘protective response’.  For the majority of the 
measured cytokines and chemokines, a greater MOI of Texas/50/12, or a longer period 
of infection was required to induce a response, showing that for the majority, a greater 
host immune response required successful viral entry and infection.  
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Combined it was quite clear from these experiments that there are three separate 
time points that induce immune responses, initial, early, and late (Table 5.2). Based on 
what was seen in Chapter 4, at 0.5 and 2hrs there is very little viral infection, so 
responses at these times are likely to be independent of viral RNA sensing. This would 
be a novel induction of an immune response with the main trigger for the innate 
response in macrophages being viral RNA sensing (Chen et al., 2018). The next step in 
the investigation was to analyse the cell signalling pathways to identify aspects of the 
immune system that were activated at different stages of infection.   
Table 5.2 Summary of cytokine, chemokine, and type I IFN induction time in MPI macrophages infected 
with Perth/16/09. 
 
 
 
Activation of signalling pathways confirm a distinct time difference in innate signalling 
responding to IAV infection in MPI macrophages. An initial activation of p38 and NF-kB, 
which are both maintained over the course of the infection, and then a secondary late 
activation of TBK-1 and IRF-3 (Figure 5.11). These two distinct responses reinforce the 
existence of both RNA replication dependent and independent immunity to IAV 
infection in MPI macrophages. Both TBK-1 and IRF-3 have been shown to be down-
stream of PRR’s sensing dsRNA (RIG-I and TLR-3 respectively) and with IAV being an 
ssRNA virus, replication must take place to activate these pathways. On the other hand 
NF-kB and p38 activation occur downstream of both cell surface PRRs and endosomal 
PRRs, with NF-kB also down stream of dsRNA sensing PRRs (Guillot et al., 2005; Kato et 
 0.5hr 2hr 16hr 
Cytokine / 
Chemokine 
TNF-α, 
MIP-2 
IL-6, 
IP-10, 
MIP-1α 
IL-1α, 
IL-1β, 
RANTES, 
type- I IFN 
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al., 2006). This would explain the early phosphorylation of these, and the continued 
activation throughout the infection period (Figure 5.11). 
Comparisons of the signal inductions between Perth/16/09 and Texas/50/12 shows a 
reduction in either intensity of activation (p38, IRF-3), delayed activation (p38), or un-
sustained activation (NF-kB). Interestingly TBK-1 activation was not delayed or reduced 
significantly in Texas/50/12 infection compared with Perth/16/09, however this is 
likely due to experimental variation with Perth/16/09 phosphorylation of TBK-1.  
The activation of p38 by Texas/50/12 explains the RANTES induction seen in Figure 
5.4A, as p38 activation has been shown to control RANTES production.(Lee et al., 
2005a; Mori et al., 2003) Although there is a 2.8-fold difference between p38 
activation between the two strains, this does not appear to have a biological effect on 
the downstream RANTES production which remained statistically the same. Moreover 
the p38 and NF-kB activation by Texas/50/12 also explains the IP-10 induction seen in 
Figure 5.4B, both are involved in IP-10 inducible signalling, (Liu et al., 2011). NF-kB 
causes the early IP-10 response and the later p38 causes the later response. As with 
RANTES, the 2.8-fold difference in p38 activation, has no biological relevance on the 
downstream IP-10 production. 
It appears that both the transcription factor NF-kB and the MAPK p38 have a role in 
both the early and the late IAV induced immune response. In order to further examine 
the role of not only p38, but the other MAPKs ERK and JNK, in this early and late 
response, specific inhibitors against each were used, and the resultant cytokine and 
chemokine responses at 2hr (early) and 16hr (late) were measured. Although from 
Figure 5.2 and Figure 5.4, TNF-α and MIP-2 are the key early responses, and IL-1α, IL-
1β, and RANTES are the key late responses, all cytokines and chemokines previously 
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measured (IL-6, TNF-α, IL-1α, IL-1β, RANTES, IP-10, MIP-1α, and MIP-2) were repeated 
for this MAPK analysis to get a more complete picture.  
MEK/ERK was inhibited by UO126 treatment, (Figure 5.12 and Figure 5.13)  and 
showed to be key for the early 2hr immune response, with TNF-α, MIP-1α, and MIP-2 
all being reduced and also plays a significant role in the later 16hr response, with IL-6, 
TNF-α, IL-1α, IL-1β, MIP-1α, and MIP-2. The role of ERK1/2 in the later stages of the 
immune response, is a better understood mechanism, with studies showing the 
ERK1/2 activation occurs during the late phase of infection, and is important in the 
nuclear export of viral RNPs (Gaur et al., 2011; Pleschka et al., 2001). This up-regulated 
ERK activation by IAV to aid in the infection of the cell by increasing nuclear export of 
RNPs, results in the increased expression if TNF-α and IL-1β, which are both blocked 
with MEK/ERK inhibition in this chapter as well as in the work of Shang et al. (2010). 
The early activation of MEK/ERK is also suggested to be caused by the viral hijacking of 
cellular mechanisms to escape from the endosome, in the early phases of infection. 
Activated ERK co-localises with the E subunit of V-ATPase V1 domain, resulting in the 
acidification of the endosome (Marjuki et al., 2011). This early activation of MEK/ERK 
then possibly induces TNF-α, MIP-1α and MIP-2 production early as a by-product of 
this endosomal acidification (Lentzsch et al., 2003; Shang et al., 2010; Tateno et al., 
2013). 
p38 was inhibited with SB203580 treatment, (Figure 5.14 and Figure 5.15) and showed 
different effects for the early and late immune response depending on the cytokine or 
chemokine measured. It had been previously shown that p38 activation is involved in 
RANTES and IP-10 production (Lee et al., 2005a; Liu et al., 2011; Mori et al., 2003), 
however with IAV infection in MPI macrophages this is not the case. Both IP-10 and 
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RANTES production in response to IAV infection in this model are independent of p38 
activation.  
Activation of p38 also has a more limited role in the early IAV response than what was 
observed with MEK/ERK, with TNF-α and MIP-1α only having slight 2-fold and 1.6-fold 
decrease respectively. In later responses, p38 inhibition followed the general 
understanding in the literature, with induction of IL-6 reduced and TNF-α dependent 
on p38 activation (Lee et al., 2005a). 
Several unexpected results were seen with p38 inhibition, with the early IL-6 response 
increased as well as the late IL-1α, and MIP-2. Overall this would point to p38 
activation acting as a negative-feed back to regulate the immune response. Huang et 
al. (2009) identified a signalling cascade of p38 – MSK1/2 – CREB/ATF1 to limit 
inflammation, this feedback has been found to affect JNK activation but not ERK (Chen 
et al., 2000). Moreover RANTES and IP-10 production remained unaffected by p38 
inhibition, despite in other studies being shown to be dependent on p38 activation 
(Lee et al., 2005a; Mori et al., 2003). The differences in the ‘late’ responses in MPI 
macrophages may be due to a dual role of p38 and IRF-3 in the induction of these 
cytokines, with a lack of both being needed to fully abolish a response (Hui et al., 
2009). 
JNK inhibition, achieved via treatment with SP600125 (Figure 5.16 and Figure 5.17) had 
much smaller effect on the resulting early and late immune responses, than what was 
observed with the other MAPKs. Of the early response, only MIP-1α was reduced at all, 
and while statistically significant, was only a 1.3-fold reduction, the late response saw a 
major effect on TNF-α but only a slight IL-6 reduction of 1.2-fold. JNK has been shown 
to be heavily involved in IFN-β as well as other cytokines, (Ludwig et al., 2001; Stark et 
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al., 1998). However, with the IAV infection in MPI macrophages it appears that only 
certain cytokines (IL-6 and TNF-α) are JNK dependent, while IFN-β (not measured) may 
be the main outcome of JNK phosphorylation.  
Despite other studies to the contrary, (Kujime et al., 2000) IL-1β, RANTES, IP-10, and 
MIP-2 remained unaffected by JNK inhibition in MPI macrophages, possibly due to 
redundancy of other MAPKs or a different mechanism entirely. Early IL-6 and IL-1α and 
late IL-1α and MIP-2 were all upregulated by JNK inhibition, suggesting that JNK 
activations has a negative feedback role. This is supported by the work of Huang et al. 
(2009) where that JNK activation phosphorylates the ubiquitin ligase itch which 
modulates the transcription factor AP-1. 
Overall MAPK activation appears to play a significant role in modulation the 
macrophage immune response to IAV infection, but with each MAPK having different 
specificity on not only the time of the response, but the cytokines and chemokines 
produced. A full summary of the changes in cytokine and chemokine production for 
each MAPK can be found in Table 5.3. 
 MEK/ERK and p38 have a greater effect on the early response, while MEK/ERK alone 
has a greater effect on the later response. On the other hand, JNK has a limited effect 
on the measured cytokines and chemokines, but maybe more crucial in type I IFN 
production.  
The MAPKs MEK/ERK, p38, and JNK ultimately activate the AP-1 transcription factor 
(Figure 1.8) and the activation of these MAPKs appears to be crucial in an early innate 
immune response. At later time-points, while not as crucial in the innate immune 
response they still play a role in the production of key cytokines and chemokines, such 
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as IL-6, TNF-α, IL-1α, and MIP-2. However activation of these pathways have been 
determined to be the result of viral RNA in the endosome or exiting the nucleus, (Gaur 
et al., 2011) something that is highly unlikely to happen at 0.5hr post infection, where 
TNF-α and MIP-1α are produced. Because of this it is hypothesised that there is a PRR-
PAMP recognition preceding the uptake of the virus into the endosome, at the binding 
stage. 
Table 5.3 Summary of cytokine and chemokine changes with different MAPK inhibitors when MPI 
macrophages are infected with IAV. 
 
 
 
 
 
 
 Early Response (2hr) Late Response (16hr) 
Inhibition Up Down No Change Up Down No Change 
MEK/ERK  TNF-α, 
MIP-1α, 
MIP-2 
IL-6, 
IL-1α, 
IL-1β, 
RANTES, 
IP-10 
 IL-6,  
TNF-α, 
IL-1α, 
IL-1β, 
MIP-1α, 
MIP-2 
RANTES, 
IP-10 
p38 IL-6 TNF-α, 
MIP-1α 
IL-1α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-2 
IL-1α, 
MIP-2 
IL-6, 
TNF-α 
IL-1β, 
RANTES, 
IP-10, 
MIP-1α 
JNK IL-6, 
IL-1α 
MIP-1α TNF-α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-2 
 IL-6, 
TNF-α 
IL-1α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-1α, 
MIP-2 
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To investigate if there was an immune response at the binding stage of IAV infection 
similar experiments, as those in chapter 4 were performed to block certain receptors, 
and then measure the resulting immune response. Unfortunately, sialidase, mannan 
and asialofetuin treatment of MPI macrophages yielded high levels of background 
cytokines and chemokines. This was probably as these are bacterial components that 
are extracted for use as blocking agents, no other study has used them in conjunction 
with a measured immune response. This unfortunately meant that the only receptor 
that could be analyse was MARCO, due to being able to use the KO MPI macrophages.  
The majority of the cytokines and chemokines measured were reduced quite 
significantly in MPI macrophages lacking MARCO, although all those measured were 
still inducible at higher MOIs apart from RANTES and type I IFN (Figure 5.6, Figure 5.7, 
and Figure 5.8). The kinetics of those that were induced were also pushed back to a 
later point, suggesting a perhaps a greater viral load can induce a response, even with 
the absence of MARCO (Figure 5.9 and Figure 5.10). This is expected based on the 
current understanding of IAV induced immune responses being induced by an 
accumulation of viral RNA, summarised by Goraya et al. (2015). 
However, TNF-α remained fully inducible in MPI lacking MARCO albeit lower viral MOIs 
were less efficient at TNF-α induction. The kinetics of TNF-α production in MPI lacking 
MARCO were very similar to the WT MPI, but with the response lasting longer before 
peaking and diminishing. IL-1α was similar to TNF-α, with lower MOIs unable to induce 
production, but higher MOI’s inducing comparable levels to WT MPIs. This would 
suggest that TNF-α, and to a lesser extent IL-1α are both inducible independently of 
MARCO, which has been established to be crucial in IAV infection of MPI macrophages. 
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A full summary of the changes in cytokines, chemokines, and type I interferons can be 
found in Figure 5.4Table 5.4. 
 
Table 5.4 Summary of cytokine and chemokine changes in loss of MARCO in MPI macrophages infected 
with IAV. 
 
There have been suggestions of cell surface receptors playing a role in the innate 
immune response, with CLRs acting as co-receptors for IAV uptake (Ng et al., 2014; 
Reading et al., 2000; Reading et al., 2007; Upham et al., 2010) which has been 
confirmed in this thesis. These CLRs are able to prime the immune system upon 
binding to PAMPs with some of the signalling pathways well characterised in non-viral 
responses (Brown et al., 2018; Dambuza and Brown, 2015). It would make sense that 
the binding of these receptors to viral glycoproteins would also prime innate immune 
response to aid in faster viral clearance, however at this time there is no direct 
evidence that CLR interactions with influenza are important for macrophage activation 
(York et al., 2019). 
Moreover, surface detection of IAV has been hypothesised as a possible cause of the 
greater immune response to avian strains, compared to human (Cheng et al., 2010; 
 Early Response (2hr) vs WT Late Response (16hr) vs WT 
 Up Down No 
Change 
Up Down No Change 
MARCO 
KO 
 IL-6, 
IP-10, 
MIP-1α, 
MIP-2 
TNF-α, 
IL-1α*, 
IL-1β*, 
RANTES* 
 IL-6, 
IL-1α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-1α, 
MIP-2, 
type I IFN 
TNF-α 
* No significant production in WT or KO MPI 
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Lee et al., 2009). IAV recognition by cell surface receptors could occur differently 
depending on their binding preference, of either SAα2,3 or SAα2,6. Avian IAV strains, 
attaching via SAα2,3 would result in increased cytokine production and inflammation, 
while human IAV strains attaching via SAα2,6 would have a delayed response (Ramos 
et al., 2011; Ramos and Fernandez-Sesma, 2012).  
Currently the only confirmation of a cell surface receptor inducing an immune 
response against seasonal IAV, is PDGFRβ (Vrijens et al., 2019). IAV binding results in 
raf/MEK/ERK signalling, similar to what has been observed with the early (2hr) IAV 
response seen in MPI macrophages (5.2.3). 
To confirm that this early response was indeed mediated by a cell surface receptor, 
and not endosomal or IAV replication dependent, these aspects of the viral infection 
cycle were blocked separately. Endosomal entry, endosomal release, and RNA 
replication were all inhibited and the resulting cytokines and chemokines measured to 
identify the specific thresholds of induction.  
Endosomal formation was inhibited by blocking dynamin-dependent endocytosis and 
macropinocytosis, (Figure 5.20, Figure 5.21, Figure 5.22, and Figure 5.23) both of which 
have been shown to be utilised by MPI macrophages. In both forms of inhibition, all 
late responses (16hr) were reduced, with the exception of IL-1α, with the majority of 
early responses also reduced, apart from IL-1α, IL-6, and RANTES (with EIPA only). 
These small increases in early IL-6 and RANTES, while statistically significant, are 
unlikely to be biologically relevant as the increase was less than 2-fold, and not seen 
with the dynamin inhibitor. The key finding here is that early TNF-α production is 
dependent on viral uptake, while early IL-1α is not. It can be inferred then, that IL-1α 
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production at any time is completely independent of viral entry into the cell, while the 
early TNF-α at least requires endosomal uptake.  
These findings are confirmed when looking at the responses with endosomal escape 
mechanisms inhibited, with both the IL-1α and TNF-α responses still inducible. This 
inhibition of viral escape also confirmed that the ‘build-up’ of viral RNA in the 
endosome enhanced the early innate immune response. All cytokine and chemokine 
responses that were induced at 2hrs were increased with viral inability to escape the 
endosome. This would suggest that the 2hr response seen in MPI macrophages is TLR-
3 or TLR-7/8 dependent. Due to the supposed lack of dsRNA at this stage of the viral 
life cycle, TRL-7/8 is the most reasonable PRR initiating this response, due to its 
reported sensing of ssRNA, activating both NF-kB (inflammatory cytokines) and IRF-7 
(type I interferons) (Blasius and Beutler, 2010; Diebold et al., 2004; Kawai and Akira, 
2010; Lee et al., 2007). However, in experiments in MPI macrophages no type I 
interferons were detected at an early time point, which would suggest NF-kB signalling 
is induced sooner and is required for the 2hr innate immune response.  
To analyse to role of RNA replication, IAV was exposed to UV radiation to degrade 
genetic material but keep the virion intact to facilitate entry and endosome release. 
The UV exposure of IAV was able to effectively block infection in MPI macrophages, as 
measured by fluorescence microscopy (Figure 5.24), allowing the resulting cytokines 
and chemokines to be measured (Figure 5.25 and Figure 5.26). 
As expected, the early 2hr response was not reduced with UV-IAV with IL-1α, RANTES, 
and IP-10 unaffected, while IL-6, TNF-α, MIP-1α, and MIP-2 all increased. This 
increased response, may be due to prolonged TLR-7/8 signalling by viral ssRNA, 
without the progression to dsRNA activation of TLR-3 and RIG-I. Nearly all of the late 
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16hr response was reduced with UV-IAV, continuing the idea that at this time the 
response is generated by viral RNA replication. TNF-α, even at this time is still 
independent of viral RNA replication, with a greater production without it, confirming 
that this response is endosomal driven. This appeared to also be the case with late 
MIP-2 production that was also increased with UV-IAV, where endosomal escape had 
also not prevented a reduced MIP-2 response. A full summary of the changes in the 
cytokine and chemokine production, with the different aspects of the viral cycle 
blocked can be found in Table 5.5. 
Table 5.5 Summary of cytokine and chemokine changes in MPI macrophages when different aspects of 
IAV infection are blocked. 
The activation of signal transduction pathways confirms the hypothesis that this early 
replication independent response is mediated by NF-kB and MAPK activation. The early 
 Early Response (2hr) Late Response (16hr) 
Blocked 
Aspect 
Up Down No 
Change 
Up Down No 
Change 
Viral 
Replication 
IL-6, 
TNF-α, 
MIP-1α, 
MIP-2 
 IL-1α, 
IL-1β, 
RANTES, 
IP-10 
TNF-α, 
MIP-2 
IL-6, 
IL-1α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-1α 
Endosomal 
Escape 
IL-6, 
IL-1α, 
RANTES 
 TNF-α, 
IL-1β, 
IP-10, 
MIP-1α, 
MIP-2 
 IL-6, 
IL-1β 
TNF-α, 
IL-1α, 
RANTES, 
IP-10, 
MIP-1α, 
MIP-2 
Endosomal 
Formation 
IL-6*, 
IL-1α, 
RANTES* 
TNF-α, 
IP-10, 
MIP-1α, 
MIP-2 
IL-6**, 
IL-1β, 
RANTES** 
 IL-6, 
TNF-α, 
IL-1β, 
RANTES, 
IP-10, 
MIP-1α, 
MIP-2 
IL-1α 
 
* EIPA only 
** Dynamin only 
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phosphorylation of NF-kB and p38 (0.5hr) was the same in both replication deficient 
IAV and replicating IAV (Figure 5.27). Moreover as seen in Figure 5.28 there is no 
relevant increase in viral replication in MPI macrophages, until after 2hrs post 
infection, again showing responses found up to this point do not require active viral 
RNA replication.  
Not only is this early response to IAV novel, but the existence of a conventional ‘later’ 
response, without the requirement of replicating IAV has also not been shown before. 
Studies have looked at UV-IAV infections, and found an abolishment of the TNF-α 
response, as well as a reduction in other cytokines and chemokines, with the exception 
of IP-10 (Kleinerman et al., 1976; Wang et al., 2012). The issue with these previous 
experiments was the use of the PR8 strain, which already poorly infects macrophages, 
meaning results on viral infection using this strain cannot by relied upon. 
In the MPI model, IAV infection produces three distinct stages of an innate immune 
response, based on different aspects of the viral infection cycle (Figure 5.37). The first 
stage is induced by IAV binding to the cell surface of the macrophage and detected by 
a currently undetermined PRR. This initial early response yields IL-1α production, likely 
via MAPK and/or NF-kB activation, which may result in an IL-1α mediated antiviral 
response; activating T-cells, increasing B-cell proliferation, and upregulating 
endothelial adhesion molecules to aid in leukocyte migration (Fitzgerald, 2009; Mayer-
Barber and Yan, 2017; Orzalli et al., 2018). There is the possibility that this 
undetermined PRR may be PDGFRβ, which upon aiding in IAV entry, results in strong 
Raf/MEK/Erk activation, similar to what was observed here (Vrijens et al., 2019). 
However, the receptor-IAV interaction is yet to be confirmed in macrophages.   
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The second stage in the MPI innate immune response to IAV, is also an ‘early’ 
response, occurring by 2hrs post infection. This response is likely mediated by the 
endosomal PRRs TLR-7/8 sensing of ssRNA, utilising NF-kB and ERK signalling. The 
effect of this second stage in the innate immune response to IAV is the production of 
TNF-α, IL-6, IP-10, MIP-1α, and possibly IL-1α. These chemokines and cytokines 
enhance the inflammatory response to the IAV infection, promoting leukocyte 
migration, proliferation and activation (see 1.3.3).  It is possible that the initial 
production of IL-1α acts to aid in the production of these responses (Schett et al., 
2016), which increases the influx of innate and adaptive immune cells to the infection. 
Moreover, this 2hr response likely provides the source for the initial Inflammasome 
signal. With NF-κB activation inducting the transcription of NLRP3 and pro IL-1/18 
genes (Allen et al., 2009). 
The third and final stage in the MPI innate response to IAV is the traditional RNA 
replication dependent response occurring by 16hrs post infection. At this point MPI 
macrophages produced high levels of both IL-1β and type I interferons, as well as 
continued cytokine and chemokine production. These responses are likely induced by 
RIG-I and TLR-3 PRRs, signalling via TBK-1 and IRF3 to induce a full anti-viral state and 
start the killing of IAV and IAV infected cells. Interestingly, blocking of this phase 
appears to exacerbate the early ‘priming’ responses, possibly showing a mechanism by 
which some IAV strains are more highly pathogenic than others. Strains that can evade 
this part of the immune system by sequestering TBK-1 (Wu et al., 2014), or evading 
‘priming’ in the first place by not inducing early cytokine production of TNF-α, (van Riel 
et al., 2011)  may enable them to replicate productively, and induce a ‘cytokine storm’ 
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that results in uncontrolled inflammation, with increases morbidity and mortality (Liu 
et al., 2016; Sakabe et al., 2011). 
Proving the role of these PRR’s at each stage in the immune response was attempted, 
by using specific inhibitors to block activation or signalling. Using these inhibitors in 
combination with IAV infection the results were unable to identify the role of specific 
PRRs. In most cases the selected concentrations that did not affect MPI viability or 
activation alone were unable to effectively block these PRRs using both IAV and 
positive PAMP controls.  
RIG-I, NOD-2 and TLR-3 inhibitors had no change on the production of IL-6, TNF-α, IL-
1α, and IL-1β (Figure 5.31, Figure 5.32, Figure 5.34). The TLR-7,8,9 inhibitor used was 
able to successfully reduced TNF-α production 2.2 fold upon R844 stimulation, 
however this was not replicated with any other cytokine, nor when IAV was used as a 
stimulus (Figure 5.35) Inhibition of C-type lectin was able to show a reduction in IAV 
induced IL-6 and TNF-α, 1.8 and 4.2 fold reductions respectively (Figure 5.36). 
However, this was not reproduced when using the C-type lectin PAMP β-Glucan (Figure 
5.36). In fact, the only significant reduction when using β-Glucan was with IL-1α (3-
fold), yet there was no effect with IAV stimulation (Figure 5.36).  
The only PRR inhibitor that appeared to work was Isoliquiritigenin inhibition of the 
inflammasome. There was a successful reduction in the measured IL-1β output with a 
positive stimulus of LPS/ATP by 2-fold, as well as with IAV (3.2-fold) (Figure 5.33). In 
fact, with the presence of this inhibitor the IL-1β production with both IAV and 
LPS/ATP was deemed not significant when compared to non-stimulated cells. 
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Overall these experiments using PRR inhibitors to determine the role each plays in IAV 
sensing and immune output provided no additional information with any real 
confidence. Even those that appear to provide information such as Isoliquiritigenin 
have doubt cast upon them due to the issues caused with the other PRR inhibitors. 
Ideally to fully confirm the findings on the kinetics of the immune response and what 
roles certain PRRs play, specific receptor lacking MPI clones would need to be 
generated. The benefit of using such cells can quite clearly be seen with the MARCO 
KO MPI macrophages used in this thesis.  
Hopefully the identification of these novel aspects in the innate immune response to 
IAV opens up new mechanisms and targets for treatments and therapies. This chapter 
also shows how vital MPI macrophages might be in testing this in the future, in an 
effort to reduce the numbers of animals used, while maintain accuracy to in vivo 
models.  
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Figure 5.37 The three identified points in the MPI immune response to IAV infection 1. Immune 
response upon viral binding to MPI cells. 2. Immune response upon viral recognition in the endosome. 3. 
Immune response upon viral RNA replication detection. Dashed arrows show key signalling pathways 
from the PRR, while solid arrows show effector molecules produced. 
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6 Chapter Six: General Conclusions 
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IAV infection is an annual burden on human health, with added threat of the 
emergence of pandemic high pathogenic strains an ever constant. Because of this the 
mechanisms of infection have been studied extensively in epithelial cells, which are the 
primary infected cells. However, understanding the early immune response which is 
heavily influenced by the lung resident AMs is lacking. Much of this can be attributed 
to the lack of a good model of primary AMs, which are available at high enough cell 
numbers, to be used in functional assays. Using the established AM-like MPI 
macrophages, this research has been able to fulfil several key objectives established in 
the rationale.  
I. Successfully establish MPI macrophages as a superior model to study early IAV 
innate immunity, compared to BMDMs. 
II. Successfully identify specific IAV strains, isolates, and propagation techniques 
to be used, explaining any differences identified.  
III. Successfully determine the role of established IAV attachment receptors and 
identify novel targets that may have been missed by previous studies. 
IV. Successfully investigate he mechanisms of viral uptake and release in 
macrophages. 
V. Successfully determine which aspects the viral infection cycle induce innate 
responses in macrophages.  
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I. Establish MPI macrophages as a superior model to study early IAV innate 
immunity, compared to BMDMs. 
MPI macrophages were shown to be positively infected by seasonal IAV, but display 
the macrophage characteristic abortive replication associated with this infection, with 
no infectious virions produced (Londrigan et al., 2015). Upon IAV infection MPI 
macrophages produced much higher levels of cytokines, chemokines and type I IFNs 
than BMDMs. MPIs were able to maintain this production even at reduced viral loads, 
compared to BMDMs, which required higher MOI to yield any production. This is in 
line with AMs role as initial IAV sensors and primary recruiters of infiltrating 
lymphocytes (Hoeve et al., 2012; Kim et al., 2008). 
This MPI sensitivity to airway pathogens, which has been seen in other studies, (Fejer 
et al., 2013) is a characteristic of AMs, and along with the surface marker expression 
similarities and abundant numbers makes them an excellent model for studying innate 
immunity against all lung pathogens. 
II. Identify specific IAV strains, isolates, and propagation techniques to be used, 
explaining any differences identified.  
Two IAV H3N2 isolates were identified as strains to bring forward for the remainder of 
the studies; a high immune yielding Perth/16/09 and a low immune yielding 
Texas/50/12. The H3N2 strain was the majority circulating strain at this time, (Public 
Health England, 2015) and induced much better immune responses in MPI 
macrophages than the H1N1 isolates. Texas/50/12 was unable to bind to and infect 
macrophages as efficiently as Perth/16/09, however the opposite was observed with 
MDCK infectivity.  
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One possible reason for this is Perth/16/09 HA is more glycosylated than Texas/50/12, 
with glycosylation being a key component of viral uptake in macrophages (Londrigan et 
al., 2011; Tate et al., 2011a; Tate et al., 2014). However predicted glycosylation sites 
using the two viral genomes showed only slight differences in the numbers of possible 
glycosylation positions of the two strains, in favour of the Texas/50/12 isolate. This 
does not take into account any variations due to post-translational modifications 
during replication and unfortunately the glycosylation of HA in the two strains was not 
directly compared in this research. 
When propagating these isolates, it was evident that cell culture-grown viruses were 
less efficient at infecting MPI macrophages and induced poorer cytokine and type I IFN 
responses, than chemokines. Initially it was hypothesised that the addition of a 
protease (TPKC-treated trypsin) during the cell culture growth, required for HA 
cleavage to infectious form, was having secondary effects. The removal of HA stalk N-
linked glycoproteins by this protease could limit its infection in macrophages, as they 
have been shown to be utilised by macrophage receptors to facilitate viral entry 
(Londrigan et al., 2011; Tate et al., 2011a; Tate et al., 2014). This was not the case 
however, instead the cleavage effects of TPCK-treated trypsin were much less efficient 
than the egg counterpart, resulting in lower HA cleavage, IAV infection and resulting 
cytokine and IFN response. However, it appears that chemokine production is much 
less dependent on successful infection for production, which was analysed in further 
experiments. 
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III. Determine the role of established IAV attachment receptors and identify 
novel targets that may have been missed by previous studies. 
Several c-type lectins have previously been implicated in macrophage uptake of IAV, 
both independently and in co-operation with the traditional IAV receptor, sialic acid 
(Reading et al., 2000; Upham et al., 2010). In MPI macrophages the c-type lectins MMR 
and MGL were also shown to be used in IAV uptake, however to a lesser extent than 
what was observed in these other studies. A novel IAV entry receptor was also shown 
in MPI macrophages, the scavenger receptor MARCO. The lack of this receptor, 
significantly reduced IAV infection, but was only fully diminished with subsequent sialic 
acid removal. This would suggest that MARCO independent entry in MPI macrophages 
does occur but is dependent on sialic acid. As IAV did not bind directly to MARCO, the 
mechanism involved may be that of a co-receptor, with sialic acid concentrating IAV on 
the cell surface, and MARCO co-binding (possibly to N-glycan’s) to facilitate uptake. 
IV. Investigate mechanisms of viral uptake and release in macrophages. 
Both macropinocytosis and clathrin-mediated endocytosis have been implicated in 
viral entry in non-immune epithelial cells, but not in macrophages (de Vries et al., 
2011; Sun et al., 2013). In epithelial cells both mechanisms work in a redundant 
partnership, with inhibition of both processes being required to block viral uptake. 
However, in MPI macrophage this was not the case and inhibition of either pathway 
drastically reduced viral entry, with macropinocytosis marginally more important. 
Therefore it is hypothesised that in macrophages both pathways are required to 
ensure successful viral infection, possibly due to the pleomorphic nature of IAV, with 
spherical and filamentous viruses requiring separate mechanisms for uptake (Rossman 
et al., 2012). 
279 
 
The current model of IAV endosomal escape was also shown to be the same as that in 
MPI macrophages. With blocked endosomal acidification, preventing the conformal 
change in HA, and blocking vRNP escape facilitated by HA fusion to the endosome 
(Cline et al., 2017). However this did not completely block the infection, merely 
reducing it, showing that IAV strain specific endosomal pH threshold, (Marvin et al., 
2017) may also be specific to the individual virions of the strain.  
V. Determine which aspects of the viral infection cycle induce innate responses 
in macrophages, and the innate pathways involved. 
From analysis of the induction of the innate immune response using MPI macrophages 
as a model, it showed quite clear divides in the response, suggesting a response 
tailored to different aspects of the IAV infection cycle. There appeared to be three 
distinct phases of cytokine, chemokine and type I IFN production, which could be 
attributed to separate aspects of the known replication cycle in macrophages. The first 
phase is induced upon cell surface recognition of IAV by an unidentified PAMP, 
resulting in MAPK/NF-kB regulated IL-1α production. The hypothesised role of this 
initial response is induction of a fast antiviral response and recruitment of lymphocytes 
(Fitzgerald, 2009; Mayer-Barber and Yan, 2017; Orzalli et al., 2018). The second phase 
is a second early response, facilitated by IAV recognition in the endosome. This is likely 
a TLR-7/8 recognition and signalling via NF-kB and the MAPK ERK to produce a broader 
range of cytokines and chemokines, enhancing the migration of innate and adaptive 
immune cells to the infection site.  
Finally, a ‘late’ 16hr response occurs upon the detection of viral RNA by RIG-1 and 
possibly TLR-3, resulting in TBK1 and IRF3 mediated production of cytokines, 
chemokines, and importantly type I IFNs. This late response starts the process of 
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antiviral mechanisms in the cells of the lung airway and begins the killing of IAV and 
infected cells. This late response appears to resolve the earlier responses, likely a 
result of viral clearance and the removal of stimuli inducing this early response.  
These findings provide a novel understanding of IAV infections in macrophages and the 
nature of the innate response. However, there are several areas for further studies to 
expand upon what has been found here.  
I. Re-asses the role of macrophage PRRs to determine roles in the three stages of 
immune response to IAV and identify the unknown PRR at the first stage. This 
was attempted via specific inhibitors for PRR and suspected c-type lectins but 
was not successful in properly blocking the PRR signalling. The C-type lectin 
blockers, due to being extracted from bacterial sources, activated MPI 
macrophages alone, and therefore were of no use for cytokine, chemokine, and 
type I IFN assays. The PRR inhibitors used were not effective when used at 
concentrations that would not activate or damage MPI macrophages, again 
limiting their use in cytokine, chemokine and type I IFN assays. However, based 
on the success of MARCO deficient MPI macrophages, PRR knock-out or CRISPR 
deletion would appear to be the better methodologies.  
II. Investigate the multi-cellular impacts these findings have by using ex vivo lung 
models, to investigate macrophage interactions of the epithelial lining during 
IAV infections. - Air Liquid interface models are currently under investigation by 
this research group to study these interactions but have not been used with IAV 
infection yet.  
III. Compare the different immune responses in MPI macrophages with seasonal 
and high pathogenic strains of IAV. Biosafety limits of research facilities have 
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thus far prevented these experiments, but the upcoming addition of BSL 3 
facilities at the University of Plymouth will allow for this work.   
In conclusion, this work has identified novel aspects of the IAV infectious process in 
macrophages, and the innate immune response, while also demonstrating the 
significance IAV propagation has on the research outcome. MPI macrophages, with 
their unique AM-like phenotype and relative abundance, has allowed for the functional 
experiments to show this. The novel findings here alter the understanding of IAV-
macrophage interactions and should provide the foundations for future therapies and 
drug targets to combat the increasing risks of IAV infection, both seasonally and of 
pandemic outbreaks. 
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